in O O
this O O
case O O
, O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
induced O O
polymyositis O B-ADR
and O O
cardiomyopathy B-ADR B-ADR
is O O
diagnosed O O
in O O
a O O
33-yr-old O O
male O O
patient O O
with O O
history O O
of O O
chronic O O
hepatitis O O
b O O

an O O
asymptomatic O O
hiv-infected O O
woman O O
experienced O O
right-sided O B-ADR
renal B-ADR I-ADR
colicky I-ADR I-ADR
pain I-ADR I-ADR
during O O
treatment O O
with O O
indinavir B-DRUG B-DRUG

in O O
view O O
of O O
our O O
experience O O
in O O
the O O
present O O
case O O
, O O
it O O
should O O
be O O
stressed O O
that O O
close O O
monitoring O O
of O O
coagulation O O
capacity O O
is O O
necessary O O
in O O
critically O O
ill O O
patients O O
in O O
order O O
to O O
avoid O O
fatal B-ADR B-ADR
haemorrhage I-ADR I-ADR
after O O
initiating O O
warfarin B-DRUG B-DRUG
therapy O O
regardless O O
of O O
the O O
dosage O O

methods O O
/ O O
results O O
: O O
this O O
paper O O
presents O O
a O O
new O O
case O O
of O O
rifabutin B-DRUG B-ADR
uveitis B-ADR I-ADR
and O O
a O O
review O O
of O O
the O O
various O O
published O O
reports O O
to O O
date O O

in O O
the O O
present O O
paper O O
, O O
we O O
describe O O
two O O
patients O O
with O O
active O O
uc O O
who O O
developed O O
a O O
severe B-ADR B-ADR
systemic I-ADR I-ADR
cmv I-ADR I-ADR
infection I-ADR I-ADR
during O O
a O O
treatment O O
with O O
an O O
oral O O
microemulsion O O
form O O
of O O
cyclosporine B-DRUG B-DRUG

esophageal B-ADR B-ADR
candidiasis I-ADR I-ADR
was O O
diagnosed O O
at O O
endoscopy O O
in O O
two O O
patients O O
receiving O O
omeprazole B-DRUG B-DRUG
therapy O O

background O O
: O O
methotrexate O B-DRUG
( O O
mtx B-DRUG B-DRUG
) O O
may O O
induce O O
liver B-ADR O
damage I-ADR O
, O O
which O O
in O O
some O O
psoriatics O O
will O O
lead O O
to O O
fibrosis O B-ADR
or O O
cirrhosis O B-ADR

he O O
was O O
started O O
on O O
digoxin B-DRUG B-DRUG
, O O
0.25 O O
mg O O
daily O O
, O O
because O O
of O O
echocardiographically O O
demonstrated O O
left B-ADR O
ventricular I-ADR O
dilatation I-ADR O
and O O
functional O O
impairment O O
; O O
he O O
died O O
of O O
ventricular O B-ADR
fibrillation O I-ADR
15 O O
days O O
later O O

objective O O
: O O
1 O O
) O O
to O O
describe O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
receiving O O
adalimumab B-DRUG B-DRUG
who O O
developed O O
fever O O
, O O
pancytopenia O O
, O O
splenomegaly B-ADR O
, O O
and O O
extreme O O
hyperferritinemia O O

neutropenic B-ADR B-ADR
colitis I-ADR I-ADR
during O O
standard O O
dose O O
combination O O
chemotherapy O O
with O O
nedaplatin O B-DRUG
and O O
irinotecan B-DRUG B-DRUG
for O O
testicular O O
cancer O O

we O O
conclude O O
that O O
( O O
a O O
) O O
cyclophosphamide B-DRUG B-DRUG
is O O
a O O
human B-ADR O
teratogen I-ADR O
, O O
( O O
b O O
) O O
a O O
distinct O O
phenotype O O
exists O O
, O O
and O O
( O O
c O O
) O O
the O O
safety O O
of O O
cp O B-ADR
in O O
pregnancy O O
is O O
in O O
serious O O
question O O

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate B-DRUG B-DRUG
with O O
folinic O O
acid O O
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate O O
shower O O
syndrome O O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia O O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia B-ADR O
and O O
tetany O O
, O O
with O O
metabolic O O
acidosis O O
and O O
acute O O
renal O O
impairment O O
) O O
are O O
described O O

we O O
reported O O
3 O O
patients O O
who O O
developed O O
acute B-ADR O
generalized I-ADR O
dystonia I-ADR O
and O O
akinetic O B-ADR
rigid O I-ADR
syndrome O I-ADR
following O O
an O O
initial O O
therapy O O
with O O
d-penicillamine B-DRUG B-DRUG
125-500 O O
mg O O
daily O O

paradoxical B-ADR B-ADR
pulmonary I-ADR I-ADR
vasoconstriction I-ADR I-ADR
induced O O
by O O
nitroglycerin B-DRUG B-DRUG
in O O
idiopathic O O
pulmonary O O
hypertension O O

in O O
case O O
1 O O
, O O
a O O
total O O
daily O O
dose O O
of O O
25 O O
mg O O
sertraline O B-DRUG
, O O
with O O
nondetectable O O
sertraline O B-DRUG
and O O
desmethylsertraline B-DRUG O
blood O O
levels O O
, O O
resulted O O
in O O
a O O
doubling B-ADR O
of I-ADR O
the I-ADR O
lamotrigine I-ADR O
blood I-ADR O
level I-ADR O
with O O
symptoms O O
of O O
toxicity O O

phenytoin-induced O O
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR

anaphylaxis B-ADR B-ADR
to O O
intrathecal O O
diamorphine B-DRUG B-DRUG

within O O
3 O O
weeks O O
of O O
beginning O O
continuous O O
daily O O
isoniazid O B-DRUG
and O O
rifampin B-DRUG B-DRUG
therapy O O
for O O
pulmonary O O
tuberculosis O O
, O O
a O O
patient O O
developed O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR

he O O
developed O O
fever O O
, O O
nausea O O
, O O
diarrhea O O
, O O
and O O
malaise B-ADR O
and O O
stopped O O
taking O O
on O O
the O O
third O O
day O O
after O O
commencing O O
pentasa B-DRUG B-DRUG

we O O
describe O O
a O O
case O O
of O O
clozapine-induced O O
seizures B-ADR B-ADR
in O O
a O O
patient O O
with O O
treatment-resistant O O
schizophrenia O O

rifampin-induced O O
hypothyroidism B-ADR B-ADR
without O O
underlying O O
thyroid O O
disease O O

the O O
case O O
of O O
a O O
patient O O
with O O
infectious O O
mononucleosis O O
treated O O
with O O
cephalexin B-DRUG B-DRUG
who O O
later O O
showed O O
a O O
rash B-ADR O
is O O
presented O O
and O O
the O O
previous O O
literature O O
is O O
reviewed O O

methods O O
: O O
a O O
68-year-old O O
man O O
developed O O
intense O O
conjunctival O O
hyperemia O O
and O O
cystoid O B-ADR
macula O I-ADR
edema O I-ADR
after O O
switching O O
from O O
latanoprost O B-DRUG
to O O
bimatoprost B-DRUG O
9 O O
months O O
after O O
cataract O O
surgery O O
in O O
an O O
eye O O
at O O
low-risk O O
for O O
this O O
cystoid B-ADR O
macular I-ADR O
edema I-ADR O

the O O
potential O O
development O O
of O O
sjs B-ADR O
/ O O
ten O O
, O O
a O O
severe O O
life-threatening O O
illness O O
, O O
emphasizes O O
the O O
need O O
for O O
judicious O O
use O O
of O O
tmp-sx B-DRUG B-DRUG
and O O
close O O
monitoring O O
and O O
follow-up O O
for O O
patients O O
who O O
were O O
given O O
tmp-sx B-DRUG B-DRUG
for O O
sstis O O

transient O B-ADR
leucopenia B-ADR I-ADR
and O O
thrombocytopenia O B-ADR
associated O O
with O O
sodium B-DRUG B-DRUG
nitroprusside I-DRUG I-DRUG
infusion O O

transtubular O O
potassium O O
gradient O O
( O O
ttkg O O
) O O
also O O
decreased O O
and O O
an O O
inverse O O
correlation O O
was O O
found O O
between O O
ttkg O O
and O O
doses O O
of O O
phosphate B-DRUG O
( O O
r O O
= O O
- O O
0.37 O O
; O O
p O O
< O O
0.02 O O
; O O
n O O
= O O
38 O O

methotrexate-associated O O
nephropathy B-ADR B-ADR
is O O
a O O
rare O O
complication O O
in O O
pediatric O O
oncology O O
, O O
and O O
a O O
review O O
of O O
the O O
literature O O
suggests O O
that O O
exposure O O
to O O
nephrotoxic O O
agents O O
may O O
be O O
a O O
significant O O
but O O
perhaps O O
underrecognized O O
risk O O
factor O O
for O O
its O O
development O O

she O O
was O O
placed O O
on O O
adjuvant O O
adriamycin B-DRUG B-DRUG
( O O
doxorubicin O B-DRUG
) O O
chemotherapy O O
, O O
but O O
6 O O
months O O
later O O
died O O
of O O
adriamycin B-ADR B-ADR
toxicity I-ADR I-ADR

a O O
toxic O B-ADR
encephalopathy O I-ADR
characterized O O
by O O
depressed B-ADR O
level I-ADR O
of I-ADR O
consciousness I-ADR O
, O O
marked O O
irritability O O
, O O
and O O
ataxia O O
developed O O
in O O
seven O O
children O O
, O O
5 O O
years O O
of O O
age O O
and O O
younger O O
, O O
following O O
administration O O
of O O
an O O
antiemetic O O
combination O O
of O O
pentobarbital O B-DRUG
and O O
pyrilamine B-DRUG B-DRUG
maleate I-DRUG I-DRUG

flare O O
of O O
kaposi O O
's O O
sarcoma O O
( O O
ks B-ADR O
) O O
is O O
well O O
described O O
in O O
immunosuppressed O O
patients O O
treated O O
with O O
corticosteroids O O
and O O
rituximab B-DRUG B-DRUG
, O O
but O O
has O O
not O O
yet O O
been O O
reported O O
during O O
treatment O O
with O O
imatinib O B-DRUG

the O O
authors O O
describe O O
a O O
case O O
of O O
combined O O
lithium O B-DRUG
and O O
haloperidol B-DRUG B-DRUG
toxicity O O
characterized O O
by O O
hyperpyrexia O O
, O O
severe O O
rigidity O O
, O O
mutism O O
, O O
and O O
development O O
of O O
irreversible B-ADR B-ADR
tardive I-ADR I-ADR
dyskinesia I-ADR I-ADR

the O O
cause O O
of O O
these O O
previously O O
unreported O O
side O O
effects O O
of O O
niacin B-DRUG B-DRUG
therapy O O
is O O
uncertain O O
but O O
may O O
be O O
related O O
to O O
prostaglandin-mediated O O
vasodilatation O O
, O O
hyperalgesia B-ADR O
of I-ADR O
sensory I-ADR O
nerve I-ADR O
receptors I-ADR O
, O O
and O O
potentiation O O
of O O
inflammation O O
in O O
the O O
gingiva O O
with O O
referral O O
of O O
pain O O
to O O
the O O
teeth O O

both O O
colchicine O B-DRUG
and O O
statin B-DRUG B-DRUG
therapy O O
may O O
be O O
associated O O
with O O
myopathy B-ADR O
, O O
which O O
usually O O
occurs O O
after O O
several O O
months O O
of O O
therapy O O

a O O
22-year-old O O
black O O
man O O
developed O O
fever O O
, O O
chills O O
, O O
fatigue O O
, O O
night O O
sweats O O
, O O
tender O O
lymphadenopathy O O
, O O
and O O
a O O
generalized B-ADR O
, I-ADR O
pruritic I-ADR O
, I-ADR O
macular I-ADR O
eruption I-ADR O
3 O O
weeks O O
after O O
starting O O
minocycline B-DRUG B-DRUG
therapy O O
for O O
acne O O

acute B-ADR B-ADR
myelogenous I-ADR I-ADR
leukemia I-ADR I-ADR
in O O
patients O O
receiving O O
chlorambucil B-DRUG B-DRUG
as O O
long-term O O
adjuvant O O
chemotherapy O O
for O O
stage O O
ii O O
breast O O
cancer O O

delayed B-ADR B-ADR
hypersensitivity I-ADR I-ADR
to O O
flurbiprofen B-DRUG B-DRUG

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O O
jerks O O
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin B-ADR O
syndrome I-ADR O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

the O O
findings O O
were O O
judged O O
to O O
be O O
consistent O O
with O O
soft-tissue B-ADR O
injury I-ADR O
associated O O
with O O
intravenous O O
administration O O
of O O
phenytoin B-DRUG B-DRUG
, O O
also O O
termed O O
purple O B-ADR
glove O I-ADR
syndrome O I-ADR

we O O
report O O
on O O
a O O
young O O
adolescent O O
with O O
benign B-ADR O
intracranial I-ADR O
hypertension I-ADR O
which O O
we O O
attribute O O
to O O
the O O
use O O
of O O
minocycline B-DRUG B-DRUG
for O O
acne O O

we O O
describe O O
a O O
57-year-old O O
man O O
with O O
acral O O
erythrocyanosis O O
progressing O O
to O O
acute O O
digital O O
ischemia O O
and O O
gangrene B-ADR O
that O O
developed O O
after O O
combined O O
chemotherapy O O
( O O
bleomycin O O
and O O
methotrexate B-DRUG B-DRUG
) O O
used O O
to O O
treat O O
a O O
metastatic O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
hypopharynx O O

we O O
report O O
a O O
4-year-old O O
girl O O
who O O
presented O O
with O O
acute O O
bilateral O O
blindness O O
, O O
a O O
focal O O
seizure O O
and O O
hypertension B-ADR O
10 O O
days O O
after O O
commencing O O
oxybutynin B-DRUG B-DRUG
to O O
treat O O
enuresis O O

data O O
synthesis O O
: O O
genetic O O
deficiencies O O
in O O
dpd O O
, O O
the O O
rate-limiting O O
enzyme O O
responsible O O
for O O
5-fu B-DRUG B-DRUG
catabolism O O
, O O
may O O
occur O O
in O O
3 O O
% O O
or O O
more O O
of O O
patients O O
with O O
cancer O O
putting O O
them O O
at O O
increased O O
risk O O
for O O
unusually O O
severe O O
adverse O O
reactions O O
( O O
e.g. O O
, O O
diarrhea B-ADR O
, O O
stomatitis O O
, O O
mucositis O O
, O O
myelosuppression O O
, O O
neurotoxicity O O
) O O
to O O
standard O O
doses O O
of O O
5-fu B-DRUG B-DRUG

acute B-ADR O
ischaemia I-ADR O
of I-ADR O
the I-ADR O
leg I-ADR O
following O O
accidental O O
intra-arterial O O
injection O O
of O O
dissolved O O
flunitrazepam B-DRUG B-DRUG
tablets O O

this O O
profile O O
should O O
trigger O O
a O O
" O O
red O O
flag O O
" O O
as O O
to O O
the O O
possibility O O
of O O
phenobarbital B-DRUG B-DRUG
behavioral O O
side O O
effects O O
or O O
exacerbation B-ADR O
of I-ADR O
preexisting I-ADR O
maladaptive I-ADR O
behaviors I-ADR O

we O O
report O O
a O O
case O O
of O O
thrombotic B-ADR B-ADR
thrombocytopenic I-ADR I-ADR
purpura I-ADR I-ADR
occurring O O
as O O
an O O
allergic O O
response O O
to O O
trimethoprim-sulfamethoxazole O B-DRUG
therapy O O
( O O
bactrim O O
, O O
septra O O
) O O
in O O
a O O
jehovah O O
's O O
witness O O
patient O O

both O O
patients O O
developed O O
hypoadrenalism B-ADR B-ADR
while O O
on O O
o,p B-DRUG O
'- I-DRUG O
ddd I-DRUG B-DRUG
and O O
apparently O O
adequate O O
dexamethasone O B-DRUG
replacement O O
therapy O O

ballistic B-ADR B-ADR
movements I-ADR I-ADR
due O O
to O O
ischemic O B-ADR
infarcts O I-ADR
after O O
intravenous O O
heroin B-DRUG B-DRUG
overdose O O
: O O
report O O
of O O
two O O
cases O O

although O O
they O O
had O O
complex O O
medical O O
problems O O
, O O
the O O
high O O
serum O O
concentrations O O
of O O
ampicillin B-DRUG B-DRUG
at O O
the O O
time O O
of O O
seizures B-ADR B-ADR
without O O
their O O
recurrence O O
after O O
discontinuing O O
the O O
antibiotic O O
suggest O O
that O O
the O O
seizures B-ADR B-ADR
were O O
related O O
to O O
the O O
ampicillin B-DRUG B-DRUG
therapy O O

a O O
7-year-old O O
with O O
congenital O O
toxoplasmosis O O
who O O
took O O
pyrimethamine B-DRUG B-DRUG
and O O
sulfadiazine O B-DRUG
for O O
reactivated O O
chorioretinitis O O
developed O O
fever O O
, O O
severe O O
cutaneous O O
involvement O O
, O O
swelling O O
, O O
abdominal O O
pain O O
and O O
transaminitis B-ADR O
, O O
persisting O O
weeks O O
after O O
withholding O O
medicines O O

a O O
case O O
of O O
priapism B-ADR B-ADR
associated O O
with O O
trazodone B-DRUG B-DRUG
is O O
described O O

postoperative O B-ADR
hypocalcemic B-ADR I-ADR
tetany I-ADR I-ADR
caused O O
by O O
fleet O O
phospho-soda O B-DRUG
preparation O O
in O O
a O O
patient O O
taking O O
alendronate B-DRUG B-DRUG
sodium I-DRUG I-DRUG
: O O
report O O
of O O
a O O
case O O

we O O
report O O
a O O
cae O O
of O O
paranoid B-ADR B-ADR
psychosis I-ADR I-ADR
following O O
use O O
of O O
a O O
decongestant O O
containing O O
ppa B-DRUG B-DRUG
and O O
summarize O O
the O O
case O O
report O O
literature O O
of O O
psychiatric O O
adverse O O
effects O O
to O O
ppa B-DRUG B-DRUG
in O O
which O O
doses O O
were O O
known O O
and O O
stated O O
to O O
be O O
within O O
recommended O O
guidelines O O

case O O
summary O O
: O O
a O O
25-year-old O O
postpartum O O
white O O
woman O O
developed O O
multiple O O
watery O O
stools O O
and O O
abdominal B-ADR O
cramping I-ADR O
on O O
day O O
6 O O
of O O
therapy O O
with O O
clindamycin B-DRUG B-DRUG
vaginal O O
cream O O
for O O
bacterial O O
vaginosis O O

a O O
diagnosis O O
of O O
masked O O
theophylline B-ADR B-DRUG
poisoning I-ADR O
should O O
be O O
considered O O
in O O
similar O O
situations O O
involving O O
a O O
rapid O O
decrease O O
of O O
insulin O B-DRUG
requirements O O

the O O
case O O
histories O O
are O O
presented O O
of O O
two O O
patients O O
who O O
developed O O
lung O B-ADR
disease O I-ADR
associated O O
with O O
the O O
use O O
of O O
nitrofurantoin B-DRUG B-DRUG
with O O
histological O O
features O O
of O O
bronchiolitis B-ADR O
obliterans I-ADR O
organising I-ADR O
pneumonia I-ADR O
( O O
boop O O
) O O
, O O
a O O
rare O O
but O O
recognised O O
form O O
of O O
drug O O
induced O O
injury O O

because O O
the O O
combination O O
of O O
bleomycin B-DRUG B-DRUG
and O O
vinca O O
alkaloids O O
is O O
commonly O O
used O O
for O O
the O O
treatment O O
of O O
aids-related O O
kaposi O O
's O O
sarcoma O O
, O O
clinicians O O
should O O
be O O
aware O O
of O O
the O O
risk O O
of O O
provoking O O
acral B-ADR B-ADR
necrosis I-ADR I-ADR
in O O
patients O O
who O O
develop O O
raynaud O O
's O O
phenomenon O O
under O O
chemotherapy O O

two O O
patients O O
with O O
extrinsic O O
asthma O O
and O O
coexistent O O
insulin-dependent O O
diabetes O O
mellitus O O
sustained O O
an O O
anaphylactoid B-ADR B-ADR
reaction I-ADR I-ADR
after O O
the O O
intravenous O O
administration O O
of O O
50 O O
% O O
solution O O
of O O
dextrose B-DRUG B-DRUG

two O O
patients O O
with O O
ovarian O O
cancer O O
who O O
had O O
received O O
multiple O O
courses O O
of O O
cisplatin B-DRUG B-DRUG
without O O
complications O O
experienced O O
hypersensitivity O O
reactions O O
to O O
cisplatin B-DRUG B-DRUG
: O O
one O O
, O O
involving O O
intrahepatic O O
artery O O
infusion O O
, O O
manifested O O
general B-ADR O
erythema I-ADR O
, O O
dyspnea O O
, O O
and O O
hypotension O O
; O O
the O O
other O O
, O O
involving O O
intravenous O O
infusion O O
, O O
manifested O O
abdominal O O
pain O O
, O O
general B-ADR O
erythema I-ADR O
, O O
and O O
fever O B-ADR

although O O
its O O
side O O
effects O O
are O O
few O O
, O O
tamoxifen B-DRUG B-DRUG
increases O O
the O O
incidence O O
of O O
proliferative B-ADR O
lesions I-ADR O
of I-ADR O
the I-ADR O
endometrium I-ADR O
, O O
which O O
theoretically O O
should O O
be O O
preventable O O
with O O
progestational O O
agents O O

we O O
present O O
a O O
case O O
of O O
stroke B-ADR B-ADR
after O O
ppa B-DRUG B-DRUG
ingestion O O
that O O
occurred O O
4 O O
months O O
after O O
the O O
recall O O
in O O
an O O
8-year-old O O
boy O O
on O O
chronic O O
peritoneal O O
dialysis O O

intracranial B-ADR O
hemorrhage I-ADR O
and O O
focal O O
seizures O O
secondary O O
to O O
use O O
of O O
l-asparaginase B-DRUG B-DRUG
during O O
induction O O
therapy O O
of O O
acute O O
lymphocytic O O
leukemia O O

drug O O
induced O O
polymyositis B-ADR B-ADR
secondary O O
to O O
leuprolide B-DRUG B-DRUG
acetate I-DRUG I-DRUG
( O O
lupron O B-DRUG
) O O
therapy O O
for O O
prostate O O
carcinoma O O

administration O O
of O O
steroid O O
and O O
decreasing O O
the O O
dose O O
of O O
ptu B-DRUG B-DRUG
produced O O
a O O
good O O
clinical O O
response O O
and O O
the O O
anca B-ADR O
disappeared O O

the O O
cough B-ADR B-ADR
continued O O
for O O
the O O
duration O O
of O O
therapy O O
with O O
quinapril B-DRUG B-DRUG

conclusion O O
: O O
significant O O
weight B-ADR O
loss I-ADR O
is O O
a O O
potential O O
adverse O O
event O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
treated O O
with O O
leflunomide B-DRUG B-DRUG

rapamycin O O
/ O O
sirolimus O B-DRUG
( O O
sr O O
) O O
, O O
trade O O
named O O
rapammune B-DRUG O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression O O
, O O
hypertension O O
, O O
hyperlipidemia B-ADR O
, O O
and O O
infection O O

angioimmunoblastic B-ADR B-ADR
lymphadenopathy I-ADR I-ADR
with I-ADR O
dysproteinemia I-ADR B-ADR
following O O
doxycycline B-DRUG B-DRUG
administration O O

the O O
results O O
clearly O O
demonstrate O O
that O O
cph82 B-DRUG B-DRUG
was O O
associated O O
with O O
suppression B-ADR O
of I-ADR O
the I-ADR O
endogeneous I-ADR O
production I-ADR O
of I-ADR O
acth I-ADR O
and I-ADR O
cortisol I-ADR O
with O O
a O O
concomitant O O
paradoxical O O
picture O O
of O O
clinical O O
hypercortisolism O O

from O O
1996 O O
to O O
2002 O O
several O O
medications O O
were O O
changed O O
due O O
to O O
their O O
adverse O O
effects O O
: O O
indinavir B-DRUG O
( O O
renal B-ADR O
colic I-ADR O
and O O
fever O O
) O O
, O O
nelfinavir O O
( O O
cutaneous O O
rash O O
) O O
, O O
and O O
efavirenz O B-DRUG
( O O
nausea O O
and O O
temporary O O
memory O O
loss O O

rifampicin-induced O O
renal B-ADR B-ADR
failure I-ADR I-ADR

this O O
communication O O
describes O O
a O O
patient O O
who O O
developed O O
schneiderian B-ADR B-ADR
first-rank I-ADR I-ADR
symptoms I-ADR I-ADR
in O O
the O O
course O O
of O O
treatment O O
with O O
fluvoxamine B-DRUG B-DRUG

it O O
was O O
concluded O O
that O O
potassium O B-ADR
loss O I-ADR
occurred O O
by O O
a O O
non-renal O O
( O O
intestinal O O
) O O
route O O
in O O
phosphate-induced O O
hypokalemia B-ADR B-ADR

data O O
synthesis O O
: O O
genetic O O
deficiencies O O
in O O
dpd O O
, O O
the O O
rate-limiting O O
enzyme O O
responsible O O
for O O
5-fu B-DRUG B-DRUG
catabolism O O
, O O
may O O
occur O O
in O O
3 O O
% O O
or O O
more O O
of O O
patients O O
with O O
cancer O O
putting O O
them O O
at O O
increased O O
risk O O
for O O
unusually O O
severe O O
adverse O O
reactions O O
( O O
e.g. O O
, O O
diarrhea B-ADR O
, O O
stomatitis O O
, O O
mucositis O O
, O O
myelosuppression O O
, O O
neurotoxicity O O
) O O
to O O
standard O O
doses O O
of O O
5-fu B-DRUG B-DRUG

he O O
had O O
an O O
immediate O O
hypersensitivity O O
reaction O O
during O O
the O O
initiation O O
of O O
the O O
mtx B-DRUG B-DRUG
infusion O O
with O O
diffuse O O
urticaria O O
, O O
facial O O
swelling O O
, O O
cough O O
, O O
and O O
chest B-ADR O
tightness I-ADR O

methods O O
: O O
a O O
68-year-old O O
man O O
developed O O
intense B-ADR O
conjunctival I-ADR O
hyperemia I-ADR O
and O O
cystoid O B-ADR
macula O I-ADR
edema O I-ADR
after O O
switching O O
from O O
latanoprost O B-DRUG
to O O
bimatoprost B-DRUG O
9 O O
months O O
after O O
cataract O O
surgery O O
in O O
an O O
eye O O
at O O
low-risk O O
for O O
this O O
cystoid O O
macular O O
edema O O

thoracoscopic O O
biopsy O O
to O O
confirm O O
metastasis O O
revealed O O
instead O O
fibrotic B-ADR B-ADR
lesions I-ADR I-ADR
apparently O O
attributable O O
to O O
bleomycin O B-DRUG
or O O
cyclophosphamide B-DRUG B-DRUG

one O O
patient O O
had O O
mri B-ADR O
t2 I-ADR O
abnormalities I-ADR O
compatible O O
with O O
cyclosporin B-DRUG B-DRUG
neurotoxicity O B-ADR

l-asparaginase-induced O O
pancreatitis O B-ADR
is O O
an O O
uncommon O O
but O O
potential O O
lethal B-ADR O
complication I-ADR O
of O O
the O O
treatment O O
of O O
leukemia O O

we O O
report O O
the O O
case O O
of O O
a O O
lung O O
cancer O O
patient O O
with O O
bronquiloalveolar O O
carcinoma O O
( O O
bac O O
) O O
presenting O O
with O O
boop O B-ADR
after O O
chemotherapy O O
with O O
docetaxel B-DRUG B-DRUG
and O O
gemcitabine O B-DRUG
producing O O
severe B-ADR O
respiratory I-ADR O
insufficiency I-ADR O
, O O
and O O
simulating O O
a O O
progression O O
of O O
the O O
tumor O O

allergic B-ADR B-ADR
contact I-ADR I-ADR
dermatitis I-ADR I-ADR
from O O
4-chloro-7-nitrobenzofurazan B-DRUG B-DRUG

despite O O
a O O
response O O
of O O
the O O
meningeal O O
tumor O O
the O O
patient O O
developed O O
in O O
the O O
third O O
week O O
of O O
mtx O B-DRUG
treatment O O
a O O
progressive O O
visual O O
loss O O
and O O
loss O O
of O O
consciousness O O
which O O
worsened O O
during O O
subsequent O O
ara-c B-DRUG B-DRUG
treatment O O
and O O
led O O
to O O
death B-ADR B-ADR
within O O
3 O O
weeks O O

therapy O O
with O O
ifn-beta B-DRUG B-DRUG
has O O
rarely O O
been O O
associated O O
with O O
the O O
development O O
of O O
autoimmune B-ADR B-ADR
disorders I-ADR I-ADR

a O O
transient O O
tonic O O
pupillary O O
response O O
, O O
denervation B-ADR O
supersensitivity I-ADR O
, O O
and O O
abnormal O O
visual-evoked O O
potentials O O
in O O
quinine B-DRUG B-DRUG
toxicity O O
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O

serious O O
phenytoin B-DRUG B-DRUG
hypersensitivity B-ADR O
reactions I-ADR O
may O O
appear O O
as O O
dermatologic O O
, O O
lymphoid O O
, O O
or O O
hepatic O O
syndromes O O

a O O
33-year-old O O
man O O
with O O
a O O
history O O
of O O
recreational O O
benztropine B-DRUG B-DRUG
abuse O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
confusion B-ADR O
, O O
abdominal O O
pain O O
, O O
and O O
distention O O

patients O O
: O O
two O O
patients O O
, O O
ages O O
40 O O
and O O
51 O O
years O O
, O O
undergoing O O
treatment O O
with O O
interferon B-DRUG B-DRUG
alfa I-DRUG I-DRUG
for O O
malignant O O
neoplasms O O
experienced O O
sudden B-ADR O
bilateral I-ADR O
, I-ADR O
sequential I-ADR O
visual I-ADR O
loss I-ADR O
with O O
disc-related O O
field O O
defects O O
and O O
segmental O O
optic O O
disc O O
edema O O

however O O
, O O
an O O
association O O
of O O
ritalin B-DRUG B-DRUG
with O O
glaucoma B-ADR B-ADR
has O O
been O O
reported O O

we O O
report O O
two O O
patients O O
with O O
anhedonic B-ADR O
ejaculation I-ADR O
( O O
ejaculation O O
without O O
orgasm O O
) O O
associated O O
with O O
initiation O O
of O O
treatment O O
with O O
desipramine B-DRUG B-DRUG

cicatricial B-ADR B-ADR
entropion I-ADR I-ADR
associated O O
with O O
chronic O O
dipivefrin B-DRUG B-DRUG
application O O

based O O
on O O
the O O
clinical O O
status O O
of O O
the O O
patient O O
, O O
it O O
was O O
suspected O O
that O O
several O O
conditions O O
contributed O O
to O O
the O O
abnormal B-ADR O
hypersensitivity I-ADR O
to O O
warfarin B-DRUG B-DRUG

we O O
describe O O
two O O
women O O
who O O
developed O O
hus B-ADR B-ADR
after O O
mmc B-DRUG B-DRUG
therapy O O
and O O
presented O O
massive O B-ADR
pulmonary O I-ADR
bleeding O I-ADR

bleomycin B-DRUG B-DRUG
and O O
cyclophosphamide O B-DRUG
toxicity O O
simulating O O
metastatic B-ADR O
nodules I-ADR O
to O O
the O O
lungs O O
in O O
childhood O O
cancer O O

we O O
describe O O
a O O
case O O
of O O
disseminated O O
muscular O B-ADR
cysticercosis O I-ADR
followed O O
by O O
myositis O O
( O O
fever O O
, O O
diffuse O O
myalgia O O
, O O
weakness O O
of O O
the O O
lower O O
limbs O O
, O O
and O O
inflammatory B-ADR O
reaction I-ADR O
around I-ADR O
dying I-ADR O
cysticerci I-ADR O
) O O
induced O O
by O O
praziquantel B-DRUG B-DRUG
therapy O O
, O O
an O O
event O O
not O O
described O O
previously O O

in O O
this O O
report O O
, O O
one O O
patient O O
who O O
developed O O
gangrene B-ADR B-ADR
after O O
bleomycin O B-DRUG
and O O
vincristine B-DRUG O
/ O O
vinblastine O B-DRUG
chemotherapy O O
for O O
aids-related O O
kaposi O O
's O O
sarcoma O O
and O O
another O O
hiv-infected O O
patient O O
who O O
exhibited O O
symptoms O O
of O O
severe O O
raynaud O O
's O O
phenomenon O O
related O O
to O O
the O O
same O O
regimen O O
are O O
presented O O

purple O B-ADR
glove O I-ADR
syndrome O I-ADR
, O O
named O O
for O O
its O O
distinctive O O
purple B-ADR O
discoloration I-ADR O
and O O
swelling O O
of O O
the O O
hands O O
in O O
the O O
distribution O O
of O O
a O O
glove O O
, O O
is O O
an O O
uncommon O O
complication O O
of O O
intravenous O O
phenytoin B-DRUG B-DRUG
administration O O
through O O
small O O
dorsal O O
veins O O
of O O
the O O
hands O O

a O O
retrospective O O
review O O
of O O
ttp O O
patients O O
with O O
quinine-associated O O
thrombotic B-ADR O
microangiopathy I-ADR O
( O O
tma O O
) O O
for O O
whom O O
adamts13 O B-DRUG
was O O
measured O O
before O O
plasma O O
exchange O O
was O O
performed O O

conclusions O O
: O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
seems O O
to O O
be O O
the O O
probable O O
cause O O
of O O
the O O
seizures B-ADR B-ADR

5-fluorouracil B-DRUG B-DRUG
cardiotoxicity B-ADR B-ADR
complicating O O
treatment O O
of O O
stage O O
iib O O
cervical O O
cancer O O
-- O O
case O O
report O O

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O O
jerks O O
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin B-ADR O
syndrome I-ADR O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

in O O
case O O
no O O
. O O
2 O O
, O O
the O O
pathogenic O O
mechanism O O
seemed O O
to O O
be O O
persistent O O
light O O
reaction O O
preceded O O
by O O
systemic O O
photoallergy O O
, O O
as O O
he O O
had O O
taken O O
mequitazine B-DRUG B-DRUG
for O O
6 O O
months O O
, O O
and O O
there O O
were O O
strong O O
positive O O
photopatch O O
test O O
results O O
with O O
immediate O O
erythema O O
reaction O O
, O O
cross-reaction O O
to O O
promethazine O B-DRUG
, O O
decreased O O
med O O
to O O
both O O
uva O O
and O O
uvb O O
, O O
and O O
persistence B-ADR O
of I-ADR O
the I-ADR O
photosensitivity I-ADR O
over O O
a O O
3-year O O
follow-up O O
period O O
after O O
discontinuation O O
of O O
the O O
mequitazine B-DRUG B-DRUG

rhabdomyolysis B-ADR B-ADR
has O O
been O O
recognized O O
as O O
a O O
complication O O
of O O
tocolytic O B-DRUG
therapy O O
with O O
ritodrine B-DRUG B-DRUG
hydrochloride I-DRUG I-DRUG

successful O O
treatment O O
of O O
visceral O O
leishmaniasis O O
with O O
allopurinol O B-DRUG
plus O O
ketoconazole O B-DRUG
in O O
an O O
infant O O
who O O
developed O O
pancreatitis B-ADR B-ADR
caused O O
by O O
meglumine B-DRUG B-DRUG
antimoniate I-DRUG I-DRUG

anaphylactoid B-ADR O
shock I-ADR O
, O O
disseminated O O
intravascular O O
coagulation O O
, O O
and O O
anuric O O
renal O O
failure O O
requiring O O
dialysis O O
occurred O O
in O O
a O O
patient O O
receiving O O
zomepirac B-DRUG B-DRUG
sodium O I-DRUG
for O O
toothache O O

a O O
51-yr-old O O
nonsmoking O O
male O O
patient O O
without O O
any O O
history O O
of O O
previous O O
allergies O O
, O O
asthma O O
, O O
hay O O
fever O O
, O O
or O O
urticaria O O
developed O O
attacks B-ADR O
of I-ADR O
asthma I-ADR B-ADR
when O O
captopril O B-DRUG
was O O
added O O
to O O
the O O
nadolol O O
and O O
dyazide B-DRUG B-DRUG
treatment O O
for O O
his O O
high O O
blood O O
pressure O O

we O O
reported O O
a O O
case O O
of O O
disulfiram-induced O O
hepatitis B-ADR B-ADR
with O O
unique O O
clinical O O
features O O
and O O
compared O O
our O O
case O O
with O O
others O O
in O O
the O O
literature O O

we O O
consider O O
asterixis O B-ADR
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity B-ADR B-ADR
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium O O
or O O
clozapine B-DRUG B-DRUG
are O O
used O O
in O O
combination O O
with O O
cbz O B-DRUG

we O O
report O O
a O O
case O O
of O O
a O O
patient O O
with O O
pulmonary O O
hypertension O O
and O O
undifferentiated O O
connective O O
tissue O O
disease O O
who O O
, O O
after O O
2 O O
months O O
of O O
treatment O O
with O O
epoprostenol B-DRUG B-DRUG
, O O
presented O O
with O O
rapidly O O
progressive O O
erythema O O
, O O
scaling O O
, O O
nausea B-ADR O
and O O
vomiting O O
, O O
and O O
fever O B-ADR

two O O
patients O O
are O O
described O O
who O O
developed O O
sensory B-ADR B-ADR
neuropathy I-ADR I-ADR
after O O
the O O
ingestion O O
of O O
30.6 O O
and O O
114 O O
g O O
metronidazole B-DRUG B-DRUG
respectively O O

the O O
cause O O
of O O
these O O
previously O O
unreported O O
side O O
effects O O
of O O
niacin B-DRUG B-DRUG
therapy O O
is O O
uncertain O O
but O O
may O O
be O O
related O O
to O O
prostaglandin-mediated O O
vasodilatation O O
, O O
hyperalgesia O O
of O O
sensory O O
nerve O O
receptors O O
, O O
and O O
potentiation B-ADR O
of I-ADR O
inflammation I-ADR O
in I-ADR O
the I-ADR O
gingiva I-ADR O
with O O
referral O O
of O O
pain O O
to O O
the O O
teeth O O

agranulocytosis B-ADR B-ADR
and O O
granulocytopenia O B-ADR
associated O O
with O O
quetiapine B-DRUG B-DRUG

a O O
patient O O
is O O
described O O
with O O
the O O
characteristic O O
features O O
of O O
phenytoin B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
( O O
phs O O
) O O
including O O
fever O O
, O O
erythroderma O O
, O O
tibial B-ADR O
and I-ADR O
facial I-ADR O
oedema I-ADR O
, O O
pinhead-sized O O
facial O O
pustules O O
and O O
abnormal O O
liver O O
function O O
tests O O

treatment O O
with O O
infliximab B-DRUG B-DRUG
is O O
known O O
to O O
produce O O
an O O
increase O O
of O O
autoantibodies O O
( O O
antinuclear B-ADR O
antibodies I-ADR O
, O O
anti-double-stranded O O
dna O O
) O O
, O O
but O O
not O O
clinical O O
disease O O

he O O
developed O O
recurrent O O
skin O O
rash O O
, O O
fever B-ADR O
, O O
hypereosinophilia O O
, O O
and O O
acute O O
renal O O
failure O O
after O O
rechallenge O O
with O O
chlorambucil B-DRUG B-DRUG

bleomycin B-DRUG B-ADR
pneumonitis B-ADR I-ADR
potentiated O O
by O O
oxygen O O
administration O O

the O O
present O O
report O O
suggests O O
that O O
clarithromycin O B-DRUG
coadministration O O
induces O O
increased O O
plasma O O
carbamazepine B-DRUG B-DRUG
concentrations O O
, O O
which O O
may O O
result O O
in O O
carbamazepine B-ADR B-ADR
toxicity I-ADR I-ADR

we O O
suggest O O
that O O
sarcoidosis B-ADR B-ADR
may O O
develop O O
in O O
chronic O O
hepatitis O O
c O O
patients O O
during O O
interferon O B-DRUG
alpha O I-DRUG
and O O
/ O O
or O O
ribavirin B-DRUG B-DRUG
treatment O O
, O O
and O O
diagnostic O O
tests O O
for O O
this O O
adverse O O
effect O O
should O O
be O O
performed O O
during O O
the O O
follow-ups O O

the O O
authors O O
postulate O O
that O O
two O O
types O O
of O O
combined O O
lithium-neuroleptic O B-ADR
toxicity O I-ADR
occur O O
: O O
a O O
neuroleptic O O
malignant O O
extrapyramidal O O
syndrome O O
and O O
a O O
lithium B-ADR B-ADR
toxicity I-ADR I-ADR
that O O
occurs O O
in O O
combination O O
with O O
phenothiazines O O
, O O
primarily O O
thioridazine B-DRUG O

methods O O
: O O
in O O
an O O
institutional O O
practice O O
setting O O
, O O
two O O
women O O
, O O
aged O O
25 O O
and O O
45 O O
, O O
developed O O
acute B-ADR B-ADR
myopia I-ADR I-ADR
after O O
starting O O
topiramate B-DRUG B-DRUG
for O O
epilepsy O O

transient B-ADR B-ADR
anuria I-ADR I-ADR
following O O
administration O O
of O O
angiotensin O O
i-converting O O
enzyme O O
inhibitor O O
( O O
sq B-DRUG O
14225 I-DRUG O
) O O
in O O
a O O
patient O O
with O O
renal O O
artery O O
stenosis O O
of O O
the O O
solitary O O
kidney O O
successfully O O
treated O O
with O O
renal O O
autotransplantation O O

intravenous O O
verapamil B-DRUG B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea B-ADR O
, O O
hypotension O O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death O O
; O O
quinidine O B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

conclusions O O
: O O
topical O O
brimonidine B-DRUG B-DRUG
may O O
be O O
associated O O
with O O
central B-ADR O
nervous I-ADR O
system I-ADR O
depression I-ADR O
in O O
infants O O

stroke-like B-ADR B-ADR
syndrome I-ADR I-ADR
after O O
gold B-DRUG B-DRUG
sodium I-DRUG I-DRUG
thiomalate I-DRUG I-DRUG
induced O O
vasomotor O B-ADR
reaction O I-ADR

colonic B-ADR B-ADR
necrosis I-ADR I-ADR
is O O
known O O
as O O
a O O
rare O O
complication O O
following O O
the O O
administration O O
of O O
kayexalate O B-DRUG
( O O
sodium B-DRUG B-DRUG
polystryrene I-DRUG I-DRUG
sulfonate I-DRUG I-DRUG
) O O
in O O
sorbitol O O

temporary B-ADR O
neurologic I-ADR O
abnormalities I-ADR O
were O O
observed O O
in O O
one O O
out O O
of O O
23 O O
patients O O
undergoing O O
chemotherapy O O
with O O
high-dose O O
methotrexate B-DRUG B-DRUG
( O O
hd-mtx O B-DRUG
) O O
for O O
osteogenic O O
sarcoma O O

although O O
major O O
hazards O O
of O O
treatment O O
of O O
hypophosphatemic O O
osteomalacia O O
with O O
phosphate B-DRUG O
and O O
calcitriol O B-DRUG
are O O
secondary O O
hyperparathyroidism O O
and O O
vitamin O O
d O O
intoxication O O
, O O
potassium B-ADR B-ADR
loss I-ADR I-ADR
also O O
should O O
be O O
kept O O
in O O
mind O O

vogt-koyanagi-harada B-ADR B-ADR
disease I-ADR I-ADR
occurring O O
during O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
therapy O O
for O O
chronic O O
hepatitis O O
c O O

purpose O O
: O O
to O O
report O O
a O O
case O O
of O O
angiographically O O
documented O O
cystoid B-ADR B-ADR
macula I-ADR I-ADR
edema I-ADR I-ADR
occurring O O
after O O
switching O O
a O O
pseudophakic O O
patient O O
from O O
latanoprost O B-DRUG
to O O
bimatoprost B-DRUG B-DRUG

conclusions O O
: O O
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
to O O
cyclosporine O B-DRUG
are O O
due O O
to O O
cremophor B-DRUG O
el I-DRUG O

cisplatin-induced O O
syndrome B-ADR O
of I-ADR O
inappropriate I-ADR O
antidiuretic I-ADR O
hormone I-ADR O
( O O
siadh O O
) O O
in O O
a O O
patient O O
with O O
neuroendocrine O O
tumor O O
of O O
the O O
cervix O O
: O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

in O O
addition O O
, O O
an O O
immediate O O
erythematous B-ADR B-ADR
macule I-ADR I-ADR
was O O
observed O O
on O O
the O O
photopatch O O
test O O
site O O
of O O
mequitazine B-DRUG B-DRUG
directly O O
after O O
uv O O
exposure O O
which O O
was O O
similar O O
to O O
the O O
immediate O O
erythema O B-ADR
noted O O
in O O
chlorpromazine O B-DRUG
photoallergy O O

we O O
strongly O O
suspect O O
that O O
this O O
lethal B-ADR B-ADR
anuria I-ADR I-ADR
was O O
mainly O O
due O O
to O O
ifosfamide B-DRUG B-DRUG
, O O
occurring O O
in O O
a O O
patient O O
having O O
received O O
previous O O
cisplatin O B-DRUG
chemotherapy O O
and O O
with O O
poor O O
kidney O O
perfusion O O
due O O
to O O
transient O O
hypotension O O

de B-ADR O
novo I-ADR O
absence I-ADR O
status I-ADR O
of O O
late O O
onset O O
following O O
withdrawal O O
of O O
lorazepam B-DRUG B-DRUG
: O O
a O O
case O O
report O O

we O O
report O O
an O O
additional O O
case O O
of O O
isotretinoin B-DRUG B-DRUG
teratogenicity O B-ADR
in O O
which O O
the O O
patient O O
had O O
agenesis B-ADR O
of I-ADR O
the I-ADR O
cerebellar I-ADR O
vermis I-ADR O
, O O
multiple O O
leptomeningeal O O
neuroglial O O
heterotopias O O
, O O
hydrocephalus O O
, O O
and O O
abnormalities O O
of O O
the O O
corticospinal O O
tracts O O

the O O
purpose O O
of O O
this O O
report O O
is O O
to O O
document O O
a O O
new O O
case O O
of O O
in O O
utero O O
cp B-DRUG O
exposure O O
with O O
multiple O O
congenital O O
anomalies O O
and O O
to O O
establish O O
an O O
apparent O O
cp B-DRUG O
embryopathy B-ADR O
phenotype O O

when O O
sasp O B-DRUG
was O O
changed O O
to O O
5-aminosalicylic O O
acid O O
( O O
5-asa B-DRUG O
) O O
, O O
his O O
skin O O
eruptions O O
were O O
resolved O O
, O O
however O O
, O O
he O O
developed O O
weakness B-ADR O
and O O
atrophy O O
in O O
his O O
right O O
arm O O
as O O
well O O
as O O
progressive O O
worsening O O
of O O
the O O
dysesthesia O O
in O O
his O O
legs O O
and O O
gait O O
disturbance O O

discontinuation O O
of O O
simvastatin B-DRUG B-DRUG
and O O
cyclosporine O B-DRUG
resulted O O
in O O
resolution O O
of O O
rhabdomyolysis B-ADR O
and O O
normalization O O
of O O
renal O O
function O O

a O O
patient O O
is O O
described O O
who O O
developed O O
a O O
poorly O B-ADR
differentiated O I-ADR
sarcoma B-ADR I-ADR
after O O
cyclophosphamide B-DRUG B-DRUG
was O O
used O O
to O O
treat O O
his O O
rheumatoid O O
arthritis O O

theophylline B-ADR B-ADR
intoxication I-ADR I-ADR
following O O
viloxazine B-DRUG B-DRUG
induced O O
decrease O O
in O O
clearance O O

shortly O O
after O O
chemotherapy O O
and O O
an O O
injection O O
of O O
pegfilgrastim B-DRUG B-DRUG
, O O
the O O
patient O O
developed O O
poorly O O
defined O O
, O O
rapidly B-ADR O
progressive I-ADR O
erythema I-ADR O
, O O
edema O O
, O O
and O O
pain O O
in O O
his O O
right O O
forearm O O

while O O
most O O
physicians O O
are O O
aware O O
of O O
heparin-induced O O
thrombocytopenia O B-ADR
and O O
skin B-ADR O
necrosis I-ADR O
, O O
the O O
association O O
of O O
heparin B-DRUG B-DRUG
and O O
hyperkalemia O O
is O O
less O O
well O O
recognized O O

lithium B-DRUG B-DRUG
treatment O O
was O O
terminated O O
in O O
1975 O O
because O O
of O O
lithium B-ADR B-DRUG
intoxication I-ADR O
with O O
a O O
diabetes O O
insipidus-like O O
syndrome O O

it O O
is O O
suggested O O
that O O
the O O
patient O O
had O O
sulfasalazine-induced O O
lupus O B-ADR
, O O
which O O
manifested O O
with O O
serositis B-ADR O
and O O
pulmonary O O
parenchymal O O
involvement O O
in O O
the O O
absence O O
of O O
joint O O
symptoms O O

objective O O
: O O
to O O
investigate O O
the O O
mechanisms O O
involved O O
in O O
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
to O O
cyclosporine B-DRUG B-DRUG
and O O
determine O O
the O O
feasibility O O
of O O
future O O
cyclosporine B-DRUG B-DRUG
use O O

we O O
describe O O
a O O
5-year-old O O
girl O O
showed O O
recovery O O
of O O
vincristine B-DRUG B-DRUG
induced O O
cranial B-ADR B-ADR
polyneuropathy I-ADR I-ADR
with O O
pyridoxine O O
and O O
pyridostigmine O B-DRUG
treatment O O

systemic B-ADR B-ADR
allergic I-ADR I-ADR
contact I-ADR I-ADR
dermatitis I-ADR I-ADR
to O O
8-methoxypsoralen O B-DRUG
( O O
8-mop B-DRUG O

we O O
report O O
on O O
three O O
patients O O
who O O
developed O O
acute O B-ADR
liver B-ADR I-ADR
damage I-ADR I-ADR
during O O
therapy O O
with O O
itraconazole B-DRUG B-DRUG
, O O
and O O
in O O
whom O O
liver O O
biopsy O O
specimens O O
were O O
obtained O O

marked O O
qt O O
prolongation O O
and O O
torsades B-ADR B-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR
secondary O O
to O O
acute O O
ischemia O O
in O O
an O O
elderly O O
man O O
taking O O
dofetilide B-DRUG B-DRUG
for O O
atrial O O
fibrillation O O
: O O
a O O
cautionary O O
tale O O

we O O
report O O
the O O
case O O
histories O O
of O O
identical O O
twin O O
brothers O O
who O O
developed O O
concordant O O
acute O O
lymphoblastic O O
leukemia O O
at O O
the O O
age O O
of O O
4 O O
years O O
and O O
who O O
later O O
developed O O
leukoencephalopathy B-ADR B-ADR
and O O
hydrocephalus O O
related O O
to O O
central O O
nervous O O
system O O
prophylaxis O O
by O O
, O O
in O O
the O O
first O O
case O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
, O O
in O O
the O O
second O O
by O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
cranial O O
irradiation O O

nine O O
delirious B-ADR O
patients O O
suffering O O
from O O
lithium B-DRUG B-DRUG
intoxication O O
were O O
examined O O
with O O
the O O
mini-mental O O
state O O
exam O O
( O O
mms O O
) O O
to O O
describe O O
the O O
clinical O O
course O O
of O O
the O O
disorder O O

we O O
report O O
the O O
case O O
of O O
a O O
40-year-old O O
woman O O
who O O
developed O O
fulminant O O
hepatic O O
failure O O
and O O
aplastic B-ADR B-ADR
anaemia I-ADR I-ADR
following O O
a O O
course O O
of O O
oral O O
flucloxacillin B-DRUG B-DRUG

cefoxitin B-DRUG B-DRUG
therapy O O
for O O
mycobacterium O O
fortuitum O O
bacteremia O O
with O O
associated O O
granulomatous B-ADR O
hepatitis I-ADR O

allergic B-ADR B-ADR
contact I-ADR I-ADR
angioedema I-ADR I-ADR
to O O
benzoyl B-DRUG B-DRUG
peroxide I-DRUG I-DRUG

according O O
to O O
the O O
naranjo O O
probability O O
scale O O
, O O
the O O
papular B-ADR B-ADR
eruption I-ADR I-ADR
was O O
probably O O
caused O O
by O O
methotrexate B-DRUG B-DRUG

since O O
ethambutol B-DRUG B-DRUG
is O O
actively O O
excreted O O
via O O
the O O
renal O O
system O O
, O O
compromise O O
of O O
renal O O
function O O
such O O
as O O
due O O
to O O
renal O O
tuberculosis O O
may O O
lead O O
to O O
serum O O
concentration O O
elevations O O
of O O
ethambutol B-DRUG B-DRUG
sufficient O O
to O O
produce O O
optic B-ADR B-ADR
neuropathy I-ADR I-ADR

the O O
sulfonamides B-DRUG B-DRUG
are O O
the O O
best O O
verified O O
drug-trigger O O
for O O
erythema O O
multiforme O O
and O O
stevens-johnson B-ADR O
syndrome I-ADR O

when O O
vague B-ADR O
symptoms I-ADR O
develop O O
during O O
desmopressin B-DRUG B-DRUG
therapy O O
, O O
hyponatremia O B-ADR
must O O
be O O
considered O O
as O O
part O O
of O O
the O O
differential O O
diagnosis O O

a O O
case O O
of O O
oculogyric B-ADR B-ADR
crisis I-ADR I-ADR
induced O O
by O O
metoclopramide B-DRUG B-DRUG
is O O
described O O
in O O
this O O
paper O O

physicians O O
should O O
be O O
aware O O
of O O
the O O
risk O O
of O O
severe O O
aiha B-ADR B-ADR
in O O
cll O O
patients O O
with O O
a O O
history O O
of O O
aiha B-ADR O
or O O
positivation O O
of O O
the O O
dat O O
during O O
previous O O
fludarabine B-DRUG B-DRUG
administration O O
, O O
or O O
in O O
case O O
of O O
secondary O O
fixation O O
of O O
complement O O
to O O
the O O
red O O
cell O O
membrane O O
occurring O O
during O O
fludarabine B-DRUG B-DRUG
treatment O O

the O O
authors O O
report O O
two O O
cases O O
of O O
acute B-ADR O
dystonic I-ADR O
reactions I-ADR O
( O O
adrs O B-ADR
) O O
as O O
a O O
side O O
effect O O
of O O
lamivudine B-DRUG B-DRUG

we O O
present O O
a O O
case O O
of O O
hus B-ADR B-ADR
in O O
an O O
advanced O O
ovarian O O
cancer O O
patient O O
treated O O
with O O
carboplatin B-DRUG B-DRUG
and O O
gemcitabine O B-DRUG
, O O
and O O
described O O
its O O
favorable O O
outcome O O
after O O
chemotherapy O O
interruption O O
and O O
supportive O O
care O O
with O O
a O O
1 O O
year O O
follow-up O O

we O O
describe O O
2 O O
patients O O
with O O
prior O O
amputation O O
who O O
experienced O O
phantom B-ADR O
limb I-ADR O
pain I-ADR O
( O O
plp O B-ADR
) O O
after O O
receiving O O
paclitaxel B-DRUG B-DRUG
therapy O O

fatal B-ADR O
complication I-ADR O
of O O
intravesical O O
formalin B-DRUG B-DRUG
during O O
control O O
of O O
intractable O O
hemorrhage O O
from O O
radiation O O
cystitis O O

hyperkalaemia O B-ADR
with O O
renal B-ADR O
tubular I-ADR O
dysfunction I-ADR O
by O O
sulfamethoxazole-trimethoprim B-DRUG B-DRUG
for O O
pneumocystis O O
carinii O O
pneumonia O O
in O O
patients O O
with O O
lymphoid O O
malignancy O O

quinine B-DRUG B-DRUG
and O O
its O O
isomer O O
quinidine O B-DRUG
are O O
well-known O O
causes O O
of O O
iatrogenic B-ADR B-ADR
hypoglycaemia I-ADR I-ADR
, O O
due O O
to O O
excessive O O
insulin O B-DRUG
secretion O O

the O O
authors O O
report O O
a O O
case O O
of O O
urinary B-ADR O
incontinence I-ADR O
( O O
ui O O
) O O
that O O
occurred O O
in O O
a O O
woman O O
after O O
administration O O
of O O
venlafaxine B-DRUG B-DRUG

hepatolithiasis B-ADR B-ADR
( O O
intrahepatic O O
stone O O
) O O
during O O
octreotide B-DRUG B-DRUG
therapy O O
for O O
acromegaly O O
: O O
a O O
case O O
report O O

these O O
cases O O
and O O
a O O
review O O
of O O
the O O
literature O O
suggested O O
that O O
hepatotoxicity B-ADR B-ADR
, O O
though O O
rare O O
, O O
should O O
be O O
added O O
to O O
the O O
list O O
of O O
adverse O O
reactions O O
to O O
d-penicillamine B-DRUG B-DRUG

possible O O
interaction O O
between O O
lopinavir B-DRUG O
/ O O
ritonavir O B-DRUG
and O O
valproic O B-DRUG
acid O I-DRUG
exacerbates O O
bipolar B-ADR B-ADR
disorder I-ADR I-ADR

results O O
: O O
a O O
44-year-old O O
man O O
taking O O
naproxen B-DRUG B-DRUG
for O O
chronic O O
low O O
back O O
pain O O
and O O
a O O
20-year-old O O
woman O O
on O O
oxaprozin O B-DRUG
for O O
rheumatoid O O
arthritis O O
presented O O
with O O
tense O O
bullae O O
and O O
cutaneous B-ADR O
fragility I-ADR O
on O O
the O O
face O O
and O O
the O O
back O O
of O O
the O O
hands O O

a O O
62-year-old O O
woman O O
treated O O
with O O
pranlukast B-DRUG B-DRUG
for O O
2 O O
months O O
developed O O
interstitial O B-ADR
pneumonitis O I-ADR
with O O
a O O
high B-ADR O
fever I-ADR O

physicians O O
should O O
be O O
aware O O
that O O
indinavir B-DRUG B-DRUG
nephrolithiasis O B-ADR
may O O
cause O O
papillary B-ADR B-ADR
necrosis I-ADR I-ADR

radiologic O O
recognition O O
of O O
adriamycin B-DRUG B-DRUG
cardiotoxicity B-ADR B-ADR

conclusions O O
: O O
although O O
mirtazapine B-DRUG B-DRUG
offers O O
clinicians O O
a O O
combination O O
of O O
strong O O
efficacy O O
and O O
good O O
safety O O
, O O
we O O
suggest O O
bearing O O
ss B-ADR B-ADR
in O O
mind O O
when O O
prescribing O O
this O O
drug O O
, O O
especially O O
in O O
frail O O
, O O
elderly O O
patients O O
with O O
underlying O O
chronic O O
conditions O O

this O O
case O O
emphasizes O O
the O O
importance O O
of O O
the O O
evaluation O O
of O O
lithium-associated O O
polyuria B-ADR B-ADR
with O O
a O O
direct O O
measurement O O
of O O
plasma O O
vasopressin O B-DRUG
, O O
interpreted O O
with O O
simultaneous O O
plasma O O
and O O
urine O O
osmolality O O
to O O
secure O O
the O O
correct O O
diagnosis O O
and O O
ensure O O
appropriate O O
therapeutic O O
management O O

therefore O O
, O O
we O O
concluded O O
that O O
this O O
patient O O
's O O
pulmonary B-ADR B-ADR
disease I-ADR I-ADR
was O O
caused O O
by O O
calcium B-DRUG B-DRUG
stearate I-DRUG I-DRUG
, O O
an O O
additive O O
for O O
an O O
antihistaminic O O
drug O O

the O O
disease-modifying O O
drugs O O
he O O
was O O
taking O O
, O O
cyclosporin B-DRUG B-DRUG
and O O
methotrexate O B-DRUG
, O O
were O O
stopped O O
, O O
and O O
the O O
lymphoma B-ADR B-ADR
resolved O O
spontaneously O O
without O O
the O O
use O O
of O O
chemotherapy O O

we O O
postulate O O
that O O
the O O
bolus O O
of O O
sulprostone B-DRUG B-DRUG
resulted O O
in O O
possible O O
coronary B-ADR O
spasm I-ADR O
that O O
resulted O O
in O O
cardiac O B-ADR
arrest O I-ADR

these O O
observations O O
indicate O O
that O O
submassive O B-ADR
hepatic O I-ADR
necrosis O I-ADR
may O O
result O O
from O O
treatment O O
with O O
propylthiouracil B-DRUG B-DRUG
and O O
are O O
consistent O O
with O O
the O O
notion O O
that O O
sensitization O O
mechanisms O O
may O O
be O O
responsible O O
for O O
the O O
hepatic B-ADR B-ADR
injury I-ADR I-ADR
induced O O
by O O
this O O
drug O O

objectives O O
: O O
the O O
authors O O
described O O
a O O
case O O
of O O
hashimoto B-ADR B-ADR
's I-ADR I-ADR
disease I-ADR I-ADR
during O O
interferon-alpha O B-DRUG
( O O
ifn-alpha B-DRUG B-DRUG
) O O
treatment O O
for O O
chronic O O
viral O O
c O O
hepatitis O O
in O O
a O O
patient O O
with O O
the O O
specific O O
genetic O O
susceptibility O O
associated O O
with O O
the O O
thyroid O O
disease O O

a O O
case O O
of O O
severe B-ADR B-ADR
acute I-ADR I-ADR
hepatitis I-ADR I-ADR
caused O O
by O O
cyproterone B-DRUG B-DRUG
acetate I-DRUG I-DRUG
in O O
a O O
71 O O
year O O
old O O
man O O
with O O
prostatic O O
carcinoma O O
is O O
reported O O
with O O
a O O
review O O
of O O
the O O
literature O O
on O O
hepatic O O
reactions O O
to O O
this O O
drug O O

the O O
findings O O
were O O
judged O O
to O O
be O O
consistent O O
with O O
soft-tissue O O
injury O O
associated O O
with O O
intravenous O O
administration O O
of O O
phenytoin B-DRUG B-DRUG
, O O
also O O
termed O O
purple B-ADR B-ADR
glove I-ADR I-ADR
syndrome I-ADR I-ADR

two O O
patients O O
with O O
ovarian O O
cancer O O
who O O
had O O
received O O
multiple O O
courses O O
of O O
cisplatin B-DRUG B-DRUG
without O O
complications O O
experienced O O
hypersensitivity O O
reactions O O
to O O
cisplatin B-DRUG B-DRUG
: O O
one O O
, O O
involving O O
intrahepatic O O
artery O O
infusion O O
, O O
manifested O O
general O O
erythema O O
, O O
dyspnea O O
, O O
and O O
hypotension O O
; O O
the O O
other O O
, O O
involving O O
intravenous O O
infusion O O
, O O
manifested O O
abdominal O O
pain O O
, O O
general O O
erythema O O
, O O
and O O
fever B-ADR B-ADR

results O O
: O O
quetiapine B-DRUG B-DRUG
was O O
associated O O
with O O
leucopenia B-ADR B-ADR
in O O
two O O
patients O O
and O O
clinically O O
apparent O O
agranulocytosis O B-ADR
in O O
one O O
patient O O

here O O
we O O
present O O
the O O
case O O
of O O
a O O
woman O O
who O O
received O O
high O O
doses O O
of O O
methylprednisolone B-DRUG B-DRUG
( O O
1 O O
g O O
iv O O
daily O O
) O O
for O O
active O O
graves' O O
ophthalmopathy O O
, O O
and O O
developed O O
severe B-ADR B-ADR
hypertension I-ADR I-ADR
followed O O
by O O
myocardial O B-ADR
infarction O I-ADR
on O O
the O O
fifth O O
day O O
of O O
treatment O O

a O O
girl O O
with O O
cystic O O
fibrosis O O
and O O
cyclic O O
neutropenia O O
developed O O
an O O
erythematous B-ADR B-ADR
papular I-ADR I-ADR
eruption I-ADR I-ADR
without O O
fever O O
or O O
neutrophilia O B-ADR
7 O O
months O O
after O O
commencing O O
therapy O O
with O O
g-csf B-DRUG B-DRUG

we O O
describe O O
the O O
clinical O O
response O O
, O O
as O O
determined O O
by O O
increases B-ADR O
in I-ADR O
total I-ADR O
hb I-ADR O
and O O
decreased O O
transfusion O O
needs O O
, O O
in O O
five O O
patients O O
with O O
thalassemia O O
intermedia O O
treated O O
with O O
hu B-DRUG O
alone O O
or O O
in O O
combination O O
with O O
spb O B-DRUG

coagulopathy B-ADR B-ADR
associated O O
with O O
the O O
use O O
of O O
cephalosporin O B-DRUG
or O O
moxalactam B-DRUG O
antibiotics O O
in O O
acute O O
and O O
chronic O O
renal O O
failure O O

discussion O O
: O O
the O O
main O O
adverse O O
effects O O
of O O
leflunomide B-DRUG B-DRUG
consist O O
of O O
diarrhea O O
, O O
nausea O O
, O O
liver O O
enzyme O O
elevation O O
, O O
hypertension O O
, O O
alopecia B-ADR O
, O O
and O O
allergic O O
skin O O
reactions O O

to O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
case O O
of O O
lithium-associated O O
cdi O B-ADR
and O O
ndi B-ADR O
presenting O O
concurrently O O

we O O
report O O
a O O
50-year-old O O
male O O
patient O O
with O O
a O O
15-year O O
history O O
of O O
psoriasis O O
including O O
mutilating O O
psoriatic O O
arthritis O O
, O O
in O O
whom O O
the O O
withdrawal O O
of O O
cyclosporin B-DRUG B-DRUG
a I-DRUG O
induced O O
a O O
generalised B-ADR O
pustular I-ADR O
exacerbation I-ADR O
and O O
a O O
aggravation O O
of O O
the O O
joint O O
condition O O

the O O
female O O
patient O O
received O O
clozapine B-DRUG B-DRUG
in O O
a O O
daily O O
dose O O
of O O
400 O O
mg O O
, O O
which O O
induced O O
agranulocytosis B-ADR B-ADR
after O O
2 O O
months O O

an O O
unusual O O
case O O
of O O
ecstasy B-ADR B-ADR
poisoning I-ADR I-ADR

when O O
thrombosis B-ADR B-ADR
develops O O
during O O
heparin B-DRUG B-DRUG
treatment O O
, O O
it O O
is O O
important O O
to O O
suspect O O
hitts O B-ADR
and O O
to O O
assay O O
for O O
the O O
associated O O
antibodies O O
, O O
regardless O O
of O O
the O O
actual O O
platelet O O
count O O

behavioral O O
side O O
effects O O
associated O O
with O O
clonazepam B-DRUG B-DRUG
may O O
include O O
agitation O O
, O O
aggression O O
, O O
hyperactivity O O
, O O
irritability B-ADR O
, O O
property O O
destruction O O
, O O
and O O
temper O O
tantrums O O

the O O
fifth O O
patient O O
exhibited O O
paraesthesia B-ADR O
and O O
agitation O O
caused O O
by O O
olanzapine B-DRUG B-DRUG
that O O
was O O
misdiagnosed O O
as O O
psychotic O B-ADR
agitation O I-ADR

the O O
vomiting B-ADR B-ADR
occurred O O
on O O
switching O O
to O O
different O O
pancreatic O O
enzymes O O
preparations O O
, O O
ie O O
, O O
creon B-DRUG O
10 I-DRUG O
, O O
viokase O O
, O O
and O O
pancrease O O
mt O O
16 O O

gold-induced O O
pneumonitis B-ADR B-ADR

cyclosporin B-DRUG B-DRUG
side O O
effects O O
included O O
hirsutism O O
, O O
hypertension B-ADR O
, O O
increased O O
blood O O
levels O O
of O O
urea O O
and O O
creatinine O O
, O O
and O O
abnormalities O O
in O O
liver O O
function O O
tests O O

thalidomide B-DRUG B-DRUG
was O O
withdrawn O O
from O O
world O O
markets O O
in O O
1961 O O
following O O
recognition O O
of O O
its O O
teratogenic B-ADR B-ADR
effects I-ADR I-ADR

a O O
64 O O
year O O
old O O
man O O
with O O
recurrent O O
metastatic O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
head O O
and O O
neck O O
developed O O
severe O O
skin O O
rash O O
and O O
bone B-ADR O
marrow I-ADR O
aplasia I-ADR O
4 O O
and O O
7 O O
days O O
, O O
respectively O O
, O O
following O O
a O O
single O O
dose O O
of O O
40 O O
mg O O
/ O O
m2 O O
methotrexate O O
( O O
mtx B-DRUG B-DRUG

severe O B-ADR
serotonin B-ADR I-ADR
syndrome I-ADR I-ADR
induced O O
by O O
mirtazapine B-DRUG B-DRUG
monotherapy O O

induction O O
of O O
systemic B-ADR B-ADR
lupus I-ADR I-ADR
erythematosus I-ADR I-ADR
by O O
interferon-gamma B-DRUG B-DRUG
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O

priapism B-ADR B-ADR
as O O
a O O
complication O O
of O O
heparin B-DRUG B-DRUG
therapy O O

methods O O
: O O
the O O
patient O O
required O O
insulin B-DRUG B-DRUG
desensitization O O
for O O
severe B-ADR O
urticaria I-ADR O
, O O
angioedema O O
, O O
and O O
occasional O O
wheezing O O
resulting O O
from O O
her O O
insulin B-DRUG B-DRUG
dose O O

case O O
: O O
we O O
report O O
a O O
case O O
of O O
a O O
woman O O
with O O
severe O O
human B-DRUG O
insulin-induced O O
lipoatrophy B-ADR B-ADR
who O O
has O O
been O O
treated O O
exclusively O O
with O O
recombinant O O
dna O O
human B-DRUG O
insulin I-DRUG O
since O O
the O O
onset O O
of O O
iddm O B-ADR

the O O
mild O O
immunosuppression O O
that O O
occurs O O
with O O
methotrexate B-DRUG B-DRUG
therapy O O
probably O O
places O O
patients O O
with O O
rheumatoid O O
arthritis O O
at O O
added O O
risk O O
of O O
developing O O
lymphoproliferative B-ADR O
diseases I-ADR O
, O O
but O O
coincidence O O
cannot O O
be O O
excluded O O

itraconazole-related O O
increased O O
vincristine B-ADR B-DRUG
neurotoxicity I-ADR B-ADR
: O O
case O O
report O O
and O O
review O O
of O O
literature O O

we O O
describe O O
2 O O
patients O O
with O O
cutaneous O O
lupus O O
erythematosus O O
who O O
developed O O
severe O O
dapsone B-DRUG B-DRUG
reaction O O
after O O
low O O
dose O O
therapy O O
, O O
with O O
a O O
fatal B-ADR O
outcome O O
in O O
one O O

a O O
65-year-old O O
woman O O
, O O
in O O
the O O
intensive O O
care O O
unit O O
because O O
of O O
septic O O
shock O O
and O O
acute O O
renal O O
failure O O
, O O
had O O
a O O
small-bowel B-ADR B-ADR
obstruction I-ADR I-ADR
due O O
to O O
amphojel B-DRUG B-DRUG
concretions O O

linezolid-associated O O
acute B-ADR O
interstitial I-ADR O
nephritis I-ADR O
and O O
drug O O
rash O O
with O O
eosinophilia O O
and O O
systemic O O
symptoms O O
( O O
dress O O
) O O
syndrome O O

a O O
patient O O
suffering O O
from O O
heparin-associated O O
thrombocytopenia B-ADR O
( O O
hat O O
) O O
, O O
recurrent O O
arteriothromboses O O
, O O
and O O
acute O O
renal O O
failure O O
after O O
treatment O O
with O O
standard O O
heparin B-DRUG B-DRUG
is O O
described O O

mequitazine O B-DRUG
seemed O O
to O O
play O O
a O O
part O O
similar O O
to O O
chlorpromazine O B-DRUG
, O O
and O O
absence O O
of O O
mequitazine-induced O O
photosensitivity B-ADR B-ADR
may O O
be O O
due O O
to O O
a O O
relatively O O
low O O
dosage O O
of O O
the O O
drug O O

we O O
report O O
a O O
myeloma O O
patient O O
who O O
developed O O
severe B-ADR B-ADR
paralytic I-ADR I-ADR
ileus I-ADR I-ADR
during O O
bortezomib B-DRUG B-DRUG
therapy O O
, O O
which O O
presented O O
in O O
the O O
context O O
of O O
progressive O O
constipation O O
without O O
other O O
known O O
causes O O
and O O
which O O
regressed O O
promptly O O
with O O
medical O O
management O O
after O O
drug O O
cessation O O
, O O
suggesting O O
a O O
direct O O
causal O O
relationship O O

acute B-ADR B-ADR
generalized I-ADR I-ADR
exanthematous I-ADR I-ADR
pustulosis I-ADR I-ADR
induced O O
by O O
salazosulfapyridine B-DRUG B-DRUG
in O O
a O O
patient O O
with O O
ulcerative O O
colitis O O

intravenous O O
verapamil B-DRUG B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension O O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial B-ADR O
flutter I-ADR O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death O O
; O O
quinidine O B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

the O O
development O O
of O O
systemic B-ADR O
lupus I-ADR O
erythematosus I-ADR O
( O O
sle O B-ADR
) O O
after O O
38 O O
months O O
of O O
therapy O O
with O O
recombinant O O
human O O
interferon O O
gamma O O
( O O
rifn-gamma B-DRUG O
) O O
was O O
observed O O
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O

risperidone B-DRUG B-DRUG
is O O
a O O
frequently O O
used O O
member O O
of O O
a O O
new O O
class O O
of O O
atypical O O
antipsychotics-the O O
serotonin-dopamine O O
antagonists O O
( O O
sdas O O
)- O O
due O O
to O O
its O O
comparatively O O
high O O
efficacy O O
and O O
low O O
d2 O O
/ O O
5ht2 O O
binding O O
ratio O O
, O O
which O O
results O O
in O O
a O O
low O O
incidence O O
of O O
extrapyramidal O O
side O O
effects O O
including O O
tardive B-ADR O
dyskinesia I-ADR O
( O O
td O B-ADR

acute B-ADR O
myopathy I-ADR O
with O O
selective O O
degeneration O O
of O O
myosin O O
filaments O O
following O O
status O O
asthmaticus O O
treated O O
with O O
methylprednisolone O B-DRUG
and O O
vecuronium B-DRUG O

fatal B-ADR B-ADR
eosinophilia I-ADR I-ADR
myalgia I-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
marrow O O
transplant O O
patient O O
attributed O O
to O O
total O O
parenteral O O
nutrition O O
with O O
a O O
solution O O
containing O O
tryptophan B-DRUG B-DRUG

pneumonitis B-ADR B-ADR
is O O
emerging O O
as O O
one O O
of O O
the O O
most O O
unpredictable O O
and O O
potentially O O
serious O O
, O O
adverse O O
effects O O
of O O
treatment O O
with O O
mtx B-DRUG B-DRUG

here O O
we O O
present O O
the O O
case O O
of O O
a O O
woman O O
who O O
received O O
high O O
doses O O
of O O
methylprednisolone B-DRUG B-DRUG
( O O
1 O O
g O O
iv O O
daily O O
) O O
for O O
active O O
graves' O O
ophthalmopathy O O
, O O
and O O
developed O O
severe O B-ADR
hypertension O I-ADR
followed O O
by O O
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
on O O
the O O
fifth O O
day O O
of O O
treatment O O

reactivation B-ADR O
of I-ADR O
cytomegalovirus I-ADR B-ADR
probably O O
followed O O
the O O
treatment O O
of O O
wegener O O
's O O
granulomatosis O O
with O O
corticosteroids O O
and O O
azathioprine B-DRUG B-DRUG

we O O
present O O
a O O
case O O
of O O
sotalol-induced O O
bradycardia B-ADR B-ADR
reversed O O
by O O
glucagon O B-DRUG

in O O
case O O
1 O O
, O O
a O O
total O O
daily O O
dose O O
of O O
25 O O
mg O O
sertraline O B-DRUG
, O O
with O O
nondetectable O O
sertraline O B-DRUG
and O O
desmethylsertraline B-DRUG O
blood O O
levels O O
, O O
resulted O O
in O O
a O O
doubling O O
of O O
the O O
lamotrigine O O
blood O O
level O O
with O O
symptoms B-ADR O
of I-ADR O
toxicity I-ADR O

eye B-ADR B-ADR
movement I-ADR I-ADR
disorders I-ADR I-ADR
in O O
bone O O
marrow O O
transplant O O
patients O O
on O O
cyclosporin B-DRUG B-DRUG
and O O
ganciclovir O B-DRUG

ptosis B-ADR B-ADR
occurring O O
24 O O
h O O
after O O
chloroquine B-DRUG B-DRUG
therapy O O
, O O
with O O
full O O
recovery O O
48 O O
h O O
after O O
cessation O O
of O O
chloroquine B-DRUG B-DRUG
, O O
has O O
not O O
been O O
described O O
previously O O

despite O O
administration O O
of O O
phenytoin O B-DRUG
and O O
lorazepam O B-DRUG
, O O
the O O
seizures B-ADR B-ADR
persisted O O
and O O
occurred O O
only O O
during O O
amphotercin B-DRUG B-DRUG
b I-DRUG I-DRUG
administration O O

coadministration O O
of O O
antidepressant O O
agents O O
such O O
as O O
nefazodone B-DRUG B-DRUG
, O O
or O O
any O O
other O O
drug O O
that O O
inhibits O O
the O O
cyp3a4 O O
isoenzyme O O
subfamily O O
, O O
should O O
be O O
anticipated O O
to O O
interfere B-ADR O
with I-ADR O
tacrolimus I-ADR B-DRUG
metabolism I-ADR O

the O O
reported O O
cases O O
of O O
in O O
utero O O
exposure O O
to O O
cyclosposphamide B-DRUG B-DRUG
shared O O
the O O
following O O
manifestations O O
with O O
our O O
patient O O
: O O
growth O O
deficiency O O
, O O
developmental O O
delay O O
, O O
craniosynostosis O O
, O O
blepharophimosis O O
, O O
flat O O
nasal O O
bridge O O
, O O
abnormal O O
ears O O
, O O
and O O
distal B-ADR O
limb I-ADR O
defects I-ADR O
including O O
hypoplastic O O
thumbs O O
and O O
oligodactyly O O

background O O
: O O
gemcitabine O B-DRUG
has O O
mild O O
renal O O
toxicity O O
, O O
but O O
cases O O
of O O
gemcitabine-associated O O
hemolytic-uremic B-ADR B-ADR
syndrome I-ADR I-ADR
( O O
hus O B-ADR
) O O
have O O
been O O
reported O O

seizure B-ADR B-ADR
with O O
hyponatremia O B-ADR
in O O
a O O
child O O
prescribed O O
desmopressin B-DRUG B-DRUG
for O O
nocturnal O O
enuresis O O

it O O
is O O
concluded O O
that O O
simultaneous O O
administration O O
of O O
ciprofloxacin O B-DRUG
and O O
tazobactam O O
/ O O
piperacillin B-DRUG B-DRUG
may O O
cause O O
marked O O
thrombocytosis B-ADR B-ADR

the O O
development O O
of O O
erythroid O O
leukemia O O
plus O O
carcinoma B-ADR O
in O O
these O O
two O O
men O O
suggests O O
mutagenic O O
change O O
secondary O O
to O O
cyclophosphamide B-DRUG B-DRUG
therapy O O

we O O
describe O O
a O O
patient O O
with O O
crest O O
syndrome O O
( O O
calcinosis O O
, O O
raynaud O O
's O O
phenomenon O O
, O O
esophageal O O
dysfunction O O
, O O
sclerodactyly O O
, O O
and O O
telangiectasia O O
) O O
who O O
paradoxically O O
experienced O O
worsening B-ADR O
of I-ADR O
raynaud I-ADR O
's I-ADR O
phenomenon I-ADR O
when O O
using O O
yohimbine B-DRUG B-DRUG
for O O
ed O O

background O O
: O O
gemcitabine O B-DRUG
has O O
mild O O
renal O O
toxicity O O
, O O
but O O
cases O O
of O O
gemcitabine-associated O O
hemolytic-uremic O B-ADR
syndrome O I-ADR
( O O
hus B-ADR B-ADR
) O O
have O O
been O O
reported O O

we O O
introduce O O
a O O
case O O
of O O
a O O
sixty O O
years O O
old O O
woman O O
with O O
several O O
previous O O
episodes O O
of O O
rhinitis O B-ADR
, O O
conjunctivitis B-ADR O
and O O
perspiration O O
immediately O O
after O O
the O O
administration O O
of O O
salmon O O
calcitonin O O
with O O
nasal O O
spray O O
or O O
intramuscular O O
administration O O
( O O
calsynar B-DRUG B-DRUG

this O O
case O O
showed O O
sequential O O
manifestation O O
from O O
transient O O
thyrotoxicosis O O
to O O
the O O
appearance O O
of O O
tsh-receptor O O
autoantibodies O O
, O O
and O O
then O O
the O O
occurrence O O
of O O
graves' B-ADR B-ADR
hyperthyroidism I-ADR I-ADR
during O O
ifn B-DRUG B-DRUG
therapy O O

neutrophilic B-ADR B-ADR
dermatoses I-ADR I-ADR
in O O
two O O
children O O
with O O
idiopathic O O
neutropenia O O
: O O
association O O
with O O
granulocyte O O
colony-stimulating O O
factor O O
( O O
g-csf B-DRUG O
) O O
therapy O O

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
linear O O
immunoglobulin O O
( O O
ig O O
) O O
a O O
bullous O O
dermatosis O O
( O O
labd B-ADR O
) O O
induced O O
by O O
gemcitabine B-DRUG B-DRUG

although O O
risk O O
factors O O
for O O
mtx-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
are O O
poorly O O
understood O O
, O O
the O O
presence O O
in O O
3 O O
out O O
of O O
5 O O
of O O
our O O
patients O O
of O O
pre-existing O O
lung O O
disease O O
, O O
represented O O
by O O
diffuse O O
interstitial O O
changes O O
on O O
chest O O
x-ray O O
, O O
and O O
mild O O
bronchial O O
asthma O O
in O O
two O O
ra O O
patients O O
and O O
by O O
pulmonary O O
silicosis O O
in O O
the O O
patient O O
with O O
psa O B-DRUG
may O O
account O O
for O O
a O O
predisposition O O
to O O
the O O
development O O
of O O
mtx B-DRUG B-DRUG
pneumonitis O B-ADR

rapid O O
resolution O O
of O O
topiramate-induced O O
angle-closure B-ADR B-ADR
glaucoma I-ADR I-ADR
with O O
methylprednisolone B-DRUG B-DRUG
and O O
mannitol O B-DRUG

we O O
presented O O
a O O
patient O O
with O O
status O O
asthmaticus O O
treated O O
with O O
a O O
combination O O
of O O
theophylline O B-DRUG
and O O
prednisone B-DRUG B-DRUG
who O O
developed O O
a O O
perforated B-ADR B-ADR
gastric I-ADR I-ADR
ulcer I-ADR I-ADR

a O O
14-year-old O O
female O O
developed O O
systemic O O
lupus O O
erythematosus O O
( O O
sle O O
)- O O
like O O
symptoms O O
, O O
rash O O
, O O
fever B-ADR O
, O O
leukopenia O O
and O O
positive O O
anti-nuclear O O
antibody O O
( O O
ana O O
) O O
two O O
weeks O O
after O O
administration O O
of O O
carbamazepine O B-DRUG
( O O
cbz O B-DRUG
; O O
tegretol B-DRUG O
) O O
used O O
against O O
benign O O
rolandic O O
epilepsy O O

the O O
exact O O
mechanism O O
of O O
ivig-associated O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
remains O O
unclear O O

the O O
association O O
of O O
central B-ADR O
diabetes I-ADR O
insipidus I-ADR O
( O O
cdi O O
) O O
with O O
lithium B-DRUG B-DRUG
use O O
is O O
rare O O

we O O
describe O O
two O O
patients O O
with O O
rheumatoid O O
factor-positive O O
, O O
polyarticular-onset O B-ADR
juvenile O I-ADR
rheumatoid O I-ADR
arthritis O I-ADR
in O O
whom O O
accelerated B-ADR O
nodulosis I-ADR B-ADR
developed O O
during O O
methotrexate B-DRUG B-DRUG
therapy O O

we O O
consider O O
asterixis O B-ADR
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity B-ADR B-ADR
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium B-DRUG O
or O O
clozapine O B-DRUG
are O O
used O O
in O O
combination O O
with O O
cbz O B-DRUG

the O O
spectrum O O
of O O
nitrofurantoin B-DRUG B-ADR
lung B-ADR I-ADR
injury I-ADR I-ADR
continues O O
to O O
widen O O

suxamethonium B-DRUG B-ADR
apnoea B-ADR I-ADR
terminated O O
with O O
commercial O O
serumcholinesterase O B-DRUG

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram B-DRUG B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O O
jerks O O
and O O
unsteady B-ADR O
gait I-ADR O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl O B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl O B-DRUG

mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
, O O
a O O
hydrocarbon O O
, O O
may O O
not O O
elicit O O
a O O
normal O O
protective O O
cough O O
reflex O O
and O O
may O O
impair B-ADR O
mucociliary I-ADR O
transport I-ADR O

intra-neural B-ADR B-ADR
ceroid-like I-ADR I-ADR
pigment I-ADR I-ADR
following O O
the O O
treatment O O
of O O
lepromatous O O
leprosy O O
with O O
clofazimine B-DRUG B-DRUG
( O O
b663 O O
; O O
lamprene O O

we O O
report O O
a O O
case O O
of O O
recurrent O B-ADR
torsades B-ADR I-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR
following O O
treatment O O
with O O
pentavalent O B-DRUG
antimonial O O
drugs O O
and O O
amiodarone B-DRUG B-DRUG

we O O
report O O
4 O O
patients O O
, O O
2 O O
on O O
methylphenidate O B-DRUG
and O O
2 O O
on O O
dextroamphetamine B-DRUG B-DRUG
who O O
presented O O
with O O
acral B-ADR O
cyanosis I-ADR O
, O O
livedo O O
reticularis O O
, O O
or O O
raynaud O O
phenomenon O O

in O O
a O O
postural O O
challenge O O
test O O
after O O
administration O O
of O O
isosorbide B-DRUG B-DRUG
dinitrate I-DRUG I-DRUG
( O O
5 O O
mg O O
) O O
, O O
blood O O
pressure O O
decreased O O
from O O
120 O O
/ O O
67 O O
to O O
65 O O
/ O O
35 O O
mmhg O O
, O O
followed O O
by O O
syncope O O
with O O
a O O
sudden B-ADR O
decrease I-ADR O
in I-ADR O
pulse I-ADR O
rate I-ADR O
from O O
85 O O
to O O
60 O O
beats O O
/ O O
min O O

we O O
report O O
a O O
31-year-old O O
women O O
with O O
recurrent O O
hodgkin O O
's O O
lymphoma O O
and O O
unrecognized O O
hmsn-1 O O
who O O
developed O O
severe B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
3 O O
weeks O O
after O O
the O O
first O O
cycle O O
of O O
treatment O O
including O O
2 O O
mg O O
of O O
vincristine B-DRUG B-DRUG

we O O
presented O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
a O O
cutaneous B-ADR B-ADR
reaction I-ADR I-ADR
induced O O
by O O
captopril B-DRUG B-DRUG
with O O
positive O O
patch O O
test O O

a O O
60 O O
year-old O O
woman O O
with O O
chronic O O
renal O O
failure O O
developed O O
acute O B-ADR
proximal B-ADR I-ADR
muscle I-ADR I-ADR
weakness I-ADR I-ADR
after O O
receiving O O
a O O
regular O O
dosage O O
of O O
colchicine B-DRUG B-DRUG

neurophysiological O O
mechanisms O O
which O O
aid O O
in O O
elucidating O O
the O O
role O O
of O O
disulfiram B-DRUG B-DRUG
in O O
the O O
etiology O O
of O O
catatonia B-ADR O
are O O
discussed O O

comparable O O
adverse O O
effects O O
, O O
such O O
as O O
disorientation O O
and O O
temporary B-ADR O
amnesia I-ADR O
, O O
have O O
been O O
reported O O
in O O
patients O O
in O O
the O O
analogous O O
agent O O
, O O
propranolol B-DRUG B-DRUG

hepatotoxicity B-ADR B-ADR
of O O
hycanthone B-DRUG B-DRUG
in O O
patients O O
with O O
metastatic O O
breast O O
cancer O O

case O O
report O O
: O O
we O O
report O O
a O O
case O O
of O O
acute B-ADR B-ADR
severe I-ADR I-ADR
hepatitis I-ADR I-ADR
resulting O O
from O O
erlotinib B-DRUG B-DRUG
monotherapy O O
in O O
a O O
patient O O
with O O
locally O O
advanced O O
pancreatic O O
cancer O O

severe O O
steroid-induced O O
glaucoma B-ADR B-ADR
following O O
intravitreal O O
injection O O
of O O
triamcinolone O B-DRUG
acetonide O I-DRUG

we O O
report O O
the O O
case O O
of O O
a O O
43-year-old O O
man O O
with O O
itp O O
refractory O O
to O O
steroids O O
and O O
intravenous O O
immunoglobulin O B-DRUG
who O O
developed O O
acute O O
respiratory O O
distress O O
syndrome O O
( O O
ards B-ADR B-ADR
) O O
after O O
a O O
single O O
infusion O O
of O O
rituximab B-DRUG B-DRUG

the O O
patient O O
expired O O
after O O
seven O O
cycles O O
of O O
treatment O O
had O O
been O O
completed O O
because O O
of O O
pulmonary B-ADR O
fibrosis I-ADR O
and O O
the O O
drug O O
toxicity O O
of O O
bleomycin B-DRUG B-DRUG

methadone-induced O O
myoclonus B-ADR B-ADR
in O O
advanced O O
cancer O O

we O O
discuss O O
a O O
patient O O
who O O
developed O O
severe O O
renal O O
tubular O O
dysfunction O O
secondary O O
to O O
short-term O O
therapy O O
with O O
amikacin B-DRUG B-DRUG
, O O
resulting O O
in O O
refractory O O
hypokalemia O O
, O O
hypocalcemia O O
, O O
hypomagnesemia O O
, O O
metabolic B-ADR O
alkalosis I-ADR O
, O O
and O O
polyuria O O

objective O O
: O O
the O O
purpose O O
of O O
this O O
study O O
was O O
to O O
report O O
the O O
concomitant O O
occurrence O O
of O O
multiple O O
squamous O O
cell O O
carcinomas O O
and O O
diffuse B-ADR B-ADR
nail I-ADR I-ADR
hyperpigmentation I-ADR I-ADR
associated O O
with O O
hydroxyurea B-DRUG B-DRUG
treatment O O
, O O
and O O
to O O
describe O O
a O O
successful O O
therapeutic O O
approach O O
using O O
imiquimod O O
5 O O

this O O
case O O
illustrates O O
that O O
the O O
hemophagocytic B-ADR B-ADR
syndrome I-ADR I-ADR
associated O O
with O O
reactivation O O
of O O
ebv O B-DRUG
can O O
occur O O
as O O
part O O
of O O
drug O O
hypersensitivity O O
reactions O O
in O O
ra O O
patients O O
taking O O
sulfasalazine B-DRUG B-DRUG

adverse O O
reaction O O
in O O
a O O
patient O O
with O O
aspirin-induced O O
asthma B-ADR B-ADR
treated O O
with O O
zafirlukast O B-DRUG

it O O
was O O
highly O O
suspected O O
that O O
finasteride B-DRUG B-DRUG
was O O
associated O O
with O O
the O O
anterior B-ADR B-ADR
subcapsular I-ADR I-ADR
opacity I-ADR I-ADR
on I-ADR O
the I-ADR O
lens I-ADR O
, O O
and O O
the O O
patient O O
therefore O O
discontinued O O
use O O
of O O
finasteride B-DRUG B-DRUG

amphotericin B-DRUG B-DRUG
b-induced O O
seizures B-ADR B-ADR
in O O
a O O
patient O O
with O O
aids O O

he O O
had O O
an O O
immediate O O
hypersensitivity O O
reaction O O
during O O
the O O
initiation O O
of O O
the O O
mtx B-DRUG B-DRUG
infusion O O
with O O
diffuse O O
urticaria O O
, O O
facial B-ADR O
swelling I-ADR O
, O O
cough O O
, O O
and O O
chest O O
tightness O O

although O O
both O O
the O O
spontaneous O O
occurrence O O
of O O
sle B-ADR B-ADR
and O O
the O O
psychosis O O
as O O
a O O
sign O O
of O O
cns O O
involvement O O
of O O
sle B-ADR B-ADR
cannot O O
be O O
excluded O O
, O O
sle B-ADR B-ADR
could O O
be O O
considered O O
as O O
an O O
adverse O O
effect O O
of O O
carbamazepine B-DRUG B-DRUG

case O O
summary O O
: O O
a O O
10-year-old O O
white O O
girl O O
with O O
bilateral O O
optic O O
glioma O O
developed O O
a O O
hypersensitivity B-ADR B-ADR
reaction O I-ADR
to O O
carboplatin B-DRUG B-DRUG
after O O
nine O O
courses O O

acute O O
onset O O
of O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
during O O
interferon-alpha B-DRUG B-DRUG
retreatment O O
for O O
chronic O O
active O O
hepatitis O O
c O O

a O O
65-year-old O O
woman O O
with O O
bipolar O O
disorder O O
and O O
complicated O O
cardiovascular O O
disease O O
who O O
was O O
on O O
maintenance O O
lithium O B-DRUG
therapy O O
developed O O
a O O
movement B-ADR B-ADR
disorder I-ADR I-ADR
following O O
high O O
doses O O
of O O
trazodone B-DRUG B-DRUG
for O O
treatment O O
of O O
an O O
acute O O
depression O O

discussion O O
: O O
phenolphthalein B-DRUG B-DRUG
is O O
the O O
active O O
ingredient O O
in O O
several O O
over-the-counter O O
laxative O O
preparations O O
and O O
has O O
only O O
rarely O O
been O O
reported O O
to O O
cause O O
ten B-ADR B-ADR

method O O
: O O
case O O
analysis O O
of O O
a O O
poly-drug O O
overdose O O
( O O
venlafaxine O O
, O O
topiramate O O
, O O
divalproex O O
sodium O O
, O O
risperidone B-DRUG O
, O O
and O O
carbamazepine O O
) O O
presenting O O
with O O
mixed O O
ss O B-ADR
/ O O
nms B-ADR B-ADR
features O O
and O O
whose O O
clinical O O
management O O
suggests O O
a O O
practical O O
algorithm O O
for O O
treatment O O
of O O
undifferentiated O O
ss O B-ADR
/ O O
nms B-ADR B-ADR
in O O
critical O O
care O O
settings O O

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion B-ADR O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O O
jerks O O
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

pancreatitis B-ADR B-ADR
is O O
a O O
very O O
rare O O
adverse O O
effect O O
associated O O
with O O
the O O
use O O
of O O
amiodarone B-DRUG B-DRUG
, O O
and O O
only O O
four O O
cases O O
of O O
amiodarone-induced O O
pancreatitis O B-ADR
have O O
been O O
reported O O
in O O
literature O O

phenytoin B-ADR B-ADR
toxicity I-ADR I-ADR
due O O
to O O
concomitant O O
antituberculosis O O
therapy O O

a O O
toxic O B-ADR
encephalopathy O I-ADR
characterized O O
by O O
depressed O O
level O O
of O O
consciousness O O
, O O
marked O O
irritability O O
, O O
and O O
ataxia B-ADR O
developed O O
in O O
seven O O
children O O
, O O
5 O O
years O O
of O O
age O O
and O O
younger O O
, O O
following O O
administration O O
of O O
an O O
antiemetic O O
combination O O
of O O
pentobarbital O B-DRUG
and O O
pyrilamine B-DRUG B-DRUG
maleate I-DRUG I-DRUG

a O O
case O O
of O O
acute O O
cardiomyopathy O O
and O O
pericarditis B-ADR B-ADR
associated O O
with O O
methylphenidate B-DRUG B-DRUG

the O O
goal O O
of O O
this O O
study O O
is O O
to O O
describe O O
three O O
patients O O
diagnosed O O
with O O
migraine O O
and O O
epilepsy O O
( O O
both O O
under O O
control O O
) O O
who O O
evolved O O
into O O
status B-ADR O
migrainosus I-ADR O
after O O
the O O
introduction O O
of O O
oxcarbazepine O B-DRUG
( O O
oxc O B-DRUG
) O O
, O O
as O O
part O O
of O O
a O O
switch O O
off O O
from O O
carbamazepine O B-DRUG
( O O
cbz B-DRUG B-DRUG

a O O
74-year-old O O
patient O O
with O O
idiopathic O O
parkinson O O
's O O
disease O O
was O O
evaluated O O
for O O
unintended B-ADR O
sleep I-ADR O
episodes I-ADR O
that O O
occurred O O
after O O
long-term O O
treatment O O
with O O
400 O O
mg O O
/ O O
day O O
of O O
l-dopa B-DRUG B-DRUG

case O O
report O O
: O O
we O O
present O O
a O O
case O O
of O O
a O O
28-yr-old O O
male O O
who O O
developed O O
a O O
severe O O
case O O
of O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
while O O
being O O
treated O O
for O O
relapsing O O
/ O O
remitting O O
multiple O O
sclerosis O O
( O O
rrms O O
) O O
with O O
weekly O O
injections O O
of O O
interferon B-DRUG B-DRUG
beta I-DRUG I-DRUG
1a I-DRUG I-DRUG

the O O
increasing O O
prevalence O O
of O O
methamphetamine B-DRUG B-DRUG
abuse O O
and O O
the O O
severity O O
of O O
the O O
associated O O
ulcers O O
should O O
alert O O
ophthalmologists O O
to O O
the O O
problem O O
of O O
methamphetamine-related O O
keratitis B-ADR B-ADR

interferon-induced O O
psychosis B-ADR B-ADR
as O O
a O O
" O O
psychiatric O O
contraindication O O
" O O
to O O
hepatitis O O
c O O
treatment O O
: O O
a O O
review O O
and O O
case-based O O
discussion O O

however O O
, O O
the O O
occurrence O O
and O O
management O O
of O O
akathisia B-ADR B-ADR
induced O O
by O O
fluvoxamine B-DRUG B-DRUG
have O O
not O O
been O O
described O O

docetaxel B-DRUG B-DRUG
induced O O
meibomian B-ADR B-DRUG
duct I-ADR O
inflammation I-ADR O
and I-ADR O
blockage I-ADR O
is O O
the O O
likely O O
cause O O
of O O
this O O
presentation O O
in O O
a O O
patient O O
with O O
no O O
history O O
of O O
eyelid O O
masses O O
in O O
the O O
past O O

a O O
25-year-old O O
woman O O
sought O O
medical O O
attention O O
because O O
of O O
iliocaval O O
manifestations O O
of O O
retroperitoneal B-ADR B-ADR
fibrosis I-ADR I-ADR
while O O
she O O
was O O
taking O O
methysergide B-DRUG B-DRUG

three O O
days O O
after O O
intravitreal O O
injection O O
of O O
bevacizumab B-DRUG B-DRUG
, O O
acute B-ADR B-ADR
ocular I-ADR I-ADR
ischemic I-ADR I-ADR
syndrome I-ADR I-ADR
occurred O O

escape O O
atrial O O
complexes O O
, O O
which O O
occurred O O
following O O
junctional O O
premature O O
complexes O O
, O O
failed O O
to O O
initiate O O
tachycardia B-ADR B-ADR
in O O
the O O
control O O
state O O
but O O
tachycardia B-ADR B-ADR
was O O
always O O
reinitiated O O
by O O
an O O
identical O O
escape O O
sequence O O
after O O
procainamide B-DRUG B-DRUG

amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
nephrotoxicity B-ADR B-ADR
in O O
humans O O
decreased O O
by O O
salt O O
repletion O O

case O O
summary O O
: O O
a O O
46-year-old O O
african-american O O
man O O
experienced O O
recurrent O B-ADR
grand B-ADR I-ADR
mal I-ADR I-ADR
seizures I-ADR I-ADR
during O O
intravenous O O
infusion O O
of O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
, O O
then O O
petit O O
mal O O
seizures O O
as O O
the O O
infusion O O
was O O
stopped O O
and O O
the O O
drug O O
concentrations O O
decreased O O
with O O
time O O

leishmania B-ADR B-ADR
infantum I-ADR I-ADR
leishmaniasis I-ADR I-ADR
in O O
corticosteroid B-DRUG B-DRUG
-- O O
treated O O
patients O O

we O O
describe O O
a O O
patient O O
with O O
m4 O O
aml O O
treated O O
with O O
standard O O
chemotherapy O O
followed O O
by O O
g-csf B-DRUG B-DRUG
who O O
developed O O
marked O O
monocytosis B-ADR B-ADR
on O O
day O O
8 O O
of O O
g-csf B-DRUG B-DRUG
therapy O O

lithium-associated O O
transient B-ADR B-ADR
thyrotoxicosis I-ADR I-ADR
in O O
4 O O
chinese O O
women O O
with O O
autoimmune O O
thyroiditis O O

three O O
diabetic O O
cases O O
of O O
acute B-ADR B-ADR
dizziness I-ADR I-ADR
due O O
to O O
initial O O
administration O O
of O O
voglibose B-DRUG B-DRUG

these O O
two O O
cases O O
highlight O O
the O O
importance O O
of O O
considering O O
lopinavir B-DRUG O
/ O O
ritonavir O B-DRUG
induced O O
arrhythmias B-ADR B-ADR
when O O
dealing O O
with O O
hiv-positive O O
individuals O O

the O O
possible O O
development O O
of O O
a O O
drug-induced O O
vasculitis B-ADR O
or O O
lupus-like O O
syndrome O O
should O O
be O O
added O O
to O O
the O O
list O O
of O O
rare O O
toxic O O
effects O O
of O O
vancomycin B-DRUG B-DRUG

nephropathy B-ADR B-ADR
caused O O
by O O
methicillin B-DRUG B-DRUG
therapy O O
for O O
staphylococcal O O
septicemia O O

lower O B-ADR
extremity O I-ADR
arterial B-ADR I-ADR
thrombosis I-ADR I-ADR
following O O
sonographically O O
guided O O
thrombin B-DRUG B-DRUG
injection O O
of O O
a O O
femoral O O
pseudoaneurysm O O

cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
to O O
propylthiouracil B-DRUG B-DRUG
and O O
methimazole O B-DRUG
occur O O
in O O
3 O O
%- O O
5 O O
% O O
of O O
adults O O

disopyramide-induced O O
heart B-ADR B-ADR
block I-ADR I-ADR

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic B-ADR O
jerks I-ADR O
and O O
unsteady O O
gait O O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

a O O
case O O
is O O
reported O O
of O O
theophylline B-ADR B-ADR
intoxication I-ADR I-ADR
due O O
to O O
a O O
dramatic O O
decrease O O
in O O
theophylline O B-DRUG
clearance O O
following O O
concomitant O O
administration O O
of O O
viloxazine B-DRUG B-DRUG

clostridium B-ADR O
difficile I-ADR O
toxin-induced I-ADR O
colitis I-ADR B-ADR
after O O
use O O
of O O
clindamycin B-DRUG B-DRUG
phosphate I-DRUG I-DRUG
vaginal O O
cream O O

three O O
of O O
these O O
patients O O
had O O
convulsions O B-ADR
attributed O O
to O O
imipenem B-DRUG B-DRUG
/ O O
cilastatin O B-DRUG
; O O
3.6 O O
% O O
of O O
the O O
patients O O
had O O
seizure B-ADR B-ADR
, O O
or O O
2 O O
% O O
of O O
imipenem B-DRUG O
/ O O
cilastatin O B-DRUG
administrations O O
was O O
followed O O
by O O
a O O
seizure B-ADR O
attack O O

retinopathy B-ADR B-ADR
in O O
hepatitis O O
c O O
patients O O
due O O
to O O
combination O O
therapy O O
with O O
pegylated B-DRUG B-DRUG
interferon I-DRUG I-DRUG
and O O
ribavirin O B-DRUG

with O O
the O O
first O O
cyclosporine B-DRUG B-DRUG
dose O O
, O O
the O O
patient O O
complained O O
of O O
leg B-ADR O
pain I-ADR O
that O O
was O O
most O O
severe O O
during O O
the O O
cyclosporine B-DRUG B-DRUG
infusion O O

we O O
report O O
on O O
a O O
patient O O
with O O
acromegaly O O
who O O
developed O O
severe O O
drug-induced O O
hepatitis B-ADR B-ADR
during O O
combined O O
treatment O O
with O O
the O O
long-acting O O
somatostatin-analog O O
octreotide B-DRUG B-DRUG
and O O
the O O
gh O O
receptor O O
antagonist O O
pegvisomant O B-DRUG

myoglobinuria B-ADR O
and O O
acute O O
renal O O
failure O O
were O O
observed O O
in O O
two O O
patients O O
with O O
vasopressin-treated O O
gastrointestinal O B-ADR
hemorrhage O I-ADR

a O O
patient O O
developed O O
optic B-ADR B-ADR
neuropathy I-ADR I-ADR
while O O
being O O
treated O O
with O O
isoniazid B-DRUG B-DRUG
and O O
ethambutol O B-DRUG

to O O
our O O
knowledge O O
, O O
the O O
syndrome O O
of O O
fever O O
, O O
pulmonary B-ADR O
infiltrates I-ADR O
, O O
and O O
pleural O B-ADR
effusion O I-ADR
following O O
use O O
of O O
acyclovir B-DRUG B-DRUG
has O O
not O O
been O O
previously O O
reported O O

metformin-associated O O
lactic B-ADR B-ADR
acidosis I-ADR I-ADR
( O O
mala O O
) O O
is O O
a O O
serious O O
metabolic O O
complication O O
that O O
occurs O O
because O O
of O O
metformin O B-DRUG
accumulation O O
in O O
patients O O
who O O
become O O
dehydrated O O
or O O
developed O O
acute O B-ADR
renal O I-ADR
failure O I-ADR

seizures O O
and O O
extrapyramidal B-ADR O
symptoms I-ADR O
in O O
a O O
patient O O
with O O
tourette O O
's O O
syndrome O O
, O O
asperger O O
's O O
syndrome O O
, O O
and O O
multiple O O
sclerosis O O
treated O O
with O O
interferon O B-DRUG
beta-1a O I-DRUG
and O O
clomipramine B-DRUG B-DRUG

context O O
: O O
previous O O
investigators O O
have O O
reported O O
discrepancies B-ADR O
between I-ADR O
hematologic I-ADR O
, I-ADR O
marrow I-ADR O
morphologic I-ADR O
, I-ADR O
and I-ADR O
cytogenetic I-ADR O
responses I-ADR O
to O O
imatinib B-DRUG B-DRUG
mesylate I-DRUG I-DRUG
among O O
patients O O
with O O
chronic O O
myeloid O O
leukemia O O
( O O
cml O O

objective O O
: O O
to O O
describe O O
a O O
case O O
of O O
exacerbated O O
mania B-ADR B-ADR
potentially O O
related O O
to O O
an O O
interaction O O
between O O
lopinavir O O
/ O O
ritonavir O O
and O O
valproic B-DRUG O
acid I-DRUG O
( O O
vpa O B-DRUG
) O O
and O O
propose O O
a O O
mechanism O O
of O O
action O O
for O O
this O O
interaction O O

we O O
report O O
on O O
three O O
observations O O
of O O
parkinsonian O O
patients O O
with O O
levo-dopa-induced O O
diphasic B-ADR O
dyskinesias I-ADR O
, O O
who O O
received O O
subcutaneous O O
apomorphine O B-DRUG
to O O
reduce O O
the O O
duration O O
of O O
abnormal O O
movements O O

abnormalities B-ADR O
of I-ADR O
the I-ADR O
pupil I-ADR O
and O O
visual-evoked O O
potential O O
in O O
quinine B-DRUG B-DRUG
amblyopia O O

we O O
report O O
on O O
a O O
patient O O
with O O
acromegaly O O
who O O
developed O O
severe O O
drug-induced O O
hepatitis B-ADR B-ADR
during O O
combined O O
treatment O O
with O O
the O O
long-acting O O
somatostatin-analog O O
octreotide O B-DRUG
and O O
the O O
gh O O
receptor O O
antagonist O O
pegvisomant B-DRUG B-DRUG

this O O
case O O
report O O
describes O O
a O O
patient O O
who O O
was O O
previously O O
prescribed O O
alendronate B-DRUG B-DRUG
( O O
fosamax O B-DRUG
) O O
and O O
presented O O
with O O
postoperative O O
hypophosphatemia B-ADR O
and O O
hypocalcemic O B-ADR
tetany O I-ADR
after O O
bowel O O
preparation O O
with O O
fleet O B-DRUG
phospho-soda O I-DRUG

ritonavir B-DRUG B-DRUG
should O O
be O O
added O O
to O O
the O O
list O O
of O O
drugs O O
that O O
can O O
induce O O
adverse B-ADR O
cutaneous I-ADR O
reactions I-ADR O
in O O
hiv O O
patients O O

objective O O
: O O
to O O
evaluate O O
the O O
efficacy O O
of O O
the O O
administration O O
of O O
insulin O B-DRUG
by O O
a O O
jet-injector O O
device O O
in O O
stopping O O
and O O
reversing O O
severe O O
human B-DRUG O
insulin-induced O O
lipoatrophy B-ADR B-ADR

oxcarbazepine-induced O O
drug O O
reaction O O
with O O
eosinophilia O O
and O O
systemic O O
symptoms O O
( O O
dress B-ADR B-ADR

although O O
various O O
manifestations O O
of O O
pentamidine-induced O O
cardiotoxicity O B-ADR
have O O
been O O
reported O O
, O O
to O O
our O O
knowledge O O
, O O
second-degree B-ADR O
heart I-ADR O
block I-ADR O
associated O O
with O O
this O O
agent O O
has O O
not O O
been O O
described O O

previous O O
studies O O
have O O
demonstrated O O
the O O
interaction O O
of O O
mtx B-DRUG B-DRUG
and O O
a O O
variety O O
of O O
non-steroidal O O
, O O
anti-inflammatory O O
drugs O O
( O O
nsaids O O
) O O
with O O
various O O
clinical O O
manifestations O O
including O O
acute O O
renal O O
failure O O
, O O
pancytopenia O O
, O O
vomiting O O
, O O
diarrhea B-ADR O
, O O
elevated O O
liver O O
transaminases O O
, O O
jaundice O O
, O O
mucosal O O
ulcerations O O
, O O
and O O
pyrexia O O

a O O
14-year-old O O
female O O
developed O O
systemic O O
lupus O O
erythematosus O O
( O O
sle O O
)- O O
like O O
symptoms O O
, O O
rash O O
, O O
fever O O
, O O
leukopenia O O
and O O
positive B-ADR O
anti-nuclear I-ADR O
antibody I-ADR O
( O O
ana O O
) O O
two O O
weeks O O
after O O
administration O O
of O O
carbamazepine B-DRUG B-DRUG
( O O
cbz O B-DRUG
; O O
tegretol O O
) O O
used O O
against O O
benign O O
rolandic O O
epilepsy O O

adverse O O
effects O O
of O O
amiodarone B-DRUG B-DRUG
including O O
pulmonary O O
toxicity O O
, O O
hepatotoxicity B-ADR O
, O O
aggravation O O
of O O
arrhythmia O O
, O O
and O O
thyroid O O
diseases O O
are O O
well O O
understood O O

a O O
dapsone B-DRUG B-DRUG
hypersensitivity O O
syndrome O O
, O O
consisting O O
of O O
fever O O
, O O
headache B-ADR O
, O O
nausea O O
, O O
vomiting O O
, O O
lymphadenopathy O O
, O O
hepatitis O O
, O O
hemolysis O O
, O O
leukopenia O O
, O O
and O O
mononucleosis O O
, O O
has O O
been O O
described O O
in O O
patients O O
treated O O
with O O
the O O
drug O O
for O O
leprosy O O

although O O
transient O O
increases O O
in O O
ectopy O O
after O O
bretylium B-DRUG B-DRUG
therapy O O
have O O
been O O
described O O
, O O
presumably O O
due O O
to O O
catecholamine O B-DRUG
release O O
, O O
the O O
occurrence O O
of O O
life-threatening O B-ADR
ventricular B-ADR I-ADR
arrhythmia I-ADR I-ADR
leading O O
to O O
cardiac O O
arrest O O
has O O
not O O
previously O O
been O O
emphasized O O

objective O O
: O O
to O O
describe O O
a O O
case O O
of O O
thrombocytopenia B-ADR B-ADR
associated O O
with O O
the O O
administration O O
of O O
lansoprazole B-DRUG B-DRUG

itch O B-ADR
and O O
skin B-ADR O
rash I-ADR O
from O O
chocolate O O
during O O
fluoxetine B-DRUG B-DRUG
and O O
sertraline O B-DRUG
treatment O O
: O O
case O O
report O O

six O O
patients O O
with O O
no O O
previous O O
signs O O
or O O
symptoms O O
suggestive O O
of O O
coronary O O
artery O O
disease O O
developed O O
acute B-ADR O
coronary I-ADR O
ischemia I-ADR O
/ O O
infarction O O
shortly O O
after O O
cis-diamine-dichloroplatinum B-DRUG B-DRUG
ii I-DRUG O
( O O
cisplatin O B-DRUG
) O O
- O O
based O O
chemotherapy O O

sagittal O B-ADR
sinus O I-ADR
thrombosis O I-ADR
associated O O
with O O
transient B-ADR O
free I-ADR O
protein I-ADR O
s I-ADR O
deficiency I-ADR O
after O O
l-asparaginase B-DRUG B-DRUG
treatment O O
: O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

scleritis B-ADR B-ADR
complicating O O
zoledronic B-DRUG B-DRUG
acid I-DRUG I-DRUG
infusion O O

two O O
cases O O
of O O
childhood-onset O O
schizophrenia O B-ADR
associated O O
with O O
clozapine-induced O O
akathisia B-ADR B-ADR
responsive O O
to O O
beta-blocker O B-DRUG
treatment O O
are O O
described O O

however O O
, O O
other O O
factors O O
or O O
drugs O O
( O O
e.g. O O
cresol B-DRUG O
) O O
are O O
thought O O
to O O
induce O O
mh B-ADR B-ADR

the O O
patient O O
was O O
enrolled O O
in O O
a O O
weight-loss O O
clinic O O
, O O
and O O
his O O
diabetes O O
medications O O
were O O
adjusted.subsequently O O
, O O
olanzapine B-DRUG B-DRUG
was O O
discontinued O O
because O O
of O O
weight O O
gain O O
and O O
uncontrolled B-ADR O
diabetes I-ADR O

in O O
the O O
second O O
case O O
, O O
five O O
cardiac O O
arrests O O
due O O
to O O
ventricular O O
tachycardia O O
and O O
fibrillation B-ADR B-ADR
occurred O O
during O O
several O O
hours O O
after O O
beginning O O
a O O
trial O O
of O O
bretylium B-DRUG B-DRUG
maintenance O O
therapy O O
for O O
complex O O
ventricular O O
ectopy O O

we O O
have O O
recently O O
encountered O O
a O O
patient O O
with O O
acquired O O
haemophilia O O
who O O
developed O O
a O O
thrombotic B-ADR O
left I-ADR O
middle I-ADR O
cerebral I-ADR O
artery I-ADR O
distribution I-ADR O
stroke I-ADR O
while O O
being O O
treated O O
with O O
pfviii B-DRUG B-DRUG

the O O
role O O
of O O
adriamycin B-DRUG B-DRUG
in O O
the O O
production O O
of O O
cardiotoxicity B-ADR B-ADR
is O O
reviewed O O

tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
after O O
transcatheter O O
arterial O O
infusion O O
of O O
cisplatin B-DRUG B-DRUG
and O O
embolization O O
therapy O O
for O O
liver O O
metastases O O
of O O
melanoma O O

second O O
, O O
we O O
report O O
a O O
case O O
of O O
neutropenia B-ADR B-ADR
, O O
which O O
proved O O
to O O
be O O
fatal O O
in O O
a O O
schizophrenia O O
patient O O
receiving O O
olanzapine O B-DRUG
and O O
thiazide B-DRUG B-DRUG

we O O
present O O
a O O
case O O
of O O
significant O O
over-anticoagulation B-ADR O
temporally O O
associated O O
with O O
a O O
bout O O
of O O
protracted O O
diarrhea O B-ADR
in O O
a O O
patient O O
on O O
warfarin B-DRUG B-DRUG
therapy O O

acute O B-ADR
vision O I-ADR
loss O I-ADR
after O O
intravitreal O O
injection O O
of O O
bevacizumab O B-DRUG
( O O
avastin B-DRUG B-DRUG
) O O
associated O O
with O O
ocular B-ADR B-ADR
ischemic I-ADR I-ADR
syndrome I-ADR I-ADR

possible O O
heart B-ADR B-ADR
failure I-ADR I-ADR
exacerbation I-ADR I-ADR
associated O O
with O O
rosiglitazone B-DRUG B-DRUG
: O O
case O O
report O O
and O O
literature O O
review O O

the O O
patient O O
had O O
recurrence O O
of O O
urticaria O O
and O O
angioedema B-ADR B-ADR
a O O
year O O
and O O
a O O
half O O
later O O
, O O
at O O
which O O
point O O
the O O
nph O B-DRUG
was O O
stopped O O
and O O
she O O
was O O
desensitized O O
to O O
regular O O
insulin B-DRUG B-DRUG

bilateral B-ADR B-ADR
anterior I-ADR I-ADR
uveitis I-ADR I-ADR
associated O O
with O O
clomiphene B-DRUG B-DRUG
citrate I-DRUG I-DRUG

although O O
his O O
renal O O
function O O
recovered O O
completely O O
with O O
high-dose O O
leucovorin O B-DRUG
, O O
hemodialysis O O
, O O
charcoal O O
hemoperfusion O O
, O O
and O O
carboxypeptidase O O
g2 O O
, O O
we O O
present O O
this O O
case O O
to O O
emphasize O O
that O O
signs O O
of O O
renal B-ADR B-ADR
toxicity I-ADR I-ADR
may O O
be O O
present O O
as O O
early O O
as O O
2 O O
hours O O
after O O
the O O
completion O O
of O O
a O O
4-hour O O
mtx B-DRUG B-DRUG
infusion O O
, O O
and O O
to O O
suggest O O
that O O
monitoring O O
for O O
mtx B-DRUG B-DRUG
toxicity O O
should O O
perhaps O O
begin O O
within O O
a O O
few O O
hours O O
after O O
the O O
completion O O
of O O
4-hour O O
mtx B-DRUG B-DRUG
infusion O O

conclusion O O
: O O
hypersensitivity O O
reaction O O
should O O
be O O
considered O O
in O O
patients O O
who O O
develop O O
recurrent B-ADR O
eosinophilia I-ADR O
and O O
deterioration O O
of O O
pulmonary O O
function O O
following O O
the O O
use O O
of O O
tobramycin B-DRUG B-DRUG
by O O
inhalation O O
or O O
by O O
intravenous O O
administration O O

we O O
report O O
4 O O
patients O O
, O O
2 O O
on O O
methylphenidate B-DRUG B-DRUG
and O O
2 O O
on O O
dextroamphetamine O B-DRUG
who O O
presented O O
with O O
acral B-ADR O
cyanosis I-ADR O
, O O
livedo O O
reticularis O O
, O O
or O O
raynaud O O
phenomenon O O

a O O
47 O O
year-old O O
woman O O
who O O
had O O
a O O
4-year O O
history O O
of O O
intramuscular O O
pentazocine B-DRUG B-DRUG
injections O O
in O O
the O O
lower O O
extremities O O
, O O
developed O O
gradual O O
stiffness O O
and O O
weakness B-ADR O
of I-ADR O
the I-ADR O
lower I-ADR O
extremities I-ADR O

an O O
8-year-old O O
child O O
with O O
familial O O
mediterranean O O
fever O O
exhibited O O
signs O O
of O O
colchicine B-ADR B-ADR
intoxication I-ADR I-ADR
while O O
receiving O O
prophylactic O O
doses O O
of O O
the O O
drug O O

the O O
frequency O O
and O O
relationship O O
of O O
granulocytopenia B-ADR B-ADR
caused O O
by O O
sustained-release O O
procainamide B-DRUG B-DRUG
in O O
patients O O
with O O
tachyarrhythmias O O
are O O
briefly O O
discussed O O
, O O
and O O
prior O O
reported O O
cases O O
are O O
reviewed O O

both O O
had O O
impaired O O
lung O O
function O O
and O O
abnormal B-ADR O
computed I-ADR O
tomographic I-ADR O
scans I-ADR O
, O O
and O O
their O O
condition O O
improved O O
when O O
nitrofurantoin B-DRUG B-DRUG
was O O
withdrawn O O
and O O
corticosteroid O O
treatment O O
commenced O O

hyperkalaemia B-ADR B-ADR
with O O
renal O O
tubular O O
dysfunction O O
by O O
sulfamethoxazole-trimethoprim B-DRUG B-DRUG
for O O
pneumocystis O O
carinii O O
pneumonia O O
in O O
patients O O
with O O
lymphoid O O
malignancy O O

it O O
is O O
hoped O O
that O O
this O O
case O O
report O O
creates O O
awareness O O
that O O
ofloxacin-induced O O
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
is O O
possible O O

anaphylaxis B-ADR B-ADR
to O O
calcitonin B-DRUG B-DRUG

a O O
79-year-old O O
man O O
with O O
ischemic O O
heart O O
disease O O
, O O
chronic O O
atrial O O
fibrillation O O
, O O
chronic O O
renal O O
failure O O
, O O
hypothyroidism O O
, O O
and O O
gout O O
arthritis O O
was O O
hospitalized O O
because O O
of O O
fatigue B-ADR O
, O O
myalgia O O
, O O
and O O
leg O O
weakness O O
, O O
shortly O O
after O O
starting O O
treatment O O
with O O
colchicine B-DRUG B-DRUG

intravenous O O
verapamil B-DRUG B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension O O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden B-ADR O
death I-ADR O
; O O
quinidine O B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

the O O
development O O
of O O
an O O
igg B-ADR O
lambda-type I-ADR O
monoclonal I-ADR O
gammopathy I-ADR O
and O O
subsequent O O
multiple O B-ADR
myeloma O I-ADR
in O O
an O O
epilepsy O O
patient O O
on O O
diphenylhydantoin B-DRUG B-DRUG
( O O
dilantin O B-DRUG
) O O
therapy O O
for O O
20 O O
years O O
is O O
reported O O

we O O
report O O
a O O
case O O
of O O
interstitial B-ADR O
pulmonary I-ADR O
disease I-ADR O
that O O
occurred O O
together O O
with O O
lymphocytic O B-ADR
colitis O I-ADR
during O O
treatment O O
with O O
ticlopidine B-DRUG B-DRUG

we O O
describe O O
two O O
cases O O
that O O
illustrate O O
the O O
use O O
of O O
lithium B-DRUG B-DRUG
in O O
the O O
treatment O O
of O O
veterans O O
with O O
ptsd O O
who O O
complained O O
of O O
serious O O
problems O O
with O O
irritability O O
or O O
angry B-ADR O
outbursts I-ADR O

methimazole-induced O O
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
in O O
third O O
exposure O O
: O O
successful O O
treatment O O
with O O
recombinant O O
human O O
granulocyte O O
colony-stimulating O O
factor O O

we O O
describe O O
the O O
exceptional O O
development O O
of O O
aml O B-ADR
and O O
lung B-ADR O
cancer I-ADR O
in O O
a O O
patient O O
with O O
previously O O
diagnosed O O
cll O O
in O O
minimal O O
residual O O
disease O O
status O O
after O O
fludarabine B-DRUG B-DRUG
treatment O O
followed O O
by O O
autologous O O
peripheral O O
blood O O
stem-cell O O
transplantation O O

a O O
second O O
episode O O
of O O
jaundice B-ADR B-ADR
followed O O
the O O
intravaginal O O
administration O O
of O O
a O O
mixture O O
of O O
furazolidone O B-DRUG
and O O
nifuroxime B-DRUG B-DRUG

case O O
report O O
of O O
withdrawal O B-ADR
dyskinesia B-ADR I-ADR
associated O O
with O O
amoxapine B-DRUG B-DRUG

albuterol-induced O O
hypokalemia B-ADR B-ADR
and O O
its O O
potential O O
cardiac O B-ADR
toxicity O I-ADR
are O O
discussed O O
briefly O O

we O O
describe O O
the O O
development O O
of O O
ischemic B-ADR B-ADR
colitis I-ADR I-ADR
in O O
a O O
woman O O
who O O
was O O
treated O O
with O O
tegaserod B-DRUG B-DRUG
and O O
review O O
the O O
relationship O O
among O O
ischemic B-ADR O
colitis I-ADR O
, O O
tegaserod B-DRUG B-DRUG
use O O
, O O
and O O
irritable O O
bowel O O
syndrome O O

we O O
report O O
a O O
case O O
of O O
graves' B-ADR B-ADR
hyperthyroidism I-ADR I-ADR
induced O O
by O O
long-term O O
interferon B-DRUG O
( O O
ifn O B-DRUG
) O O
therapy O O

central O O
nervous O O
system O O
effects O O
secondary O O
to O O
ciprofloxacin B-DRUG B-DRUG
treatment O O
are O O
uncommon O O
and O O
usually O O
consist O O
only O O
of O O
minor O O
dizziness O O
or O O
mild B-ADR O
headache I-ADR O
, O O
although O O
rare O O
occurrences O O
of O O
seizures O O
and O O
hallucinations O O
have O O
been O O
reported O O

results O O
: O O
a O O
clinical O O
diagnosis O O
of O O
fixed B-ADR B-ADR
drug I-ADR I-ADR
eruption I-ADR I-ADR
owing O O
to O O
use O O
of O O
the O O
pde5 O O
inhibitor O O
tadalafil O B-DRUG
( O O
cialis B-DRUG B-DRUG
) O O
was O O
made O O

olanzapine-induced O O
hyperglycaemic O B-ADR
coma O I-ADR
and O O
neuroleptic B-ADR O
malignant I-ADR O
syndrome I-ADR O
: O O
case O O
report O O
and O O
review O O
of O O
literature O O

our O O
series O O
of O O
3 O O
patients O O
supports O O
a O O
causal O O
connection O O
between O O
bleomycin B-DRUG B-DRUG
and O O
scleroderma B-ADR O

persistent B-ADR B-ADR
light I-ADR I-ADR
reactivity I-ADR I-ADR
from O O
systemic O O
quinine B-DRUG B-DRUG

sotalol-induced O O
bradycardia B-ADR B-ADR
reversed O O
by O O
glucagon O B-DRUG

this O O
is O O
the O O
first O O
description O O
, O O
to O O
our O O
knowledge O O
, O O
of O O
ductopenia B-ADR B-ADR
apparently O O
caused O O
by O O
clindamycin B-DRUG B-DRUG

though O O
hypotension B-ADR O
, O O
dry O O
mouth O O
, O O
and O O
constipation O O
are O O
well-documented O O
possible O O
adverse O O
effects O O
, O O
the O O
possibility O O
of O O
clonidine-induced O O
bradycardia O B-ADR
is O O
less O O
well O O
recognized O O
and O O
is O O
rare O O

a O O
patient O O
with O O
ulcerative O O
colitis O O
developed O O
skin B-ADR O
pigmentation I-ADR O
and O O
diffuse O O
pulmonary O O
shadowing O O
without O O
respiratory O O
symptomatology O O
, O O
while O O
taking O O
sulfasalazine B-DRUG B-DRUG

conclusions O O
: O O
this O O
report O O
indicates O O
clindamycin B-DRUG B-DRUG
phosphate I-DRUG I-DRUG
vaginal O O
cream O O
as O O
the O O
most O O
probable O O
cause O O
of O O
cdic B-ADR B-ADR
due O O
to O O
the O O
temporal O O
relationship O O
between O O
the O O
occurrence O O
of O O
diarrhea O O
and O O
clindamycin O B-DRUG
administration O O
, O O
lack O O
of O O
concomitant O O
medications O O
, O O
and O O
documentation O O
of O O
c. O O
difficile O O
toxin O O

agranulocytosis B-ADR B-ADR
induced O O
by O O
vancomycin B-DRUG B-DRUG
in O O
an O O
esrd O O
patient O O
on O O
capd O B-DRUG

background O O
: O O
methotrexate B-DRUG B-DRUG
( O O
mtx O B-DRUG
) O O
may O O
induce O O
liver O O
damage O O
, O O
which O O
in O O
some O O
psoriatics O O
will O O
lead O O
to O O
fibrosis B-ADR B-ADR
or O O
cirrhosis O B-ADR

we O O
report O O
a O O
case O O
of O O
reversible O O
dka B-ADR O
and O O
new-onset O O
dm O O
that O O
developed O O
in O O
a O O
demented O O
patient O O
who O O
was O O
treated O O
with O O
quetiapine B-DRUG B-DRUG
for O O
14 O O
days O O

approximately O O
15 O O
min O O
after O O
the O O
first O O
administration O O
of O O
nebulised O O
morphine B-DRUG B-DRUG
the O O
patient O O
became O O
markedly O O
bradypneic B-ADR O
( O O
respiratory O O
rate O O
: O O
4-5 O O
bpm O O
) O O
, O O
hypotensive O O
( O O
bp O O
70 O O
/ O O
40 O O
mmhg O O
) O O
, O O
and O O
responded O O
only O O
partially O O
to O O
command O O

acute B-ADR B-ADR
non-lymphocytic I-ADR I-ADR
leukemia I-ADR I-ADR
in O O
patients O O
with O O
ovarian O O
carcinoma O O
following O O
long-term O O
treatment O O
with O O
treosulfan O B-DRUG
(= O O
dihydroxybusulfan B-DRUG B-DRUG

we O O
report O O
five O O
cases O O
of O O
restless O O
legs O O
syndrome O O
( O O
rls O O
) O O
and O O
periodic B-ADR O
limb I-ADR O
movements I-ADR O
during I-ADR O
sleep I-ADR O
( O O
plms O O
) O O
that O O
were O O
probably O O
associated O O
with O O
olanzapine B-DRUG B-DRUG

the O O
potential O O
development O O
of O O
sjs O O
/ O O
ten B-ADR O
, O O
a O O
severe O O
life-threatening O O
illness O O
, O O
emphasizes O O
the O O
need O O
for O O
judicious O O
use O O
of O O
tmp-sx B-DRUG B-DRUG
and O O
close O O
monitoring O O
and O O
follow-up O O
for O O
patients O O
who O O
were O O
given O O
tmp-sx B-DRUG B-DRUG
for O O
sstis O O

most O O
cases O O
of O O
pancreatitis B-ADR B-ADR
associated O O
with O O
l-asparaginase B-DRUG B-DRUG
toxicity O O
are O O
self-limiting O O
and O O
respond O O
favorably O O
to O O
nasogastric O B-ADR
decompression O I-ADR
and O O
intravenous O O
hyperalimentation O O

their O O
parkinsonism B-ADR B-ADR
improved O O
on O O
discontinuation O O
of O O
metoclopramide B-DRUG B-DRUG
therapy O O

physicians O O
should O O
be O O
aware O O
of O O
the O O
potentially O O
lethal B-ADR O
side O O
effects O O
of O O
dapsone B-DRUG B-DRUG

we O O
report O O
the O O
case O O
histories O O
of O O
identical O O
twin O O
brothers O O
who O O
developed O O
concordant O O
acute O O
lymphoblastic O O
leukemia O O
at O O
the O O
age O O
of O O
4 O O
years O O
and O O
who O O
later O O
developed O O
leukoencephalopathy O B-ADR
and O O
hydrocephalus B-ADR O
related O O
to O O
central O O
nervous O O
system O O
prophylaxis O O
by O O
, O O
in O O
the O O
first O O
case O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
, O O
in O O
the O O
second O O
by O O
intrathecally O O
administered O O
methotrexate B-DRUG B-DRUG
and O O
cranial O O
irradiation O O

rapamycin B-DRUG O
/ O O
sirolimus O B-DRUG
( O O
sr O O
) O O
, O O
trade O O
named O O
rapammune O O
( O O
wyeth-ayerst O O
, O O
sydney O O
, O O
australia O O
) O O
, O O
is O O
a O O
potent O O
immunosuppressive O O
drug O O
associated O O
with O O
myelosuppression B-ADR O
, O O
hypertension O O
, O O
hyperlipidemia O O
, O O
and O O
infection O O

however O O
, O O
dermatologists O O
should O O
be O O
cautious O O
about O O
a O O
photosensitivity B-ADR B-ADR
reaction O I-ADR
induced O O
by O O
mequitazine B-DRUG B-DRUG
or O O
other O O
phenothiazine-derivative O O
drugs O O

we O O
experienced O O
a O O
case O O
of O O
chronic O O
renal O O
failure O O
in O O
a O O
patient O O
suffering O O
from O O
acute O B-ADR
hemorrhagic O I-ADR
gastritis O I-ADR
associated O O
with O O
az B-ADR B-ADR
intoxication I-ADR I-ADR

the O O
day O O
after O O
clozapine B-DRUG B-DRUG
was O O
stopped O O
, O O
while O O
he O O
was O O
still O O
receiving O O
clomipramine O B-DRUG
150 O O
mg O O
/ O O
d O O
, O O
he O O
began O O
behaving O O
oddly O O
, O O
started O O
sweating O O
profusely O O
, O O
shivering O O
, O O
and O O
became O O
tremulous O O
, O O
agitated B-ADR O
, O O
and O O
confused O O

in O O
summary O O
, O O
we O O
report O O
herein O O
the O O
first O O
case O O
of O O
siadh B-ADR B-ADR
believed O O
to O O
be O O
an O O
adverse O O
effect O O
of O O
mizoribin B-DRUG B-DRUG
, O O
which O O
may O O
therefore O O
needed O O
to O O
be O O
added O O
to O O
the O O
list O O
of O O
drugs O O
which O O
can O O
induce O O
siadh B-ADR B-ADR

cyclophosphamide B-DRUG B-DRUG
can O O
rarely O O
cause O O
interstitial B-ADR O
pneumonitis I-ADR O
and O O
fibrosis O B-ADR

this O O
case O O
report O O
describes O O
a O O
patient O O
who O O
was O O
previously O O
prescribed O O
alendronate O B-DRUG
( O O
fosamax O B-DRUG
) O O
and O O
presented O O
with O O
postoperative O O
hypophosphatemia O O
and O O
hypocalcemic B-ADR B-ADR
tetany I-ADR I-ADR
after O O
bowel O O
preparation O O
with O O
fleet B-DRUG B-DRUG
phospho-soda I-DRUG I-DRUG

ceftriaxone O B-DRUG
was O O
approved O O
in O O
1997 O O
for O O
the O O
treatment O O
of O O
otitis O O
media O O
despite O O
previous O O
studies O O
that O O
documented O O
an O O
association O O
of O O
ceftriaxone B-DRUG B-DRUG
with O O
elevated O O
hepato-biliary O O
enzymes O O
and O O
transient B-ADR B-ADR
biliary I-ADR I-ADR
stasis I-ADR I-ADR

six O O
patients O O
with O O
no O O
previous O O
signs O O
or O O
symptoms O O
suggestive O O
of O O
coronary O O
artery O O
disease O O
developed O O
acute O O
coronary O O
ischemia O O
/ O O
infarction B-ADR O
shortly O O
after O O
cis-diamine-dichloroplatinum O B-DRUG
ii O O
( O O
cisplatin B-DRUG B-DRUG
) O O
- O O
based O O
chemotherapy O O

we O O
report O O
a O O
patient O O
with O O
pulmonary O O
adenocarcinoma O O
complicated O O
by O O
the O O
syndrome B-ADR O
of I-ADR O
inappropriate I-ADR O
secretion I-ADR O
of I-ADR O
antidiuretic I-ADR O
hormone I-ADR O
( O O
siadh O O
) O O
following O O
systemic O O
chemotherapy O O
with O O
cisplatin O B-DRUG
( O O
cddp B-DRUG O
) O O
and O O
vindesine O O
( O O
vds O O

a O O
40-year-old O O
man O O
with O O
relapsing-remitting O O
multiple O O
sclerosis O O
( O O
ms O O
) O O
developed O O
primary O O
central O O
nervous O O
system O O
lymphoma O O
( O O
pcnsl B-ADR O
) O O
after O O
having O O
received O O
21 O O
doses O O
of O O
natalizumab B-DRUG B-DRUG
monotherapy O O

a O O
31-year-old O O
female O O
developed O O
multiple O O
episodes O O
of O O
grand B-ADR B-ADR
mal I-ADR I-ADR
seizures I-ADR I-ADR
after O O
combination O O
chemotherapy O O
with O O
cisplatin O B-DRUG
, O O
vinblastine B-DRUG B-DRUG
and O O
bleomycin O B-DRUG
for O O
germ O O
cell O O
ovarian O O
cancer O O
stage O O
ic O O

carbamazepine-related O O
hyponatremia B-ADR B-ADR
following O O
cardiopulmonary O O
bypass O O

a O O
36-year-old O O
man O O
being O O
treated O O
with O O
cisplatinum B-DRUG B-DRUG
, O O
vinblastine O B-DRUG
, O O
and O O
bleomycin O B-DRUG
for O O
testicular O O
carcinoma O O
developed O O
a O O
dense O O
left O O
homonymous O O
hemianopsia O O
, O O
encephalopathy O O
, O O
and O O
a O O
partial B-ADR O
nondominant I-ADR O
parietal I-ADR O
lobe I-ADR O
syndrome I-ADR O

sensorimotor B-ADR B-ADR
polyneuropathy I-ADR I-ADR
with O O
5-aminosalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
: O O
a O O
case O O
report O O

alopecia O B-ADR
, O O
nausea O O
, O O
and O O
vomiting B-ADR O
were O O
attributed O O
to O O
the O O
cyclophosphamide B-DRUG B-DRUG
component O O
of O O
the O O
therapy O O

the O O
current O O
report O O
describes O O
a O O
man O O
who O O
was O O
prescribed O O
zonisamide B-DRUG B-DRUG
for O O
epilepsy O O
and O O
subsequently O O
developed O O
widespread O O
skin O O
rash O O
, O O
acute B-ADR O
kidney I-ADR O
injury I-ADR O
, O O
high-grade O O
fever O O
, O O
eosinophilia O O
, O O
liver O O
dysfunction O O
, O O
lymphadenopathy O O
and O O
an O O
increase O O
in O O
antihuman O O
herpesvirus-6 O O
immunoglobulin O O
g O O
titer O O

we O O
describe O O
2 O O
patients O O
with O O
severe O O
erosive O O
rheumatoid O O
arthritis O O
and O O
rheumatoid O O
vasculitis O O
, O O
respectively O O
, O O
in O O
whom O O
infliximab B-DRUG B-DRUG
therapy O O
was O O
associated O O
with O O
peripheral O B-ADR
neuropathy O I-ADR
due O O
to O O
necrotizing B-ADR B-ADR
vasculitis I-ADR I-ADR
in O O
one O O
patient O O
and O O
to O O
progression O O
of O O
preexisting O O
mononeuritis O O
multiplex O O
in O O
the O O
other O O

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate B-DRUG B-DRUG
with O O
folinic O O
acid O O
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate O O
shower O O
syndrome O O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia B-ADR O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia O O
and O O
tetany O O
, O O
with O O
metabolic O O
acidosis O O
and O O
acute O O
renal O O
impairment O O
) O O
are O O
described O O

we O O
report O O
the O O
case O O
of O O
a O O
patient O O
with O O
multiple O O
myeloma O O
who O O
developed O O
acute O B-ADR
life-threatening B-ADR I-ADR
water I-ADR I-ADR
intoxication I-ADR I-ADR
following O O
treatment O O
with O O
oral O O
indomethacin B-DRUG B-DRUG
and O O
low O O
dose O O
intravenous O O
cyclophosphamide O B-DRUG

warfarin-induced O O
skin O O
necrosis O O
and O O
heparin-induced O O
thrombocytopenia B-ADR B-ADR
following O O
mitral O O
valve O O
replacement O O
for O O
marantic O O
endocarditis O O

administration O O
of O O
amantadine B-DRUG B-DRUG
was O O
associated O O
with O O
psychotic B-ADR B-ADR
decompensations I-ADR I-ADR
in O O
two O O
schizophrenic O O
patients O O
being O O
maintained O O
on O O
concomitant O O
neuroleptic O O
medication O O

results O O
: O O
after O O
4 O O
- O O
to O O
14-month O O
period O O
of O O
therapy O O
with O O
the O O
combination O O
of O O
indapamide O B-DRUG
( O O
2.5 O O
mg O O
/ O O
day O O
) O O
and O O
fosinopril B-DRUG O
( O O
10 O O
mg O O
/ O O
day O O
) O O
in O O
three O O
patients O O
and O O
6-month O O
period O O
of O O
monotherapy O O
with O O
indapamide O B-DRUG
( O O
2.5 O O
mg O O
/ O O
day O O
) O O
in O O
one O O
patient O O
, O O
glucose O O
levels O O
of O O
all O O
patients O O
increased O O
and O O
achieve O O
criteria O O
of O O
diabetes B-ADR O
diagnoses O O

we O O
experienced O O
a O O
male O O
patient O O
with O O
psoriasis O O
and O O
hypertension O O
whose O O
conditions O O
were O O
treated O O
with O O
tacalcitol O B-DRUG
ointment O O
and O O
thiazide B-DRUG B-DRUG
, O O
respectively O O
, O O
resulting O O
in O O
hypercalciuria O O
and O O
hypercalcemia B-ADR B-ADR

the O O
current O O
report O O
describes O O
a O O
man O O
who O O
was O O
prescribed O O
zonisamide B-DRUG B-DRUG
for O O
epilepsy O O
and O O
subsequently O O
developed O O
widespread O O
skin O O
rash O O
, O O
acute O O
kidney O O
injury O O
, O O
high-grade O O
fever O O
, O O
eosinophilia O O
, O O
liver O O
dysfunction O O
, O O
lymphadenopathy O O
and O O
an B-ADR O
increase I-ADR O
in I-ADR O
antihuman I-ADR O
herpesvirus-6 I-ADR O
immunoglobulin I-ADR O
g I-ADR O
titer I-ADR O

potential O O
causes O O
of O O
methamphetamine-related O O
keratitis B-ADR B-ADR
can O O
be O O
divided O O
into O O
four O O
categories O O
resulting O O
from O O
( O O
a O O
) O O
direct O O
pharmacologic O O
and O O
physical O O
effects O O
of O O
methamphetamine O B-DRUG
; O O
( O O
b O O
) O O
the O O
toxic O O
effects O O
of O O
diluting O O
or O O
" O O
cutting O O
" O O
agents O O
such O O
as O O
lidocaine B-DRUG B-DRUG
and O O
quinine O O
; O O
( O O
c O O
) O O
effects O O
related O O
to O O
the O O
route O O
of O O
drug O O
administration O O
( O O
intravenous O O
, O O
inhalation O O
, O O
smoking O O
) O O
; O O
and O O
( O O
d O O
) O O
manufacture-related O O
effects O O
of O O
exposure O O
to O O
unintentional O O
caustic O O
contaminants O O
in O O
the O O
final O O
product O O

we O O
report O O
on O O
a O O
56-year-old O O
female O O
who O O
exhibited O O
drug O O
refractory O O
paroxysmal O O
atrial O O
fibrillation O O
, O O
in O O
which O O
marked O O
prolongation B-ADR O
of I-ADR O
the I-ADR O
qt I-ADR O
interval I-ADR O
and O O
t O O
wave O O
inversion O O
on O O
electrocardiogram O O
was O O
demonstrated O O
reproducibly O O
shortly O O
after O O
the O O
administration O O
of O O
oral O O
pirmenol B-DRUG B-DRUG
therapy O O

pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
subsequent O O
to O O
high O O
doses O O
of O O
ccnu B-DRUG B-DRUG
for O O
chronic O O
myeloid O O
leukemia O O

amiodarone B-DRUG B-DRUG
hydrochloride I-DRUG I-DRUG
, O O
a O O
new O O
antiarrhythmic O O
agent O O
, O O
has O O
been O O
associated O O
with O O
pulmonary B-ADR O
toxicity I-ADR O
characterized O O
by O O
cough O O
, O O
dyspnea O O
and O O
diffuse O O
pulmonary O O
infiltrates O O

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate O B-DRUG
with O O
folinic B-DRUG O
acid I-DRUG O
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate O O
shower O O
syndrome O O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia O O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia O O
and O O
tetany O O
, O O
with O O
metabolic B-ADR O
acidosis I-ADR O
and O O
acute O O
renal O O
impairment O O
) O O
are O O
described O O

the O O
patient O O
continued O O
to O O
have O O
fever O O
and O O
autonomic B-ADR O
instability I-ADR O
without O O
evidence O O
of O O
infection O O
which O O
entirely O O
resolved O O
within O O
24 O O
hours O O
of O O
reinstitution O O
of O O
full O O
preadmission O O
dosing O O
of O O
oral O O
baclofen B-DRUG B-DRUG

theoretical O O
basal O O
ganglia O O
toxicologic O O
mechanisms O O
of O O
methanol B-ADR B-DRUG
poisoning I-ADR O
are O O
reviewed O O
, O O
and O O
the O O
role O O
of O O
brain O O
imaging O O
studies O O
will O O
regard O O
to O O
diagnosis O O
, O O
prognosis O O
and O O
impact O O
on O O
management O O
is O O
discussed O O

the O O
development O O
of O O
cutaneous B-ADR B-ADR
ecchymosis I-ADR I-ADR
associated O O
with O O
a O O
sudden O B-ADR
fall O I-ADR
in O I-ADR
hemoglobin O I-ADR
after O O
the O O
administration O O
of O O
alteplase B-DRUG B-DRUG
should O O
strongly O O
suggest O O
the O O
possibility O O
of O O
diffuse O O
subfascial O B-ADR
hematoma O I-ADR

the O O
patient O O
's O O
other O O
comorbidities O O
and O O
medications O O
have O O
not O O
been O O
suggested O O
as O O
possible O O
interactions O O
with O O
sertraline B-DRUG B-DRUG
that O O
can O O
cause O O
rhabdomyolysis B-ADR B-ADR

posterior B-ADR B-ADR
leukoencephalopathy I-ADR I-ADR
following O O
cisplatin O B-DRUG
, O O
bleomycin O B-DRUG
and O O
vinblastine B-DRUG B-DRUG
therapy O O
for O O
germ O O
cell O O
tumor O O
of O O
the O O
ovary O O

vitiligo B-ADR B-ADR
associated O O
with O O
alpha-interferon B-DRUG B-DRUG
in O O
a O O
patient O O
with O O
chronic O O
active O O
hepatitis O O
c O O

the O O
purpose O O
of O O
this O O
article O O
is O O
to O O
present O O
the O O
first O O
case-series O O
of O O
posterior O O
reversible O O
encephalopathy O O
syndrome O O
( O O
pres B-ADR B-ADR
) O O
associated O O
with O O
l-asparaginase B-DRUG B-DRUG
treatment O O

although O O
vasculitis B-ADR B-ADR
has O O
been O O
reported O O
in O O
the O O
course O O
of O O
hairy O O
cell O O
leukaemia O O
, O O
it O O
has O O
only O O
rarely O O
been O O
reported O O
as O O
the O O
consequence O O
of O O
cladribine B-DRUG B-DRUG
treatment O O

type O O
i O O
second-degree O O
av O O
block O O
( O O
mobitz B-ADR O
type I-ADR O
i I-ADR O
, O O
wenckebach O O
av O O
block O O
) O O
during O O
ritodrine B-DRUG B-DRUG
therapy O O
for O O
preterm O O
labor O O

we O O
report O O
4 O O
patients O O
, O O
2 O O
on O O
methylphenidate B-DRUG B-DRUG
and O O
2 O O
on O O
dextroamphetamine O B-DRUG
who O O
presented O O
with O O
acral O O
cyanosis O O
, O O
livedo B-ADR O
reticularis I-ADR O
, O O
or O O
raynaud O O
phenomenon O O

we O O
report O O
a O O
case O O
of O O
unintentional O O
overdose O O
of O O
oral O O
pilocarpine B-DRUG B-DRUG
tablets O O
that O O
resulted O O
in O O
bradycardia O O
, O O
mild B-ADR O
hypotension I-ADR O
, O O
and O O
muscarinic O O
symptoms O O
in O O
a O O
patient O O
with O O
sjogren O O
's O O
syndrome O O

we O O
report O O
the O O
case O O
of O O
a O O
female O O
acromegalic O O
patient O O
in O O
whom O O
multiple O B-ADR
hepatic B-ADR I-ADR
adenomas I-ADR I-ADR
appeared O O
soon O O
after O O
danazol B-DRUG B-DRUG
treatment O O
for O O
uterine O O
fibromatosis O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness O O
, O O
difficulty O O
with O O
speech O O
, O O
weakness O O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular B-ADR O
rash I-ADR O
was O O
noted O O

gemcitabine B-DRUG B-DRUG
should O O
be O O
added O O
to O O
the O O
list O O
of O O
drugs O O
known O O
to O O
cause O O
radiation B-ADR B-ADR
recall I-ADR I-ADR

this O O
report O O
suggests O O
that O O
anemia B-ADR B-ADR
can O O
occur O O
due O O
to O O
mmf O B-DRUG
, O O
in O O
particular O O
when O O
it O O
is O O
given O O
with O O
prednisone O B-DRUG
, O O
a O O
side O O
effect O O
well O O
documented O O
in O O
the O O
transplantation O O
literature O O
when O O
the O O
triple O O
combination O O
of O O
mmf O B-DRUG
, O O
cyclosporine B-DRUG B-DRUG
and O O
prednisone O B-DRUG
is O O
used O O

pancytopenia B-ADR B-ADR
associated O O
with O O
5-aminosalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
use O O
in O O
a O O
patient O O
with O O
crohn O O
's O O
disease O O

a O O
patient O O
with O O
chronic O O
myelomonocytic O O
leukemia O O
developed O O
drug-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
after O O
using O O
low O O
dose O O
oral O O
etoposide B-DRUG B-DRUG

due O O
to O O
the O O
severity O O
of O O
the O O
rash B-ADR O
, O O
temozolomide B-DRUG B-DRUG
was O O
permanently O O
discontinued O O

from O O
1996 O O
to O O
2002 O O
several O O
medications O O
were O O
changed O O
due O O
to O O
their O O
adverse O O
effects O O
: O O
indinavir O O
( O O
renal O O
colic O O
and O O
fever O O
) O O
, O O
nelfinavir O O
( O O
cutaneous O O
rash O O
) O O
, O O
and O O
efavirenz B-DRUG B-DRUG
( O O
nausea B-ADR O
and O O
temporary O O
memory O O
loss O O

brugada B-ADR B-ADR
type I-ADR I-ADR
electrocardiographic I-ADR I-ADR
changes I-ADR I-ADR
induced O O
by O O
concomitant O O
use O O
of O O
lithium B-DRUG B-DRUG
and O O
propafenone O B-DRUG
in O O
patient O O
with O O
wolff-parkinson-white O O
syndrome O O

we O O
report O O
a O O
case O O
in O O
which O O
hemorrhage B-ADR B-ADR
occurred O O
in O O
an O O
asymptomatic O O
falx O O
meningioma O O
known O O
beforehand O O
, O O
after O O
the O O
internal O O
use O O
of O O
low-dose O O
aspirin B-DRUG B-DRUG
for O O
16 O O
months O O

we O O
describe O O
the O O
development O O
of O O
ischemic O B-ADR
colitis O I-ADR
in O O
a O O
woman O O
who O O
was O O
treated O O
with O O
tegaserod B-DRUG B-DRUG
and O O
review O O
the O O
relationship O O
among O O
ischemic O O
colitis O O
, O O
tegaserod B-DRUG B-DRUG
use O O
, O O
and O O
irritable B-ADR O
bowel I-ADR O
syndrome I-ADR O

conclusion O O
: O O
to O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
time O O
colchicine B-ADR B-ADR
intoxication I-ADR I-ADR
in O O
this O O
age O O
group O O
has O O
been O O
described O O
in O O
the O O
english O O
literature O O

ulcerating B-ADR B-ADR
enteritis I-ADR I-ADR
associated O O
with O O
flucytosine B-DRUG B-DRUG
therapy O O

it O O
was O O
concluded O O
that O O
potassium B-ADR B-ADR
loss I-ADR I-ADR
occurred O O
by O O
a O O
non-renal O O
( O O
intestinal O O
) O O
route O O
in O O
phosphate-induced O O
hypokalemia O B-ADR

we O O
report O O
a O O
case O O
of O O
a O O
23-year-old O O
man O O
who O O
developed O O
a O O
vancomycin-induced O O
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
in O O
the O O
treatment O O
of O O
methicillin-resistant O O
staphylococcus O O
aureus O O
infection O O

vasomotor B-ADR B-ADR
reactions I-ADR I-ADR
after O O
gold B-DRUG B-DRUG
sodium I-DRUG I-DRUG
thiomalate I-DRUG I-DRUG
are O O
well O O
recognized O O

we O O
present O O
the O O
first O O
case O O
of O O
ovarian O B-ADR
endometrioid O I-ADR
carcinoma O I-ADR
and O O
endometriosis B-ADR B-ADR
in O O
a O O
postmenopausal O O
patient O O
who O O
was O O
treated O O
with O O
tamoxifen B-DRUG B-DRUG
for O O
breast O O
cancer O O

masculinization O B-ADR
of O I-ADR
a O I-ADR
female O I-ADR
fetus O I-ADR
occurred O O
in O O
5 O O
of O O
39 O O
( O O
12.8 O O
%) O O
exposed O O
to O O
norethisterone B-DRUG B-DRUG
; O O
all O O
were O O
cases O O
of O O
clitoral B-ADR B-ADR
hypertrophy I-ADR I-ADR
not O O
requiring O O
surgical O O
treatment O O

we O O
describe O O
a O O
patient O O
who O O
experienced O O
chronic O O
nausea O O
and O O
an O O
episode O O
of O O
confusion B-ADR O
while O O
treated O O
with O O
a O O
small O O
, O O
stable O O
dose O O
of O O
oral O O
morphine B-DRUG B-DRUG
in O O
the O O
setting O O
of O O
mild O O
renal O O
insufficiency O O

fever B-ADR O
, O O
lymphadenopathy O O
, O O
eosinophilia O O
, O O
lymphocytosis O O
, O O
hepatitis O O
, O O
and O O
dermatitis O O
: O O
a O O
severe O O
adverse O O
reaction O O
to O O
minocycline B-DRUG B-DRUG

in O O
deciding O O
if O O
tamoxifen B-DRUG B-DRUG
therapy O O
is O O
warranted O O
, O O
all O O
potentially O O
life-threatening O O
adverse O O
events O O
associated O O
with O O
tamoxifen B-DRUG B-DRUG
should O O
be O O
considered O O
, O O
including O O
endometrial B-ADR O
adenocarcinoma I-ADR O
or O O
uterine O O
sarcoma O O

we O O
describe O O
a O O
case O O
of O O
advanced O O
ovarian O O
carcinoma O O
who O O
developed O O
difficulty O O
walking O O
because O O
of O O
marked O O
pain O O
in O O
the O O
lower O O
extremities O O
and O O
loss B-ADR O
of I-ADR O
proprioception I-ADR O
25 O O
days O O
after O O
treatment O O
with O O
weekly O O
taxol B-DRUG B-DRUG
( O O
80 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
x3 O O

reversal O O
of O O
gold-induced O O
neutropenia B-ADR B-ADR
with O O
granulocyte O O
colony-stimulating O O
factor O O
( O O
g-csf O B-DRUG

despite O O
the O O
underlying O O
hepatitis O O
c O O
, O O
this O O
case O O
represents O O
renal B-ADR B-ADR
abnormalities I-ADR I-ADR
consistent O O
with O O
ifnalpha B-DRUG B-DRUG
therapy O O
for O O
cml O O

however O O
, O O
a O O
recent O O
post-marketing O O
survey O O
in O O
japan O O
revealed O O
that O O
interstitial B-ADR B-ADR
pneumonia I-ADR I-ADR
occurred O O
in O O
4 O O
among O O
approximately O O
2 O O
000 O O
japanese O O
patients O O
treated O O
with O O
sorafenib B-DRUG B-DRUG

although O O
gabapentin B-DRUG B-DRUG
withdrawal O O
has O O
been O O
previously O O
reported O O
and O O
usually O O
consists O O
of O O
anxiety O O
, O O
diaphoresis O O
, O O
and O O
palpitations B-ADR O
, O O
this O O
is O O
the O O
first O O
reported O O
patient O O
with O O
generalized O O
seizures O O
and O O
status O O
epilepticus O O
secondary O O
to O O
gabapentin B-DRUG B-DRUG
withdrawal O O

none O O
of O O
them O O
had O O
a O O
history O O
of O O
cardiac O O
disease O O
, O O
and O O
with O O
the O O
possible O O
exception O O
of O O
one O O
case O O
of O O
cardiac B-ADR O
arrest I-ADR O
, O O
where O O
the O O
patient O O
received O O
doxorubicin B-DRUG B-DRUG
, O O
no O O
predisposing O O
factors O O
could O O
be O O
found O O

the O O
use O O
of O O
beclomethasone B-DRUG O
diproprionate I-DRUG O
inhaler O O
complicated O O
by O O
the O O
development O O
of O O
an O O
eosinophilic B-ADR O
pneumonia I-ADR O
reaction I-ADR O

we O O
report O O
here O O
two O O
cases O O
of O O
dyserythropoietic O B-ADR
anaemia O I-ADR
associated O O
with O O
long-term O O
linezolid O B-DRUG
use O O
that O O
share O O
striking O O
similarities O O
to O O
chloramphenicol-associated O O
myelotoxicity B-ADR B-ADR

the O O
authors O O
report O O
two O O
cases O O
of O O
delayed B-ADR O
elimination I-ADR O
of O O
methotrexate B-DRUG B-DRUG
in O O
patients O O
receiving O O
ciprofloxacin O B-DRUG
, O O
with O O
severe O B-ADR
toxicity O I-ADR

toxic B-ADR B-ADR
optic I-ADR I-ADR
neuropathy I-ADR I-ADR
associated O O
with O O
ethambutol B-DRUG B-DRUG
: O O
implications O O
for O O
current O O
therapy O O

case O O
summary O O
: O O
we O O
report O O
the O O
case O O
of O O
a O O
31-year-old O O
patient O O
hospitalized O O
due O O
to O O
behavioral O O
alterations O O
and O O
treated O O
with O O
oral O O
zuclopenthixol B-DRUG B-DRUG
, O O
an O O
antipsychotic O O
from O O
the O O
thioxanthene O O
family O O
, O O
who O O
developed O O
an O O
acute O O
, O O
painful B-ADR O
erection I-ADR O

concomitant O O
administration O O
of O O
lithium B-DRUG B-DRUG
with O O
olanzapine O B-DRUG
may O O
place O O
patients O O
at O O
risk O O
for O O
nms B-ADR B-ADR

we O O
report O O
a O O
fatal O O
case O O
of O O
toxic O B-ADR
epidermal O I-ADR
necrolysis O I-ADR
( O O
ten B-ADR O
) O O
resulting O O
from O O
a O O
high O O
dose O O
of O O
cytosine B-DRUG B-DRUG
arabinoside I-DRUG I-DRUG
( O O
ara-c O B-DRUG

these O O
skin B-ADR B-ADR
lesions I-ADR I-ADR
may O O
be O O
induced O O
or O O
worsened O O
during O O
antiviral O O
therapy O O
with O O
interferon-alpha B-DRUG B-DRUG
( O O
ifn O B-DRUG

second B-ADR O
cancers I-ADR O
including O O
various O O
types O O
of O O
hematological O O
malignancy O O
have O O
been O O
reported O O
in O O
patients O O
with O O
hairy O O
cell O O
leukemia O O
treated O O
with O O
chemotherapy O O
or O O
interferon B-DRUG B-DRUG
alfa I-DRUG I-DRUG

pericardial B-ADR B-ADR
hemorrhage I-ADR I-ADR
due O O
to O O
acetylsalicylic B-DRUG B-DRUG
acid I-DRUG I-DRUG
in O O
a O O
patient O O
with O O
essential O O
thrombocythemia O O

we O O
describe O O
children O O
and O O
adolescents O O
with O O
chronic O O
hematologic O O
and O O
oncologic O O
diseases O O
who O O
exhibited O O
drug-seeking B-ADR O
behavior I-ADR O
or O O
anticholinergic O O
symptoms O O
with O O
the O O
use O O
of O O
diphenhydramine B-DRUG B-DRUG

the O O
patient O O
's O O
defects O O
may O O
be O O
due O O
to O O
methimazole B-DRUG B-DRUG
teratogenicity B-ADR B-ADR
or O O
could O O
represent O O
a O O
previously O O
undescribed O O
syndrome O O
affecting O O
ectodermal O O
structures O O

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever O O
, O O
skin O O
eruptions O O
, O O
cervical O O
lymphadenopathy O O
, O O
hepatosplenomegaly O O
, O O
atypical B-ADR O
lymphocytosis I-ADR O
, O O
and O O
eosinophilia O O
two O O
weeks O O
after O O
receiving O O
trimethoprim O O
( O O
tmp O O
)- O O
sulfamethoxazole O O
( O O
smx B-DRUG O
) O O
treatment O O

two O O
patients O O
with O O
hlh O O
developed O O
etoposide-related O O
secondary B-ADR O
acute I-ADR O
myeloid I-ADR O
leukemia I-ADR O
( O O
saml O O
) O O
following O O
therapy O O
for O O
hlh O O

a O O
51-year-old O O
man O O
developed O O
type B-ADR B-ADR
1 I-ADR I-ADR
diabetes I-ADR I-ADR
mellitus I-ADR I-ADR
following O O
24 O O
weeks O O
of O O
treatment O O
with O O
recombinant O O
alpha-2b B-DRUG O
peginterferon I-DRUG O
plus O O
ribavirin O B-DRUG
for O O
chronic O O
hepatitis O O
c O O

interventions O O
and O O
results O O
: O O
cardiac B-ADR B-ADR
complications I-ADR I-ADR
were O O
observed O O
in O O
five O O
pediatric O O
patients O O
who O O
received O O
between O O
4.6 O O
and O O
40.8 O O
mg O O
/ O O
kg O O
/ O O
d O O
of O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG

while O O
the O O
introduction O O
of O O
carmustine O B-DRUG
wafers O O
( O O
gliadel B-DRUG O
wafers O O
) O O
into O O
the O O
tumor O O
resection O O
cavity O O
has O O
been O O
shown O O
to O O
be O O
a O O
beneficial O O
therapy O O
for O O
malignant O O
glioma O O
, O O
it O O
is O O
recognized O O
that O O
clinically O O
significant O O
cerebral B-ADR B-ADR
edema I-ADR I-ADR
is O O
a O O
potential O O
adverse O O
effect O O

we O O
describe O O
a O O
73-year-old O O
woman O O
who O O
developed O O
serious O O
systemic O O
vasculitis O O
with O O
associated O O
thrombocytopenia B-ADR B-ADR
in O O
the O O
course O O
of O O
treatment O O
with O O
cladribine B-DRUG B-DRUG

the O O
ulcer B-ADR B-ADR
did O O
not O O
respond O O
to O O
antibiotic O O
treatment O O
and O O
healed O O
shortly O O
after O O
withholding O O
atra B-DRUG B-DRUG

severe O B-ADR
rhabdomyolysis O I-ADR
following O O
massive O O
ingestion O O
of O O
oolong B-DRUG B-DRUG
tea I-DRUG I-DRUG
: O O
caffeine B-ADR B-ADR
intoxication I-ADR I-ADR
with O O
coexisting O O
hyponatremia O O

pigmentary B-ADR B-ADR
disorders I-ADR I-ADR
are O O
recognized O O
adverse O O
effects O O
of O O
the O O
semi-synthetic O O
tetracycline O B-DRUG
derivative O O
antibiotic O O
, O O
minocycline B-DRUG B-DRUG

l-asparaginase-induced O O
posterior B-ADR B-ADR
reversible I-ADR I-ADR
encephalopathy I-ADR I-ADR
syndrome O I-ADR
during O O
acute O O
lymphoblastic O O
leukemia O O
treatment O O
in O O
children O O

the O O
second O O
patient O O
experienced O O
mild B-ADR O
nitritoid I-ADR B-ADR
symptoms I-ADR I-ADR
following O O
several O O
gstm B-DRUG B-DRUG
injections O O
prior O O
experiencing O O
a O O
cerebrovascular O B-ADR
accident O I-ADR
within O O
several O O
hours O O
of O O
her O O
next O O
injection O O

we O O
hypothesize O O
that O O
decreased O O
renal O O
elimination O O
of O O
mtx B-DRUG B-DRUG
induced O O
by O O
the O O
cox-2 O O
inhibitor O O
resulted O O
in O O
enhanced O O
hematopoietic O O
toxicity O O
and O O
immunosuppression B-ADR O
causing O O
the O O
ebv-associated O O
lymphoproliferative O B-ADR
disease O I-ADR

an O O
11-year-old O O
boy O O
who O O
was O O
treated O O
with O O
a O O
relatively O O
high O O
dose O O
of O O
methotrimeprazine B-DRUG O
meleate I-DRUG O
( O O
levemepromazine O O
) O O
a O O
phenothiazine O O
antipsychotic O O
drug O O
, O O
was O O
admitted O O
to O O
the O O
pediatric O O
intensive O O
care O O
unit O O
suffering O O
from O O
respiratory B-ADR B-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR

case O O
summary O O
: O O
a O O
68-year-old O O
woman O O
developed O O
a O O
dry O O
, O O
irritating B-ADR B-ADR
cough I-ADR I-ADR
within O O
one O O
month O O
of O O
starting O O
quinapril B-DRUG B-DRUG
therapy O O
for O O
the O O
treatment O O
of O O
essential O O
hypertension O O

the O O
toxic O O
effects O O
of O O
methotrexate B-DRUG B-DRUG
included O O
elevated O O
liver O O
transaminases O O
( O O
3 O O
/ O O
4 O O
) O O
, O O
nausea O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
abdominal O O
pain O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
bone O O
pain O O
( O O
2 O O
/ O O
4 O O
) O O
, O O
mild B-ADR O
neutropenia I-ADR O
( O O
1 O O
/ O O
4 O O
) O O
, O O
and O O
mild O O
pruritus O O
( O O
1 O O
/ O O
4 O O

discussion O O
: O O
to O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
case O O
report O O
illustrating O O
neuralgic B-ADR B-ADR
amyotrophy I-ADR I-ADR
triggered O O
by O O
exposure O O
to O O
the O O
antibiotics O O
vancomycin O B-DRUG
, O O
tobramycin O O
, O O
and O O
piperacillin B-DRUG O
/ O O
tazobactam O B-DRUG

we O O
believe O O
the O O
temporal O O
association O O
of O O
the O O
abnormal O O
liver O O
enzymes O O
in O O
this O O
patient O O
, O O
in O O
the O O
absence O O
of O O
other O O
offending O O
agents O O
, O O
argues O O
strongly O O
in O O
favor O O
of O O
6-tg B-DRUG B-DRUG
as O O
a O O
cause O O
of O O
liver B-ADR O
enzyme I-ADR O
abnormalities I-ADR O

vancomycin B-DRUG B-DRUG
is O O
widely O O
used O O
against O O
methicillin-resistant O O
staphylococcus O O
aureus O O
infections O O
, O O
but O O
it O O
is O O
associated O O
with O O
many O O
adverse O O
effects O O
such O O
as O O
nephrotoxicity O O
, O O
ototoxicity O O
, O O
gastrointestinal O O
disturbances O O
, O O
blood O O
disorders O O
, O O
and O O
two O O
types O O
of O O
hypersensitivity O O
reactions O O
- O O
an O O
anaphylactoid B-ADR O
reaction O O
known O O
as O O
" O O
red O O
man O O
syndrome O O
" O O
and O O
anaphylaxis O B-ADR

ards B-ADR B-ADR
is O O
rarely O O
associated O O
with O O
rituximab B-DRUG B-DRUG
infusion O O
for O O
lympho-proliferative O O
disorders O O
, O O
but O O
it O O
should O O
be O O
considered O O
by O O
those O O
administering O O
rituximab B-DRUG B-DRUG
, O O
especially O O
when O O
a O O
patient O O
develops O O
severe O B-ADR
pulmonary O I-ADR
symptoms O I-ADR
soon O O
after O O
infusion O O

conclusion O O
: O O
atovaquone B-DRUG B-DRUG
should O O
be O O
added O O
to O O
the O O
list O O
of O O
agents O O
causing O O
vortex B-ADR B-ADR
keratopathy I-ADR I-ADR
involving O O
the O O
corneal O O
epithelium O O

in O O
this O O
report O O
we O O
described O O
a O O
case O O
of O O
juvenile O O
idiopathic O O
arthritis O O
patient O O
who O O
developed O O
thymic O O
enlargement O O
( O O
true O O
thymic O O
hyperplasia O O
) O O
, O O
mediastinal O O
lymphadenopathy O O
and O O
pleurisy B-ADR O
associated O O
with O O
systemic O O
symptoms O O
under O O
etanercept B-DRUG B-DRUG
treatment O O

sensorineural B-ADR B-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR
due O O
to O O
quinine B-DRUG B-DRUG
therapy O O
for O O
malaria O O
has O O
frequently O O
been O O
mentioned O O
in O O
the O O
literature O O
but O O
has O O
not O O
been O O
a O O
subject O O
of O O
research O O
during O O
the O O
last O O
decades O O

a O O
variety O O
of O O
movement O O
disorders O O
are O O
known O O
to O O
occur O O
in O O
association O O
with O O
carbamazepine B-DRUG B-DRUG
( O O
cbz O B-DRUG
) O O
therapy O O
in O O
adults O O
and O O
children O O
, O O
but O O
development O O
of O O
tics B-ADR B-ADR
has O O
been O O
described O O
infrequently O O
and O O
only O O
in O O
patients O O
with O O
underlying O O
tourette O O
's O O
syndrome O O
or O O
other O O
movement O O
disorders O O

ofloxacin B-DRUG B-DRUG
: O O
a O O
probable O O
cause O O
of O O
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR

the O O
patient O O
developed O O
occipital O B-ADR
infarcts O I-ADR
and O O
was O O
found O O
to O O
have O O
extremely B-ADR O
elevated I-ADR O
levels I-ADR O
of I-ADR O
ppa I-ADR B-DRUG
in O O
his O O
blood O O
and O O
dialysis O O
fluid O O

taxane-induced O O
glaucoma B-ADR B-ADR

three O O
patients O O
with O O
no O O
history O O
of O O
asthma O O
or O O
allergy O O
developed O O
bronchospasm B-ADR B-ADR
while O O
taking O O
propranolol B-DRUG B-DRUG
for O O
hypertension O O

we O O
report O O
a O O
case O O
of O O
ritalin-associated O O
cataract B-ADR B-ADR
and O O
glaucoma O B-ADR

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
multiple O O
episodes O O
of O O
seizure B-ADR B-ADR
activity O I-ADR
in O O
an O O
aids O O
patent O O
following O O
amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
infusion O O

the O O
purpose O O
of O O
this O O
study O O
was O O
to O O
examine O O
the O O
incidence O O
and O O
cause O O
of O O
clostridium B-ADR B-ADR
difficile I-ADR I-ADR
colitis I-ADR I-ADR
occurring O O
after O O
cisplatin-based O O
combination O O
chemotherapy O O
in O O
ovarian O O
cancer O O
patients O O

background O O
: O O
reports O O
on O O
delated B-ADR B-ADR
cutaneous I-ADR I-ADR
reactions I-ADR I-ADR
to O O
captopril B-DRUG B-DRUG
have O O
been O O
seldom O O
reported O O

metoclopramide-induced O O
parkinsonism B-ADR B-ADR
is O O
not O O
rare O O
, O O
and O O
appropriate O O
dose O O
reduction O O
in O O
patients O O
with O O
renal O O
failure O O
will O O
help O O
reduce O O
the O O
incidence O O
of O O
this O O
morbidity O O

life-threatening O B-ADR
hyperkalemia B-ADR I-ADR
induced O O
by O O
arginine B-DRUG B-DRUG

angio-oedema B-ADR B-ADR
as O O
an O O
unusual O O
tolerable O O
side O O
effect O O
of O O
voriconazole B-DRUG B-DRUG
therapy O O

a O O
patient O O
with O O
rheumatoid O O
arthritis O O
developed O O
an O O
acute O B-ADR
intrahepatic B-ADR I-ADR
cholestasis I-ADR I-ADR
after O O
100 O O
mg O O
of O O
sodium B-DRUG B-DRUG
aurothiomalate I-DRUG I-DRUG

a O O
48-year-old O O
woman O O
who O O
was O O
treated O O
for O O
thyrotoxicosis O O
with O O
methimazole B-DRUG B-DRUG
developed O O
agranulocytosis B-ADR B-ADR

objective O O
: O O
to O O
report O O
a O O
case O O
of O O
cutaneous B-ADR O
and I-ADR O
hematologic I-ADR B-ADR
toxicity I-ADR I-ADR
in O O
a O O
patient O O
treated O O
with O O
il-2 B-DRUG B-DRUG

an O O
objective O O
causality O O
assessment O O
indicated O O
a O O
probable O O
relationship O O
between O O
clotting B-ADR O
abnormality I-ADR O
and O O
warfarin B-DRUG B-DRUG
administration O O
, O O
although O O
the O O
degree O O
of O O
elevation O O
of O O
the O O
inr O B-DRUG
was O O
unusual O O
in O O
the O O
light O O
of O O
the O O
daily O O
warfarin B-DRUG B-DRUG
dose O O
and O O
duration O O
of O O
its O O
exposure O O

five O O
cases O O
of O O
clindamycin-associated O O
pseudomembranous B-ADR B-ADR
colitis I-ADR I-ADR
in O O
leukaemic O O
patients O O
are O O
reported O O

we O O
report O O
a O O
girl O O
with O O
the O O
rett O O
syndrome O O
who O O
had O O
acute B-ADR B-ADR
encephalopathy I-ADR I-ADR
probably O O
induced O O
by O O
calcium O B-DRUG
hopantenate O I-DRUG
( O O
hopa B-DRUG O

the O O
hyperpigmentation O O
was O O
diffuse O O
scattered O O
, O O
flagellate O O
like O O
and O O
linear O O
streaking O O
which O O
was O O
thought O O
to O O
be O O
mainly O O
related O O
to O O
the O O
skin B-ADR O
toxicity I-ADR O
of O O
bleomycin B-DRUG B-DRUG

we O O
describe O O
the O O
infectious B-ADR B-ADR
toxicities I-ADR I-ADR
experienced O O
by O O
the O O
first O O
two O O
patients O O
in O O
our O O
institution O O
treated O O
with O O
dexamethasone B-DRUG B-DRUG
( O O
10 O O
mg O O
/ O O
m O O
( O O
2 O O
)/ O O
day O O
for O O
4 O O
weeks O O
with O O
gradual O O
tapering O O
) O O
during O O
induction O O
according O O
to O O
the O O
dexamethasone B-DRUG B-DRUG
arm O O
of O O
bfm O O
2000 O O
and O O
review O O
the O O
relevant O O
literature O O
that O O
suggests O O
an O O
increased O O
risk O O
of O O
infectious O O
complications O O
with O O
dexamethasone B-DRUG B-DRUG

although O O
the O O
literature O O
on O O
the O O
use O O
of O O
risperidone B-DRUG B-DRUG
in O O
elderly O O
patients O O
with O O
dementia O O
consists O O
largely O O
of O O
uncontrolled O O
trials O O
, O O
case O O
reports O O
, O O
and O O
chart O O
reviews O O
, O O
it O O
appears O O
that O O
this O O
agent O O
is O O
effective O O
for O O
managing O O
agitation O O
in O O
this O O
population O O
and O O
does O O
so O O
with O O
a O O
low O O
frequency O O
of O O
extrapyramidal O O
symptoms O O
( O O
eps B-ADR B-ADR

purpose O O
: O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
aseptic O O
meningitis O O
, O O
hemolytic O O
anemia O O
, O O
hepatitis O O
, O O
and O O
orthostatic B-ADR O
hypotension I-ADR O
simultaneously O O
during O O
treatment O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG
is O O
described O O

chronic O O
hydroxychloroquine B-DRUG B-DRUG
use O O
associated O O
with O O
qt B-ADR O
prolongation I-ADR O
and O O
refractory O O
ventricular O O
arrhythmia O O

the O O
second O O
patient O O
, O O
who O O
developed O O
cholestasis O B-ADR
after O O
receiving O O
trimethoprim-sulfamethoxazole B-DRUG B-DRUG
, O O
had O O
marked O O
duct B-ADR O
paucity I-ADR O
in O O
the O O
liver O O
biopsy O O

both O O
the O O
longitudinal O O
melanonychia O O
and O O
the O O
multiple B-ADR B-ADR
skin I-ADR I-ADR
cancers I-ADR I-ADR
first O O
appeared O O
after O O
approximately O O
6 O O
months O O
of O O
hydroxyurea B-DRUG B-DRUG
treatment O O

agranulocytosis B-ADR B-ADR
during O O
clozapine B-DRUG B-DRUG
therapy O O

thus O O
any O O
case O O
of O O
severe B-ADR B-ADR
neutropenia I-ADR I-ADR
occurring O O
in O O
a O O
patient O O
receiving O O
olanzapine B-DRUG B-DRUG
is O O
alarming O O
to O O
clinicians O O

the O O
observations O O
suggest O O
that O O
testicular B-ADR O
swelling I-ADR O
and O O
pain O O
are O O
side O O
effects O O
of O O
desipramine B-DRUG B-DRUG

although O O
the O O
essential O O
cause O O
of O O
pv B-ADR B-ADR
is O O
unclear O O
, O O
its O O
onset O O
has O O
occasionally O O
been O O
associated O O
with O O
drug O O
therapy O O
, O O
in O O
particular O O
penicillamine B-DRUG B-DRUG

to O O
date O O
, O O
there O O
have O O
been O O
few O O
reports O O
of O O
visual B-ADR B-ADR
disturbances I-ADR I-ADR
associated O O
with O O
btx-b B-DRUG B-DRUG
use O O

we O O
present O O
a O O
case O O
of O O
respiratory B-ADR B-ADR
failure I-ADR I-ADR
occurring O O
in O O
a O O
woman O O
at O O
16 O O
weeks' O O
gestation O O
who O O
was O O
being O O
treated O O
with O O
nitrofurantoin B-DRUG B-DRUG
for O O
a O O
urinary O O
tract O O
infection O O

we O O
report O O
an O O
additional O O
case O O
of O O
isotretinoin B-DRUG B-DRUG
teratogenicity B-ADR B-ADR
in O O
which O O
the O O
patient O O
had O O
agenesis O O
of O O
the O O
cerebellar O O
vermis O O
, O O
multiple O O
leptomeningeal O O
neuroglial O O
heterotopias O O
, O O
hydrocephalus O O
, O O
and O O
abnormalities O O
of O O
the O O
corticospinal O O
tracts O O

methods O O
: O O
a O O
retrospective O O
report O O
of O O
the O O
first O O
case O O
of O O
gemcitabine-related O O
hus B-ADR B-ADR
, O O
in O O
a O O
patient O O
with O O
metastatic O O
pancreatic O O
adenocarcinoma O O
, O O
treated O O
with O O
a O O
variety O O
of O O
standard O O
therapies O O
in O O
addition O O
to O O
rituximab O B-DRUG
is O O
presented O O

cases O O
: O O
two O O
postmenopausal O O
women O O
treated O O
with O O
tamoxifen B-DRUG B-DRUG
and O O
progestational O O
agents O O
for O O
breast O O
carcinoma O O
developed O O
uterine O B-ADR
enlargement O I-ADR
and O O
intermittent B-ADR O
spotting I-ADR O

severe B-ADR B-ADR
corneal I-ADR I-ADR
toxicity I-ADR I-ADR
after O O
topical O O
fluoroquinolone B-DRUG B-DRUG
therapy O O
: O O
report O O
of O O
two O O
cases O O

a O O
25-year-old O O
man O O
with O O
a O O
history O O
of O O
mid-borderline O O
( O O
bb O O
) O O
hansen O O
's O O
disease O O
developing O O
a O O
reversal B-ADR O
reaction I-ADR O
after O O
starting O O
dapsone B-DRUG B-DRUG
and O O
rifampin O B-DRUG
therapy O O
is O O
presented O O

in O O
addition O O
to O O
its O O
known O O
effect O O
on O O
gallbladder O O
stasis O O
, O O
octreotide B-DRUG B-DRUG
alters O O
bile O O
acid O O
composition O O
and O O
may O O
thus O O
hasten B-ADR O
intrahepatic I-ADR O
sludge I-ADR O
and O O
stone O O
formation O O

we O O
report O O
five O O
cases O O
of O O
restless O O
legs O O
syndrome O O
( O O
rls B-ADR O
) O O
and O O
periodic O O
limb O O
movements O O
during O O
sleep O O
( O O
plms O O
) O O
that O O
were O O
probably O O
associated O O
with O O
olanzapine B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
aild B-ADR B-ADR
in O O
an O O
80-year-old O O
male O O
who O O
presented O O
with O O
a O O
generalized O B-ADR
pruritic O I-ADR
maculopapular O I-ADR
eruption O I-ADR
and O O
fever O B-ADR
following O O
doxycycline B-DRUG B-DRUG
administration O O

liver O O
transplantation O O
for O O
fulminant B-ADR B-ADR
hepatitis I-ADR I-ADR
related O O
to O O
nevirapine B-DRUG B-DRUG
therapy O O

the O O
administration O O
of O O
" O O
sweet B-DRUG O
spirits I-DRUG O
of I-DRUG O
nitre I-DRUG O
" O O
( O O
4 O B-DRUG
% O I-DRUG
ethyl O I-DRUG
nitrite O I-DRUG
ch3ch2ono O I-DRUG
in O I-DRUG
70 O I-DRUG
% O I-DRUG
ethyl O I-DRUG
alcohol O I-DRUG
) O O
was O O
followed O O
by O O
acute O O
methemoglobinemia O O
and O O
severe O O
anoxic O O
metabolic O O
acidosis O O
in O O
infant O O
twins O O
, O O
methylene O O
blue O O
administration O O
reversed O O
methemoglobinemia O B-ADR
in O O
both O O
, O O
but O O
one O O
twin O O
died B-ADR O
from O O
the O O
consequences O O
of O O
hypoxemia O B-ADR

we O O
report O O
on O O
a O O
56-year-old O O
female O O
who O O
exhibited O O
drug O O
refractory O O
paroxysmal O O
atrial O O
fibrillation O O
, O O
in O O
which O O
marked O O
prolongation O O
of O O
the O O
qt O O
interval O O
and O O
t B-ADR O
wave I-ADR O
inversion I-ADR O
on O O
electrocardiogram O O
was O O
demonstrated O O
reproducibly O O
shortly O O
after O O
the O O
administration O O
of O O
oral O O
pirmenol B-DRUG B-DRUG
therapy O O

we O O
report O O
here O O
a O O
case O O
of O O
cardiovascular O O
and O O
neurological B-ADR B-ADR
depression I-ADR I-ADR
induced O O
by O O
oxymetalzoline B-DRUG B-DRUG
in O O
a O O
toddler O O

the O O
patient O O
had O O
recurrence O O
of O O
urticaria B-ADR O
and O O
angioedema O B-ADR
a O O
year O O
and O O
a O O
half O O
later O O
, O O
at O O
which O O
point O O
the O O
nph B-DRUG B-DRUG
was O O
stopped O O
and O O
she O O
was O O
desensitized O O
to O O
regular O O
insulin O B-DRUG

schneiderian B-ADR B-ADR
first-rank I-ADR I-ADR
symptoms I-ADR I-ADR
associated O O
with O O
fluvoxamine B-DRUG B-DRUG
treatment O O
: O O
a O O
case O O
report O O

as O O
far O O
as O O
we O O
know O O
, O O
this O O
is O O
the O O
first O O
case O O
report O O
of O O
acute B-ADR B-ADR
hemorrhagic I-ADR I-ADR
gastritis I-ADR I-ADR
associated O O
with O O
az B-DRUG B-ADR
intoxication O I-ADR

we O O
report O O
a O O
case O O
of O O
fulminant O B-ADR
neuroleptic B-ADR I-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
man O O
aged O O
70 O O
developing O O
within O O
12 O O
hours O O
of O O
starting O O
six-hourly O O
intravenous O O
metoclopramide B-DRUG B-DRUG

in O O
rare O O
cases O O
mitomycin B-DRUG O
c I-DRUG O
( O O
mmc O B-DRUG
) O O
may O O
induce O O
cancer-associated O O
hemolytic O O
uremic O O
syndrome O O
, O O
which O O
is O O
characterized O O
by O O
hemolytic O O
anemia O O
, O O
thrombocytopenia B-ADR O
and O O
progressive O O
renal O O
failure O O

we O O
describe O O
2 O O
patients O O
with O O
severe O O
erosive O O
rheumatoid O O
arthritis O O
and O O
rheumatoid O O
vasculitis O O
, O O
respectively O O
, O O
in O O
whom O O
infliximab B-DRUG B-DRUG
therapy O O
was O O
associated O O
with O O
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
due O O
to O O
necrotizing O B-ADR
vasculitis O I-ADR
in O O
one O O
patient O O
and O O
to O O
progression O O
of O O
preexisting O O
mononeuritis O O
multiplex O O
in O O
the O O
other O O

eosinophilia B-ADR B-ADR
caused O O
by O O
clozapine B-DRUG B-DRUG
was O O
observed O O
in O O
challenge O O
, O O
preceded O O
by O O
a O O
faster O O
neutrophil O O
production O O
and O O
consecutive O O
decrease O O
( O O
z O O
= O O
2.27 O O
, O O
p O O
= O O
0.01 O O

background O O
: O O
reproductive B-ADR O
endocrine I-ADR O
disorders I-ADR O
characterized O O
by O O
menstrual O O
disorders O O
, O O
polycystic O O
ovaries O O
, O O
and O O
hyperandrogenism O O
seem O O
to O O
be O O
common O O
among O O
women O O
treated O O
with O O
sodium B-DRUG B-DRUG
valproate I-DRUG I-DRUG
for O O
epilepsy O O

46-year-old O O
woman O O
developed O O
painful B-ADR B-ADR
ulcers I-ADR I-ADR
over O O
her O O
lower O O
abdomen O O
in O O
the O O
form O O
of O O
reticulate O B-ADR
erythema O I-ADR
after O O
injecting O O
interferon B-DRUG B-DRUG
beta-1b I-DRUG I-DRUG
subcutaneously O O
for O O
multiple O O
sclerosis O O

this O O
is O O
the O O
first O O
reported O O
case O O
of O O
suspected O O
dian B-ADR B-ADR
due O O
to O O
cefuroxime B-DRUG B-DRUG

skin B-ADR B-ADR
rash I-ADR I-ADR
began O O
after O O
2 O O
weeks O O
of O O
treatment O O
, O O
and O O
signs O O
of O O
hepatocellular O B-ADR
failure O I-ADR
developed O O
3 O O
weeks O O
after O O
phenobarbital B-DRUG B-DRUG
had O O
been O O
started O O

a O O
case O O
of O O
fluoxetine B-DRUG B-DRUG
induced O O
seizures B-ADR B-ADR
, O O
in O O
a O O
person O O
with O O
down O O
syndrome O O
, O O
is O O
described O O

serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
caused O O
by O O
interaction O O
between O O
citalopram O B-DRUG
and O O
fentanyl B-DRUG B-DRUG

a O O
literature O O
review O O
revealed O O
83 O O
other O O
reported O O
cases O O
of O O
rifampicin-induced O O
renal B-ADR B-ADR
insufficiency I-ADR I-ADR

ticlopidine-induced O O
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
: O O
two O O
new O O
case O O
reports O O
, O O
review O O
, O O
and O O
meta-analysis O O
of O O
55 O O
additional O O
cases O O

purpose O O
: O O
symptomatic O O
visual B-ADR B-ADR
field I-ADR I-ADR
constriction I-ADR I-ADR
thought O O
to O O
be O O
associated O O
with O O
vigabatrin B-DRUG B-DRUG
has O O
been O O
reported O O

we O O
present O O
a O O
case O O
of O O
a O O
diabetic O O
patient O O
taking O O
glyburide O B-DRUG
who O O
was O O
prescribed O O
ciprofloxacin B-DRUG B-DRUG
and O O
developed O O
prolonged B-ADR B-ADR
hypoglycemia I-ADR I-ADR
, O O
which O O
persisted O O
for O O
over O O
24 O O
hours O O

purpose O O
: O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
aseptic O O
meningitis O O
, O O
hemolytic O O
anemia O O
, O O
hepatitis B-ADR O
, O O
and O O
orthostatic O O
hypotension O O
simultaneously O O
during O O
treatment O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG
is O O
described O O

findings O O
: O O
six O O
children O O
with O O
growth B-ADR O
retardation I-ADR O
noted O O
after O O
treatment O O
with O O
high-dose O O
fluticasone B-DRUG B-DRUG
propionate I-DRUG I-DRUG
were O O
found O O
to O O
have O O
adrenal O O
suppression O O

two O O
other O O
patients O O
who O O
did O O
not O O
receive O O
prochlorperazine O B-DRUG
, O O
developed O O
retinal B-ADR B-ADR
problems I-ADR I-ADR
which O O
later O O
improved O O
, O O
one O O
after O O
only O O
15 O O
g O O
of O O
desferrioxamine B-DRUG B-DRUG

severe B-ADR O
respiratory I-ADR O
syncytial I-ADR O
virus I-ADR O
pulmonary I-ADR O
infection I-ADR O
in O O
a O O
patient O O
treated O O
with O O
fludarabine B-DRUG B-DRUG
for O O
chronic O O
lymphocytic O O
leukemia O O

mr O O
findings O O
in O O
methotrexate-induced O O
cns B-ADR B-ADR
abnormalities I-ADR I-ADR

neutropenic B-ADR B-ADR
colitis I-ADR I-ADR
during O O
standard O O
dose O O
combination O O
chemotherapy O O
with O O
nedaplatin B-DRUG B-DRUG
and O O
irinotecan O B-DRUG
for O O
testicular O O
cancer O O

massive B-ADR B-ADR
pulmonary I-ADR I-ADR
embolism I-ADR I-ADR
complicating O O
streptokinase B-DRUG B-DRUG
treatment O O
for O O
deep O O
vein O O
thrombosis O O

physicians O O
should O O
be O O
aware O O
of O O
the O O
potential O O
for O O
developing O O
a O O
gemcitabine-induced O O
radiation O O
recall O O
reaction O O
resulting O O
in O O
hemodynamically O O
significant O O
pericardial B-ADR B-ADR
effusion I-ADR I-ADR

cis-retinoic B-DRUG B-DRUG
acid I-DRUG I-DRUG
( O O
ra O O
) O O
may O O
further O O
increase O O
the O O
risk O O
of O O
developing O O
bmtn B-ADR B-ADR

we O O
report O O
a O O
patient O O
receiving O O
chronic O O
lithium B-DRUG B-DRUG
therapy O O
who O O
presented O O
with O O
a O O
transient O B-ADR
cdi B-ADR I-ADR
occurring O O
in O O
the O O
setting O O
of O O
underlying O O
chronic O O
ndi O O

amikacin-induced O O
type O O
5 O O
bartter-like O O
syndrome O O
with O O
severe B-ADR O
hypocalcemia I-ADR O

case O O
report O O
: O O
we O O
hereby O O
report O O
a O O
case O O
of O O
radiation B-ADR B-ADR
recall I-ADR I-ADR
dermatitis I-ADR I-ADR
and O O
myositis O B-ADR
occurring O O
on O O
gemcitabine B-DRUG B-DRUG
monotherapy O O
, O O
five O O
months O O
after O O
completing O O
chemoradiation O B-DRUG
for O O
locally O O
advanced O O
pancreatic O O
cancer O O

paraplegia B-ADR B-ADR
following O O
prophylactic O O
intrathecal O O
cytosine B-DRUG B-DRUG
arabinoside I-DRUG I-DRUG
( O O
ara-c O B-DRUG
) O O
is O O
described O O
in O O
a O O
patient O O
with O O
acute O O
myelogenous O O
leukemia O O
in O O
remission O O
who O O
received O O
doses O O
of O O
100 O O
mg O O
/ O O
m2 O O
/ O O
d O O
for O O
5 O O
consecutive O O
days O O

a O O
33-year-old O O
man O O
with O O
a O O
history O O
of O O
recreational O O
benztropine B-DRUG B-DRUG
abuse O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
confusion O O
, O O
abdominal O O
pain O O
, O O
and O O
distention B-ADR O

in O O
conclusion O O
, O O
rsds B-ADR B-ADR
is O O
a O O
relevant O O
osteoarticular O O
complication O O
in O O
patients O O
receiving O O
either O O
anticalcineurinic O O
drug O O
( O O
cya O O
or O O
tacrolimus B-DRUG O
) O O
, O O
even O O
under O O
monotherapy O O
or O O
with O O
a O O
low O O
steroid O O
dose O O

the O O
ocular B-ADR O
toxicity I-ADR O
of O O
dcf B-DRUG B-DRUG
, O O
previously O O
described O O
as O O
conjunctivitis O O
, O O
appears O O
to O O
be O O
a O O
keratitis O O
of O O
moderate O O
severity O O
which O O
requires O O
further O O
study O O

methods O O
: O O
three O O
patients O O
with O O
apparent O O
itraconazole-induced O O
liver B-ADR B-ADR
injury I-ADR I-ADR
were O O
studied O O

a O O
57-year-old O O
woman O O
with O O
right O O
bundle O O
branch O O
block O O
+ O O
lph O O
and O O
ventricular O O
premature O O
contractions O O
developed O O
complete B-ADR O
heart I-ADR O
block I-ADR O
( O O
chb O O
) O O
following O O
administration O O
of O O
disopyramide O B-DRUG
phosphate O I-DRUG
( O O
norpace B-DRUG O

this O O
is O O
a O O
report O O
of O O
a O O
renal O O
transplant O O
patient O O
with O O
pneumocystis O O
pneumonia O O
who O O
developed O O
chemical O O
cellulitis O O
and O O
ulceration B-ADR O
following O O
the O O
extravasation O O
of O O
intravenous O O
pentamidine B-DRUG B-DRUG
into O O
the O O
soft O O
tissues O O
of O O
the O O
left O O
hand O O
and O O
forearm O O

this O O
case O O
study O O
describes O O
an O O
atypical O O
case O O
of O O
refractory O O
, O O
sodium B-DRUG O
warfarin-induced O O
necrotizing B-ADR B-ADR
fasciitis I-ADR I-ADR
and O O
myonecrosis O O

charcoal O B-DRUG
haemoperfusion O O
and O O
cysteamine O B-DRUG
therapy O O
led O O
to O O
the O O
rapid O O
removal O O
of O O
the O O
paracetamol B-DRUG B-DRUG
from O O
the O O
body O O
and O O
consequently O O
prevented O O
the O O
development O O
of O O
severe B-ADR B-ADR
hepatic I-ADR I-ADR
necrosis I-ADR I-ADR

simvastatin-induced O O
rhabdomyolysis B-ADR B-ADR
following O O
cyclosporine B-DRUG B-DRUG
treatment O O
for O O
uveitis O O

recognizing O O
early O O
signs O O
of O O
hmsn O O
, O O
such O O
as O O
areflexia O O
and O O
pes O O
cavus O O
deformity O O
, O O
can O O
prevent O O
severe B-ADR O
neurotoxicity I-ADR B-ADR
of O O
polychemotherapy O B-ADR
by O O
avoiding O O
vincristine B-DRUG B-DRUG

this O O
severe B-ADR O
illness I-ADR O
was O O
likely O O
caused O O
by O O
minocycline B-DRUG B-DRUG
, O O
and O O
we O O
speculate O O
that O O
minocycline B-DRUG B-DRUG
may O O
have O O
acted O O
as O O
a O O
superantigen O O
, O O
causing O O
lymphocyte O O
over-activation O O
and O O
massive O O
cytokine O O
release O O

increased O O
lash O O
length O O
, O O
thickness O O
, O O
and O O
pigmentation B-ADR O
are O O
well-documented O O
side O O
effects O O
of O O
prostaglandin B-DRUG B-DRUG
analog O O
glaucoma O O
drops O O

provocation O O
of O O
non-convulsive B-ADR B-ADR
status I-ADR I-ADR
epilepticus I-ADR I-ADR
by O O
tiagabine B-DRUG B-DRUG
in O O
three O O
adolescent O O
patients O O

fatal B-ADR B-ADR
intravascular I-ADR I-ADR
autoimmune I-ADR I-ADR
hemolytic I-ADR I-ADR
anemia I-ADR I-ADR
after O O
fludarabine B-DRUG B-DRUG
treatment O O
for O O
chronic O O
lymphocytic O O
leukemia O O

we O O
report O O
a O O
case O O
of O O
a O O
patient O O
with O O
pulmonary O O
hypertension O O
and O O
undifferentiated O O
connective O O
tissue O O
disease O O
who O O
, O O
after O O
2 O O
months O O
of O O
treatment O O
with O O
epoprostenol B-DRUG B-DRUG
, O O
presented O O
with O O
rapidly O O
progressive O O
erythema O O
, O O
scaling O O
, O O
nausea O O
and O O
vomiting B-ADR O
, O O
and O O
fever O B-ADR

the O O
possibility O O
of O O
phenytoin B-DRUG B-DRUG
hypersensitivity O O
reactions O O
should O O
be O O
considered O O
when O O
patients O O
receiving O O
phenytoin B-DRUG B-DRUG
have O O
unusual O O
symptoms O O
, O O
particularly O O
fever O O
, O O
rash O O
, O O
and O O
lymphadenopathy B-ADR O

establishment O O
of O O
diuresis O B-ADR
with O O
fluids O O
and O O
iv O O
administration O O
of O O
calcium O O
may O O
provide O O
successful O O
treatment O O
of O O
magnesium B-ADR B-ADR
toxicosis I-ADR I-ADR
in O O
horses O O

conclusions O O
: O O
fixed B-ADR B-ADR
drug I-ADR I-ADR
rash I-ADR I-ADR
induced O O
by O O
methylphenidate B-DRUG B-DRUG
is O O
a O O
possible O O
but O O
rare O O
phenomenon O O

dapsone B-ADR B-ADR
syndrome I-ADR I-ADR
in O O
cutaneous O O
lupus O O
erythematosus O O

reversible O O
valproic B-DRUG B-DRUG
acid-induced O O
dementia B-ADR B-ADR
: O O
a O O
case O O
report O O

in O O
a O O
postural O O
challenge O O
test O O
after O O
administration O O
of O O
isosorbide B-DRUG B-DRUG
dinitrate I-DRUG I-DRUG
( O O
5 O O
mg O O
) O O
, O O
blood B-ADR O
pressure I-ADR O
decreased I-ADR O
from O O
120 O O
/ O O
67 O O
to O O
65 O O
/ O O
35 O O
mmhg O O
, O O
followed O O
by O O
syncope O O
with O O
a O O
sudden O O
decrease O O
in O O
pulse O O
rate O O
from O O
85 O O
to O O
60 O O
beats O O
/ O O
min O O

purpose O O
: O O
the O O
case O O
of O O
a O O
patient O O
who O O
developed O O
aseptic O O
meningitis O O
, O O
hemolytic B-ADR O
anemia I-ADR O
, O O
hepatitis O O
, O O
and O O
orthostatic O O
hypotension O O
simultaneously O O
during O O
treatment O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG
is O O
described O O

a O O
patient O O
with O O
alcoholic O O
cerebellar O O
degeneration O O
had O O
periodic B-ADR B-ADR
alternating I-ADR I-ADR
nystagmus I-ADR I-ADR
during O O
a O O
period O O
of O O
phenytoin B-DRUG B-DRUG
intoxication O O

hemorrhage B-ADR B-ADR
from O O
a O O
falx O B-ADR
meningioma O I-ADR
after O O
internal O O
use O O
of O O
low-dose O O
aspirin B-DRUG B-DRUG

conclusion O O
: O O
severe O O
and O O
sustained B-ADR B-ADR
ocular I-ADR I-ADR
hypertension I-ADR I-ADR
may O O
occur O O
after O O
intravitreal O O
ranibizumab B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
reversible O B-ADR
encephalopathy B-ADR I-ADR
syndrome I-ADR I-ADR
in O O
a O O
16-year-old O O
girl O O
with O O
acute O O
myelogenous O O
leukemia O O
( O O
aml O O
) O O
, O O
who O O
is O O
undergoing O O
during O O
consolidation O O
chemotherapy O O
composed O O
of O O
bh-ac B-DRUG O
( O O
n4-behenoyl-1-beta-d-arabinofuranosyl O O
cytosine O O
) O O
and O O
idarubicin O B-DRUG

we O O
describe O O
a O O
case O O
of O O
needle-track O O
cutaneous B-ADR O
seeding I-ADR O
of O O
hepatocellular O O
carcinoma O O
( O O
hcc O B-ADR
) O O
after O O
sonographically O O
guided O O
percutaneous O O
ethanol B-DRUG B-DRUG
injection I-DRUG O
( O O
pei O O

case O O
: O O
a O O
malignant B-ADR O
mixed I-ADR O
mesodermal I-ADR O
tumor I-ADR O
was O O
diagnosed O O
in O O
a O O
64-year-old O O
woman O O
with O O
a O O
bicornuate O O
uterus O O
while O O
she O O
was O O
taking O O
raloxifene B-DRUG B-DRUG
for O O
osteoporosis O O
prevention O O

conclusions O O
: O O
clinicians O O
should O O
be O O
aware O O
of O O
a O O
risk O O
of O O
serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
with O O
serious O O
extrapyramidal O B-ADR
reactions O I-ADR
in O O
patients O O
receiving O O
sertraline B-DRUG B-DRUG
or O O
venlafaxine O B-DRUG
when O O
metoclopramide O B-DRUG
is O O
coadministered O O
even O O
in O O
a O O
single O O
, O O
conventional O O
dose O O

pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
with O O
mefloquine B-DRUG B-DRUG

docetaxel-induced O O
meibomian B-ADR B-ADR
duct I-ADR I-ADR
inflammation I-ADR I-ADR
and I-ADR O
blockage I-ADR O
leading O O
to O O
chalazion O B-DRUG
formation O O

inadvertent O O
and O O
accidental O O
epinephrine B-DRUG B-DRUG
overdose O O
might O O
result O O
in O O
potentially O O
lethal B-ADR B-ADR
complications I-ADR I-ADR

the O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
developed O O
in O O
a O O
patient O O
receiving O O
therapy O O
with O O
gold B-DRUG B-DRUG
for O O
rheumatoid O O
arthritis O O

the O O
fifth O O
patient O O
exhibited O O
paraesthesia O O
and O O
agitation B-ADR O
caused O O
by O O
olanzapine B-DRUG B-DRUG
that O O
was O O
misdiagnosed O O
as O O
psychotic O B-ADR
agitation B-ADR I-ADR

the O O
most O O
common O O
side O O
effects O O
associated O O
with O O
amifostine B-DRUG B-DRUG
are O O
nausea B-ADR O
, O O
vomiting O O
, O O
hypotension O O
, O O
hypocalcemia O O
and O O
allergic O O
reactions O O

rapamycin B-DRUG O
/ O O
sirolimus-induced O O
pneumonitis B-ADR B-ADR
has O O
been O O
described O O
previously O O
in O O
renal O O
transplant O O
recipients O O
, O O
and O O
this O O
report O O
describes O O
a O O
stable O O
heart-lung O O
transplant O O
recipient O O
who O O
developed O O
a O O
pulmonary O B-ADR
infiltrate O I-ADR
that O O
reversed O O
after O O
ceasing O O
sr O B-DRUG
therapy O O

there O O
is O O
documentation O O
of O O
ocular B-ADR B-ADR
toxicity I-ADR I-ADR
with O O
ethambutol B-DRUG B-DRUG
when O O
administered O O
at O O
dosages O O
generally O O
pronounced O O
as O O
being O O
safe O O

a O O
transient B-ADR O
tonic I-ADR O
pupillary I-ADR O
response I-ADR O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual-evoked O O
potentials O O
in O O
quinine B-DRUG B-DRUG
toxicity O O
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O

purpose O O
: O O
to O O
investigate O O
the O O
concentration-side O O
effect O O
relationship O O
in O O
a O O
patient O O
with O O
severe O O
acyclovir-induced O O
neurotoxicity O B-ADR
and O O
to O O
summarize O O
the O O
information O O
available O O
in O O
the O O
literature O O
about O O
central B-ADR O
nervous I-ADR O
system I-ADR O
side I-ADR O
effects I-ADR O
due O O
to O O
acyclovir B-DRUG B-DRUG

severe B-ADR B-ADR
diffuse I-ADR I-ADR
interstitial I-ADR I-ADR
pneumonitis I-ADR I-ADR
induced O O
by O O
carmustine B-DRUG B-DRUG
( O O
bcnu O B-DRUG

she O O
was O O
diagnosed O O
with O O
epstein-barr O O
virus-associated O O
polymorphic O O
lymphoproliferative O O
disorder O O
( O O
lpd O B-ADR
) O O
due O O
to O O
immunodeficiency B-ADR O
caused O O
by O O
mtx B-DRUG B-DRUG
administration O O

intravenous O O
verapamil O B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension O O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death O O
; O O
quinidine B-DRUG B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long B-ADR O
qt I-ADR O
interval I-ADR O
syndrome I-ADR O

the O O
principle O O
treatment O O
for O O
dpd-deficient O O
patients O O
with O O
severe B-ADR O
acute I-ADR O
5-fu I-ADR B-DRUG
reactions I-ADR O
is O O
supportive O O
care O O
; O O
however O O
, O O
the O O
administration O O
of O O
thymidine O B-DRUG
potentially O O
may O O
reverse O O
severe O O
5-fu-induced O O
neurologic O B-ADR
symptoms O I-ADR
such O O
as O O
encephalopathy O B-ADR
and O O
coma O B-ADR

we O O
report O O
a O O
case O O
of O O
fulminant B-ADR B-ADR
hepatic I-ADR I-ADR
failure I-ADR I-ADR
associated O O
with O O
didanosine B-DRUG B-DRUG
and O O
masquerading O O
as O O
a O O
surgical O O
abdomen O O
and O O
compare O O
the O O
clinical O O
, O O
biologic O O
, O O
histologic O O
, O O
and O O
ultrastructural O O
findings O O
with O O
reports O O
described O O
previously O O

posterior O O
reversible O O
encephalopathy O O
syndrome O O
( O O
pres B-DRUG O
) O O
induced O O
by O O
cyclosporine B-ADR B-DRUG
use O O
in O O
a O O
patient O O
with O O
collapsing O O
focal O O
glomeruloesclerosis O O

we O O
report O O
a O O
44-year-old O O
woman O O
with O O
t-mds O O
( O O
refractory B-ADR O
anemia I-ADR O
with I-ADR O
excess I-ADR O
blasts I-ADR O
) O O
following O O
treatment O O
of O O
recurrent O O
anaplastic O O
astrocytoma O O
with O O
temozolomide O B-DRUG
( O O
tmz B-DRUG O

comeoscleral B-ADR B-ADR
perforation I-ADR I-ADR
after O O
pterygium O B-DRUG
excision O O
and O O
intraoperative O O
mitomycin B-DRUG B-DRUG
c I-DRUG I-DRUG

we O O
describe O O
the O O
clinical O O
course O O
of O O
2 O O
patients O O
with O O
crohn O O
's O O
disease O O
( O O
cd O O
) O O
in O O
whom O O
lymphoma B-ADR B-ADR
was O O
diagnosed O O
after O O
treatment O O
with O O
infliximab B-DRUG B-DRUG

in O O
this O O
case O O
, O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
induced O O
polymyositis B-ADR B-ADR
and O O
cardiomyopathy O B-ADR
is O O
diagnosed O O
in O O
a O O
33-yr-old O O
male O O
patient O O
with O O
history O O
of O O
chronic O O
hepatitis O O
b O O

in O O
patients O O
with O O
swallowing B-ADR O
dysfunction I-ADR O
and O O
pneumonia O O
, O O
a O O
history O O
of O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
use O O
should O O
be O O
obtained O O
and O O
a O O
diagnosis O O
of O O
elp O B-ADR
should O O
be O O
considered O O
in O O
the O O
differential O O
diagnoses O O
if O O
mineral B-DRUG B-DRUG
oil I-DRUG I-DRUG
use O O
has O O
occurred O O

we O O
have O O
described O O
three O O
patients O O
with O O
hepatitis O O
c O O
for O O
whom O O
ifn-alpha B-DRUG O
and O O
ribavirin O B-DRUG
were O O
prescribed O O
and O O
who O O
developed O O
two O O
successive O O
phases O O
of O O
silent O O
thyroiditis B-ADR O
followed O O
by O O
hyperthryroidism O B-ADR
relapse O I-ADR
due O O
to O O
graves' O O
disease O O

in O O
this O O
article O O
, O O
we O O
describe O O
a O O
japanese O O
patient O O
with O O
severe B-ADR O
interstitial I-ADR O
pneumonia I-ADR O
probably O O
caused O O
by O O
sorafenib B-DRUG B-DRUG
treatment O O
for O O
metastatic O O
renal O O
cell O O
carcinoma O O

we O O
report O O
the O O
first O O
case O O
of O O
chlorambucil-induced O O
dress B-ADR B-ADR
syndrome I-ADR I-ADR
in O O
a O O
70-year-old O O
man O O
recently O O
diagnosed O O
with O O
chronic O O
lymphocytic O O
leukaemia O O

we O O
report O O
here O O
on O O
a O O
heretofore O O
undescribed O O
respiratory O O
syncytial O O
virus O O
( O O
rsv O O
) O O
infection O O
in O O
a O O
patient O O
with O O
a O O
long-standing O O
history O O
of O O
refractory O O
cll O O
that O O
was O O
treated O O
with O O
fludarabine B-DRUG B-DRUG
phosphate I-DRUG I-DRUG

flucloxacillin-induced O O
aplastic O B-ADR
anaemia O I-ADR
and O O
liver B-ADR O
failure I-ADR O

the O O
authors O O
describe O O
a O O
case O O
of O O
combined O O
lithium O B-DRUG
and O O
haloperidol B-DRUG B-DRUG
toxicity O O
characterized O O
by O O
hyperpyrexia B-ADR O
, O O
severe O O
rigidity O O
, O O
mutism O O
, O O
and O O
development O O
of O O
irreversible O B-ADR
tardive O I-ADR
dyskinesia O I-ADR

the O O
male O O
patient O O
was O O
treated O O
with O O
225-mg O O
/ O O
day O O
clozapine B-DRUG B-DRUG
and O O
the O O
time O O
to O O
the O O
diagnosis O O
of O O
agranulocytosis B-ADR B-ADR
was O O
6 O O
weeks O O

case O O
1 O O
, O O
a O O
62-year-old O O
woman O O
, O O
developed O O
bilateral B-ADR O
optic I-ADR O
neuritis I-ADR O
with O O
decreased O O
sensation O O
of O O
vibration O O
and O O
increased O O
deep O O
tendon O O
reflex O O
in O O
the O O
lower O O
extremities O O
after O O
a O O
seven-month O O
use O O
of O O
recombinant B-DRUG B-DRUG
interferon I-DRUG I-DRUG
alpha-2a I-DRUG I-DRUG
for O O
chronic O O
active O O
hepatitis O O
c O O

although O O
taxol B-DRUG B-DRUG
has O O
shown O O
significant O O
activity O O
in O O
advanced O O
ovarian O O
cancer O O
, O O
peripheral B-ADR O
neuropathy I-ADR O
is O O
likely O O
to O O
become O O
the O O
major O O
dose-limiting O O
toxicity O O

the O O
field B-ADR O
defects I-ADR O
and O O
some O O
electrophysiological O B-ADR
abnormalities O I-ADR
persist O O
when O O
vigabatrin B-DRUG B-DRUG
therapy O O
is O O
withdrawn O O

she O O
received O O
an O O
accidental O O
450-mg O O
bolus O O
injection O O
of O O
morphine B-DRUG B-DRUG
intrathecally O O
and O O
developed O O
hypertension B-ADR O
, O O
status O O
epilepticus O O
, O O
intracerebral O O
hemorrhage O O
, O O
and O O
respiratory O O
failure O O

isoniazid B-DRUG B-DRUG
and O O
ethambutol O B-DRUG
as O O
a O O
cause O O
of O O
optic B-ADR B-ADR
neuropathy I-ADR I-ADR

although O O
there O O
is O O
one O O
case O O
report O O
of O O
cholesterol O B-ADR
crystal O I-ADR
embolization O I-ADR
following O O
t-pa B-DRUG B-DRUG
therapy O O
with O O
only O O
extrarenal O O
manifestations O O
( O O
n O O
engl O O
j O O
med O O
321:1270 O O
, O O
1989 O O
) O O
, O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
atheroembolic B-ADR O
acute I-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
following O O
t-pa B-DRUG B-DRUG
therapy O O

symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
secondary O O
to O O
a O O
glipizide-trimethoprim O O
/ O O
sulfamethoxazole O B-DRUG
drug O O
interaction O O

moreover O O
, O O
treatment O O
with O O
immunosuppressive O O
drugs O O
such O O
as O O
cyclosporine O B-DRUG
, O O
cisplatin B-DRUG B-DRUG
, O O
tacrolimus O O
, O O
and O O
interferon-alpha O B-DRUG
can O O
induce O O
a O O
condition O O
resembling O O
rpls B-ADR B-ADR

we O O
report O O
on O O
a O O
patient O O
with O O
subarachnoid O O
haemorrhage O O
who O O
developed O O
an O O
acute O O
life-threatening O O
pseudo-obstruction B-ADR O
of I-ADR O
the I-ADR O
colon I-ADR O
, O O
a O O
variant O O
of O O
adynamic O B-ADR
ileus O I-ADR
, O O
while O O
being O O
treated O O
with O O
intravenous O O
nimodipine B-DRUG B-DRUG

we O O
report O O
a O O
child O O
with O O
yolk O O
sac O O
tumor O O
who O O
developed O O
localized B-ADR B-ADR
pigmentation I-ADR I-ADR
after O O
the O O
first O O
course O O
of O O
chemotherapy O O
regimen O O
that O O
included O O
cisplatin O B-DRUG
, O O
etoposide B-DRUG O
and O O
bleomycin O B-DRUG

recombinant B-DRUG O
human I-DRUG O
interferon-alpha I-DRUG B-DRUG
has O O
been O O
used O O
in O O
the O O
treatment O O
of O O
several O O
cancers O O
, O O
but O O
there O O
have O O
been O O
several O O
reports O O
that O O
it O O
may O O
exacerbate B-ADR O
psoriasis I-ADR B-ADR
or I-ADR O
trigger I-ADR O
off I-ADR O
its I-ADR O
onset I-ADR O

heat B-ADR B-ADR
stroke I-ADR I-ADR
in O O
schizophrenia O O
during O O
clozapine B-DRUG B-DRUG
treatment O O
: O O
rapid O O
recognition O O
and O O
management O O

two O O
days O O
after O O
administration O O
of O O
kalimate B-DRUG B-DRUG
enema O O
, O O
he O O
had O O
profuse B-ADR O
hematochezia I-ADR O
, O O
and O O
a O O
sigmoidoscopy O O
showed O O
diffuse O O
colonic O B-ADR
mucosal O I-ADR
necrosis O I-ADR
in O O
the O O
rectum O O
and O O
sigmoid O O
colon O O

we O O
report O O
a O O
case O O
of O O
pancytopenia B-ADR B-ADR
in O O
a O O
23-year-old O O
man O O
with O O
crohn O O
's O O
disease O O
who O O
was O O
treated O O
with O O
5-aminosalicylic O O
acid O O
( O O
pentasa B-DRUG O
; O O
nisshin O O
, O O
tokyo O O
, O O
japan O O
) O O
3.0 O O
g O O
/ O O
day O O

a O O
49-year-old O O
man O O
with O O
crohn O O
's O O
disease O O
treated O O
with O O
prednisone O B-DRUG
and O O
mesalamine O O
( O O
5-asa B-DRUG O
) O O
developed O O
worsening B-ADR O
respiratory I-ADR O
distress I-ADR O
and O O
fever O B-ADR

theophylline B-ADR B-ADR
intoxication I-ADR I-ADR
following O O
viloxazine O B-DRUG
induced O O
decrease O O
in O O
clearance O O

olanzapine-induced O O
hyperglycaemic B-ADR B-ADR
coma I-ADR I-ADR
and O O
neuroleptic O O
malignant O O
syndrome O O
: O O
case O O
report O O
and O O
review O O
of O O
literature O O

the O O
fever B-ADR B-ADR
abated O O
promptly O O
following O O
discontinuation O O
of O O
acyclovir B-DRUG B-DRUG
, O O
and O O
radiographic O B-ADR
abnormalities O I-ADR
resolved O O
over O O
ten O O
days O O

a O O
patient O O
with O O
chronic O O
myeloid O O
leukaemia O O
treated O O
with O O
busulphan B-DRUG B-DRUG
for O O
4-5 O O
years O O
, O O
developed O O
signs O O
of O O
busulphan B-DRUG B-DRUG
toxicity O O
and O O
portal O O
hypertension O O
with O O
ascites O O
, O O
oesophageal O O
varices O O
and O O
jaundice B-ADR O

it O O
was O O
concluded O O
that O O
anca B-ADR B-DRUG
is O O
closely O O
related O O
to O O
the O O
pathogenesis O O
of O O
crescentic O B-ADR
glomerulonephritis O I-ADR
and O O
that O O
treatment O O
with O O
ptu B-DRUG B-DRUG
appeared O O
to O O
induce O O
anca B-ADR B-ADR

paradoxical B-ADR B-ADR
ventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
and O O
fibrillation O O
after O O
intravenous O O
bretylium B-DRUG B-DRUG
therapy O O

conclusions O O
: O O
colchicine-induced O O
myopathy B-ADR B-ADR
should O O
be O O
excluded O O
in O O
patients O O
with O O
fmf O B-DRUG
who O O
present O O
with O O
generalized O B-ADR
muscle O I-ADR
weakness O I-ADR

the O O
case O O
of O O
an O O
adult O O
who O O
developed O O
both O O
hepatic O O
dysfunction O O
and O O
an O O
impaired B-ADR B-ADR
macrophage I-ADR I-ADR
migration I-ADR I-ADR
after O O
exposure O O
to O O
cimetidine B-DRUG B-DRUG
is O O
discussed O O

however O O
, O O
he O O
developed O O
acute O O
renal O O
failure O O
, O O
hyperkalemia B-ADR O
, O O
and O O
hyperuricemia O O
30 O O
d O O
after O O
receiving O O
the O O
sorafenib B-DRUG B-DRUG
treatment O O

acute B-ADR B-ADR
endophthalmitis I-ADR I-ADR
following O O
intravitreal O O
bevacizumab O B-DRUG
( O O
avastin B-DRUG B-DRUG
) O O
injection O O

we O O
describe O O
a O O
patient O O
with O O
metastatic O O
prostate O O
cancer O O
who O O
developed O O
nonoliguric B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
during O O
treatment O O
with O O
suramin B-DRUG B-DRUG

duodenal B-ADR B-ADR
ulceration I-ADR I-ADR
: O O
a O O
complication O O
of O O
tolazoline B-DRUG B-DRUG
therapy O O

radiation B-ADR B-ADR
recall I-ADR I-ADR
pneumonitis I-ADR I-ADR
induced O O
by O O
gemcitabine B-DRUG B-DRUG

bull's-eye B-ADR B-ADR
maculopathy I-ADR I-ADR
associated O O
with O O
quinacrine B-DRUG B-DRUG
therapy O O
for O O
malaria O O

preliminary O O
results O O
suggest O O
that O O
the O O
higher O O
concentrations O O
of O O
dextrose B-DRUG B-DRUG
induce O O
increased B-ADR O
histamine I-ADR B-DRUG
release I-ADR O
from O O
blood O O
cells O O
, O O
and O O
that O O
this O O
phenomenon O O
is O O
more O O
marked O O
in O O
diabetic O O
, O O
and O O
particularly O O
diabetic-allergic O O
, O O
individuals O O

this O O
is O O
the O O
first O O
case O O
of O O
hydroxyurea-induced O O
acute B-ADR B-ADR
interstitial I-ADR I-ADR
pneumonitis I-ADR I-ADR
reported O O
in O O
the O O
literature O O

we O O
postulate O O
that O O
the O O
bolus O O
of O O
sulprostone B-DRUG B-DRUG
resulted O O
in O O
possible O O
coronary O O
spasm O O
that O O
resulted O O
in O O
cardiac B-ADR B-ADR
arrest I-ADR I-ADR

delusional B-ADR B-ADR
parasitosis I-ADR I-ADR
associated O O
with O O
phenelzine B-DRUG B-DRUG

well-known O O
signs O O
of O O
methotrexate B-ADR B-DRUG
toxicity I-ADR O
include O O
bone O O
marrow O O
suppression O O
and O O
oral O O
and O O
gastrointestinal O B-ADR
ulceration O I-ADR

discussion O O
: O O
after O O
exclusion O O
of O O
other O O
causes O O
, O O
the O O
onset O O
of O O
thrombocytopenia O B-ADR
after O O
administration O O
of O O
lansoprazole B-DRUG B-DRUG
, O O
the O O
resolution O O
of O O
the O O
adverse O O
reaction O O
after O O
discontinuation O O
of O O
the O O
drug O O
, O O
and O O
the O O
fact O O
that O O
no O O
other O O
medicines O O
were O O
introduced O O
during O O
this O O
time O O
frame O O
lead O O
us O O
to O O
believe O O
that O O
this O O
was O O
most O O
likely O O
an O O
idiosyncratic O O
thrombocytopenic B-ADR O
response O O
to O O
lansoprazole B-DRUG B-DRUG

flucloxacillin-induced O O
aplastic B-ADR B-ADR
anaemia I-ADR I-ADR
and O O
liver O O
failure O O

other O O
potential O O
causes O O
of O O
renal B-ADR O
failure I-ADR O
were O O
not O O
present O O
in O O
our O O
patient O O
and O O
his O O
renal O O
function O O
gradually O O
recovered O O
with O O
the O O
cessation O O
of O O
suramin B-DRUG B-DRUG
treatment O O

possible O O
induction O O
of O O
diabetes B-ADR B-ADR
by O O
treatment O O
of O O
hypertension O O
with O O
indapamide B-DRUG B-DRUG
( O O
with O O
four O O
case O O
reports O O

treatment O O
of O O
carbimazole-induced O O
agranulocytosis O B-ADR
and O O
sepsis B-ADR O
with O O
granulocyte O O
colony O O
stimulating O O
factor O O

the O O
patient O O
completed O O
a O O
10-month O O
follow-up O O
, O O
maintaining O O
a O O
complete O O
resolution O O
of O O
the O O
treated O O
skin O O
lesions O O
; O O
however O O
, O O
the O O
development O O
of O O
a O O
painful B-ADR B-ADR
hand I-ADR I-ADR
ulcer I-ADR I-ADR
, O O
possibly O O
associated O O
with O O
the O O
hydroxyurea B-DRUG B-DRUG
, O O
and O O
new O O
skin O O
cancers O O
were O O
observed O O
at O O
the O O
last O O
follow-up O O
visit O O

the O O
latter O O
form O O
( O O
macrodantin B-DRUG B-DRUG
) O O
is O O
reported O O
to O O
engender O O
less O O
gastrointestinal O O
intolerance O O
but O O
it O O
can O O
produce O O
the O O
same O O
adverse O O
effects O O
as O O
the O O
conventional O O
form O O
-- O O
liver B-ADR O
damage I-ADR O
, O O
acute O O
and O O
chronic O O
pulmonary O O
reactions O O
, O O
peripheral O O
neuropathy O O
, O O
blood O O
dyscrasias O O
and O O
allergic O O
reactions O O
-- O O
and O O
does O O
so O O
just O O
as O O
rapidly O O
and O O
floridly O O
; O O
one O O
such O O
case O O
is O O
reported O O
here O O

studies O O
performed O O
10 O O
years O O
ago O O
on O O
25 O O
patients O O
with O O
mtx-induced O O
liver O B-ADR
cirrhosis B-ADR I-ADR
indicated O O
that O O
this O O
type O O
of O O
cirrhosis B-ADR B-ADR
was O O
not O O
of O O
an O O
aggressive O O
nature O O

patient O O
b O O
developed O O
perioral B-ADR O
and I-ADR O
upper I-ADR B-ADR
extremity I-ADR I-ADR
paresthesias I-ADR I-ADR
during O O
the O O
fourth O O
cycle O O
of O O
cap B-DRUG B-DRUG
alone O O
( O O
2500 O O
mg O O
/ O O
m2 O O

in O O
conclusion O O
, O O
rsds B-ADR B-ADR
is O O
a O O
relevant O O
osteoarticular O O
complication O O
in O O
patients O O
receiving O O
either O O
anticalcineurinic O O
drug O O
( O O
cya B-DRUG O
or O O
tacrolimus O O
) O O
, O O
even O O
under O O
monotherapy O O
or O O
with O O
a O O
low O O
steroid O O
dose O O

cardiac B-ADR B-ADR
toxicity I-ADR I-ADR
related O O
to O O
bcnu B-DRUG B-DRUG
has O O
not O O
been O O
described O O
well O O

she O O
had O O
been O O
on O O
copaxone B-DRUG B-DRUG
20 O O
mg O O
/ O O
day O O
treatment O O
for O O
2 O O
years O O
when O O
she O O
first O O
exhibited O O
gastrointestinal B-ADR B-ADR
symptoms I-ADR I-ADR

this O O
article O O
reports O O
the O O
case O O
of O O
an O O
otherwise O O
healthy O O
patient O O
who O O
experienced O O
permanent O O
sensorineural B-ADR B-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR
after O O
a O O
brief O O
course O O
of O O
naproxen B-DRUG B-DRUG
and O O
reviews O O
the O O
literature O O
on O O
nsaid-related O O
permanent O O
sensorineural B-ADR B-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR

potential O O
causes O O
of O O
methamphetamine-related O O
keratitis B-ADR B-ADR
can O O
be O O
divided O O
into O O
four O O
categories O O
resulting O O
from O O
( O O
a O O
) O O
direct O O
pharmacologic O O
and O O
physical O O
effects O O
of O O
methamphetamine B-DRUG B-DRUG
; O O
( O O
b O O
) O O
the O O
toxic O O
effects O O
of O O
diluting O O
or O O
" O O
cutting O O
" O O
agents O O
such O O
as O O
lidocaine O B-DRUG
and O O
quinine O O
; O O
( O O
c O O
) O O
effects O O
related O O
to O O
the O O
route O O
of O O
drug O O
administration O O
( O O
intravenous O O
, O O
inhalation O O
, O O
smoking O O
) O O
; O O
and O O
( O O
d O O
) O O
manufacture-related O O
effects O O
of O O
exposure O O
to O O
unintentional O O
caustic O O
contaminants O O
in O O
the O O
final O O
product O O

conclusion O O
: O O
these O O
cases O O
suggest O O
that O O
moxifloxacin B-DRUG B-DRUG
may O O
interfere O O
with O O
the O O
healing O O
of O O
corneal B-ADR B-ADR
ulcers I-ADR I-ADR

conclusions O O
: O O
anastrozole B-DRUG B-DRUG
may O O
be O O
the O O
causative O O
factor O O
in O O
patients O O
with O O
sclerosing B-ADR O
glomerulonephritis I-ADR O

the O O
incidence O O
of O O
angioedema B-ADR B-ADR
secondary O O
to O O
losartan B-DRUG B-DRUG
, O O
an O O
angiotensin O O
ii O O
receptor O O
antagonist O O
, O O
is O O
unknown O O

objective O O
: O O
to O O
report O O
the O O
finding O O
of O O
squamous B-ADR O
metaplasia I-ADR O
within I-ADR O
endometrial I-ADR O
glands I-ADR O
occurring O O
as O O
a O O
result O O
of O O
progestin B-DRUG B-DRUG
therapy O O
of O O
hyperplasia O O

central B-ADR O
nervous I-ADR O
system I-ADR O
manifestations I-ADR O
of O O
an O O
ibuprofen B-DRUG B-DRUG
overdose O O
reversed O O
by O O
naloxone O B-DRUG

we O O
report O O
the O O
occurrence O O
of O O
renal B-ADR B-ADR
failure I-ADR I-ADR
due O O
to O O
cholesterol O B-ADR
crystal O I-ADR
embolization O I-ADR
following O O
thrombolytic O O
therapy O O
with O O
intravenous O O
recombinant B-DRUG O
tissue-type I-DRUG O
plasminogen I-DRUG O
activator I-DRUG O
( O O
t-pa O B-DRUG

amphotericin B-DRUG B-DRUG
b I-DRUG I-DRUG
( O O
amb O O
) O O
is O O
effective O O
, O O
but O O
its O O
use O O
is O O
limited O O
by O O
toxicity O O
: O O
renal B-ADR O
impairment I-ADR O
, O O
anaemia O O
, O O
fever O O
, O O
malaise O O
, O O
and O O
hypokalaemia O O
are O O
common O O

psychosis B-ADR B-ADR
in O O
a O O
12-year-old O O
hiv-positive O O
girl O O
with O O
an O O
increased O O
serum O O
concentration O O
of O O
efavirenz B-DRUG B-DRUG

ticlopidine-induced O O
marrow B-ADR B-ADR
aplasia I-ADR I-ADR
treated O O
with O O
cyclosporine O B-DRUG

fatal B-ADR B-ADR
lung I-ADR I-ADR
fibrosis I-ADR I-ADR
caused O O
by O O
paclitaxel B-DRUG B-DRUG
toxicity O O
has O O
not O O
been O O
reported O O
in O O
this O O
report O O
, O O
we O O
describe O O
the O O
case O O
of O O
a O O
62-year-old O O
woman O O
who O O
received O O
six O O
cycles O O
of O O
paclitaxel B-DRUG B-DRUG
and O O
carboplatin O B-DRUG
as O O
combination O O
chemotherapy O O
for O O
advanced O O
ovarian O O
cancer O O

he O O
had O O
been O O
taking O O
trimethoprim-sulfamethoxazole O B-DRUG
for O O
approximately O O
eight O O
days O O
when O O
he O O
revisited O O
his O O
family O O
physician O O
, O O
complaining O O
of O O
headaches O O
, O O
dizziness O O
, O O
difficulty O O
with O O
speech O O
, O O
weakness B-ADR O
, O O
and O O
itching O O
on O O
the O O
trunk O O
of O O
his O O
body O O
and O O
legs O O
, O O
where O O
a O O
maculopapular O O
rash O O
was O O
noted O O

we O O
report O O
four O O
cases O O
of O O
encephalopathy O B-ADR
coincident O O
with O O
elevated B-ADR O
aluminum I-ADR O
levels I-ADR O
as O O
well O O
as O O
one O O
patient O O
who O O
developed O O
seizures O B-ADR
while O O
receiving O O
continuous O O
bladder O O
irrigations O O
with O O
alum B-DRUG B-DRUG

bortezomib-induced O O
paralytic O B-ADR
ileus O I-ADR
is O O
a O O
potential O O
gastrointestinal B-ADR O
side I-ADR O
effect I-ADR O
of O O
this O O
first-in-class O O
anticancer O O
proteasome O O
inhibitor O O

in O O
two O O
patients O O
with O O
mycosis O O
fungoides O O
, O O
a O O
squamous B-ADR O
cell I-ADR O
carcinoma I-ADR O
developed O O
during O O
therapy O O
with O O
psoralens B-DRUG B-DRUG
plus O O
long-wave O O
ultraviolet O O
radiation O O
( O O
puva O B-DRUG

the O O
authors O O
describe O O
a O O
case O O
of O O
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
that O O
occurred O O
in O O
a O O
patient O O
on O O
amitriptyline B-DRUG B-DRUG
and O O
lithium O B-DRUG
carbonate O I-DRUG

we O O
have O O
cared O O
for O O
three O O
children O O
in O O
whom O O
four O O
episodes O O
of O O
dystonia O B-ADR
proceeding O O
to O O
opisthotonus B-ADR B-ADR
occurred O O
in O O
association O O
with O O
carbamazepine B-DRUG B-DRUG
use O O

the O O
concomitant O O
use O O
, O O
however O O
, O O
of O O
colchicine B-DRUG B-DRUG
and O O
statin O B-DRUG
has O O
been O O
associated O O
with O O
the O O
rapid O O
onset O O
of O O
muscle B-ADR B-ADR
weakness I-ADR I-ADR

two O O
patients O O
with O O
ovarian O O
cancer O O
who O O
had O O
received O O
multiple O O
courses O O
of O O
cisplatin B-DRUG B-DRUG
without O O
complications O O
experienced O O
hypersensitivity O O
reactions O O
to O O
cisplatin B-DRUG B-DRUG
: O O
one O O
, O O
involving O O
intrahepatic O O
artery O O
infusion O O
, O O
manifested O O
general O O
erythema O O
, O O
dyspnea O O
, O O
and O O
hypotension B-ADR O
; O O
the O O
other O O
, O O
involving O O
intravenous O O
infusion O O
, O O
manifested O O
abdominal O O
pain O O
, O O
general O O
erythema O O
, O O
and O O
fever O B-ADR

although O O
retinoic B-DRUG B-DRUG
acid I-DRUG I-DRUG
is O O
well O O
tolerated O O
by O O
the O O
majority O O
of O O
patients O O
with O O
this O O
disease O O
, O O
a O O
potentially O O
fatal B-ADR O
complication I-ADR O
of O O
this O O
kind O O
of O O
treatment O O
has O O
been O O
reported O O
: O O
" O O
the O O
retinoic B-DRUG B-ADR
acid I-DRUG I-ADR
syndrome O I-ADR

procainamide-induced O O
incessant B-ADR B-ADR
supraventricular I-ADR I-ADR
tachycardia I-ADR I-ADR
in O O
the O O
wolff-parkinson-white O O
syndrome O O

ziprasidone B-DRUG B-DRUG
is O O
an O O
atypical O O
antipsychotic O O
drug O O
that O O
is O O
believed O O
to O O
have O O
a O O
low O O
propensity O O
for O O
inducing O O
extrapyramidal B-ADR O
symptoms I-ADR O
, O O
including O O
tardive O O
dyskinesia O O
( O O
td O B-ADR

thus O O
, O O
tardive B-ADR B-ADR
seizures I-ADR I-ADR
in O O
our O O
cases O O
are O O
thought O O
to O O
be O O
related O O
to O O
piperacillin B-DRUG B-DRUG
and O O
cefotiam O B-DRUG

temozolomide-induced O O
desquamative B-ADR B-ADR
skin I-ADR I-ADR
rash I-ADR I-ADR
in O O
a O O
patient O O
with O O
metastatic O O
melanoma O O

the O O
potential O O
for O O
progressive O O
brain B-ADR O
injury I-ADR O
and O O
subsequent O O
disability O O
related O O
to O O
intraventricular O O
il-2 B-DRUG B-DRUG
therapy O O
is O O
discussed O O

carbamazepine-induced O O
systemic B-ADR B-ADR
lupus I-ADR I-ADR
erythematosus I-ADR I-ADR

conclusions O O
: O O
clinicians O O
should O O
be O O
aware O O
of O O
a O O
risk O O
of O O
serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
with O O
serious O O
extrapyramidal O B-ADR
reactions O I-ADR
in O O
patients O O
receiving O O
sertraline O B-DRUG
or O O
venlafaxine O B-DRUG
when O O
metoclopramide B-DRUG B-DRUG
is O O
coadministered O O
even O O
in O O
a O O
single O O
, O O
conventional O O
dose O O

objective O O
: O O
to O O
document O O
a O O
case O O
of O O
serotonin B-ADR O
syndrome I-ADR O
( O O
ss O B-ADR
) O O
associated O O
with O O
mirtazapine B-DRUG B-DRUG
monotherapy O O
, O O
review O O
the O O
previously O O
reported O O
cases O O
of O O
ss O B-ADR
associated O O
with O O
this O O
tetracyclic O O
antidepressant O O
, O O
and O O
discuss O O
the O O
possible O O
pathogenic O O
mechanisms O O
leading O O
to O O
this O O
serious O O
adverse O O
drug O O
reaction O O

this O O
report O O
describes O O
a O O
case O O
of O O
neuroleptic B-ADR B-ADR
malignant I-ADR I-ADR
syndrome I-ADR I-ADR
due O O
to O O
risperidone B-DRUG B-DRUG
in O O
a O O
child O O
with O O
joubert O O
syndrome O O

the O O
occurrence O O
of O O
acute O B-ADR
hepatitis B-ADR I-ADR
is O O
best O O
known O O
for O O
ketoconazole B-DRUG B-DRUG

mitomycin B-DRUG O
c I-DRUG O
( O O
mmc O B-DRUG
) O O
is O O
an O O
alkylating O O
agent O O
that O O
has O O
been O O
recently O O
associated O O
with O O
the O O
hemolytic-uremic B-ADR O
syndrome I-ADR O
( O O
hus O B-ADR

hyperammonemia O B-ADR
secondary O O
to O O
valproic B-DRUG B-DRUG
acid I-DRUG I-DRUG
as O O
a O O
cause O O
of O O
lethargy B-ADR B-ADR
in O O
a O O
postictal O O
patient O O

three O O
nephrotic O O
patients O O
who O O
had O O
reduced O O
renal O O
function O O
and O O
active O O
renal O O
disease O O
with O O
progressive O O
deterioration O O
of O O
renal O O
function O O
prior O O
to O O
the O O
use O O
of O O
mp B-DRUG O
developed O O
transient B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
following O O
an O O
mp B-DRUG B-DRUG
pulse O O
therapy O O

an O O
intertrigo-like B-ADR B-ADR
eruption I-ADR I-ADR
from O O
pegylated O O
liposomal O O
doxorubicin B-DRUG B-DRUG

case O O
summary O O
: O O
a O O
65-year-old O O
patient O O
chronically O O
treated O O
with O O
the O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
( O O
ssri O O
) O O
citalopram O B-DRUG
developed O O
confusion O O
, O O
agitation O O
, O O
tachycardia O O
, O O
tremors O O
, O O
myoclonic O O
jerks O O
and O O
unsteady B-ADR O
gait I-ADR O
, O O
consistent O O
with O O
serotonin O O
syndrome O O
, O O
following O O
initiation O O
of O O
fentanyl B-DRUG B-DRUG
, O O
and O O
all O O
symptoms O O
and O O
signs O O
resolved O O
following O O
discontinuation O O
of O O
fentanyl B-DRUG B-DRUG

three O O
of O O
these O O
patients O O
had O O
convulsions B-ADR B-ADR
attributed O O
to O O
imipenem B-DRUG B-DRUG
/ O O
cilastatin O B-DRUG
; O O
3.6 O O
% O O
of O O
the O O
patients O O
had O O
seizure O B-ADR
, O O
or O O
2 O O
% O O
of O O
imipenem B-DRUG O
/ O O
cilastatin O B-DRUG
administrations O O
was O O
followed O O
by O O
a O O
seizure O O
attack O O

although O O
both O O
patients O O
recovered O O
from O O
the O O
colitis B-ADR B-ADR
after O O
the O O
administration O O
of O O
vancomycin O B-DRUG
, O O
the O O
first O O
case O O
demonstrated O O
a O O
relapse O B-ADR
of O I-ADR
the O I-ADR
colitis B-ADR I-ADR
after O O
receiving O O
a O O
subsequent O O
course O O
of O O
the O O
same O O
chemotherapy O O
with O O
cisplatin B-DRUG B-DRUG

musculoskeletal B-ADR B-ADR
complaints I-ADR I-ADR
were O O
the O O
presenting O O
symptoms O O
in O O
four O O
of O O
44 O O
children O O
( O O
9 O O
%) O O
treated O O
for O O
relapsed O O
wilms' O O
tumors O O
with O O
ifosfamide O B-DRUG
, O O
a O O
derivative O O
of O O
cyclophosphamide B-DRUG B-DRUG

self-limited B-ADR B-ADR
edema I-ADR I-ADR
is O O
a O O
well-recognized O O
complication O O
of O O
insulin B-DRUG B-DRUG
therapy O O

acute B-ADR B-ADR
asthma I-ADR I-ADR
associated O O
with O O
sustained-release O O
verapamil B-DRUG B-DRUG

recently O O
, O O
her O O
serum O O
theophylline B-ADR B-DRUG
levels I-ADR O
had I-ADR O
increased I-ADR O
to I-ADR O
the I-ADR O
toxic I-ADR O
range I-ADR O
( O O
133.2 O O
micromol O O
/ O O
l O O
[ O O
24 O O
microg O O
/ O O
ml O O
]) O O
shortly O O
after O O
the O O
addition O O
of O O
zafirlukast O O
( O O
accolate B-DRUG O
, O O
zeneca O O
pharmaceuticals O O
, O O
wilmington O O
, O O
del O O
) O O
to O O
her O O
regimen O O

amikacin-induced O O
type B-ADR O
5 I-ADR O
bartter-like I-ADR O
syndrome I-ADR O
with O O
severe O O
hypocalcemia O O

even O O
though O O
only O O
a O O
few O O
cases O O
of O O
this O O
adverse O O
event O O
have O O
been O O
reported O O
in O O
the O O
literature O O
, O O
severe O O
docetaxel-induced O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
needs O O
to O O
be O O
considered O O
in O O
the O O
differential O O
diagnosis O O
when O O
such O O
patients O O
present O O
with O O
respiratory O O
symptoms O O

pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
associated O O
with O O
nabumetone B-DRUG B-DRUG

drug O O
induced O O
liver B-ADR B-ADR
injury I-ADR I-ADR
secondary O O
to O O
interferon-beta B-DRUG B-DRUG
( O O
ifn-beta O O
) O O
in O O
multiple O O
sclerosis O O

discontinuation O O
of O O
the O O
itraconazole B-DRUG B-DRUG
caused O O
resolution O O
of O O
the O O
drug B-ADR B-ADR
eruption I-ADR I-ADR

after O O
the O O
first O O
oral O O
dose O O
of O O
propranolol B-DRUG B-DRUG
, O O
syncope O B-ADR
developed O O
together O O
with O O
atrioventricular B-ADR O
block I-ADR O

conclusions O O
: O O
we O O
report O O
a O O
typical O O
symptoms O O
of O O
charles-bonnet O B-ADR
syndrome O I-ADR
( O O
cbs B-ADR O
) O O
in O O
patients O O
with O O
severe O O
amd O O
after O O
intravitreal O O
avastin-injections O O

the O O
former O O
patient O O
had O O
complained O O
once O O
that O O
his O O
visual B-ADR O
acuity I-ADR O
had I-ADR O
decreased I-ADR O
after O O
the O O
termination O O
of O O
ifn B-DRUG B-DRUG
therapy O O
, O O
and O O
the O O
latter O O
patient O O
complained O O
twice O O
during O O
ifn B-DRUG B-DRUG
therapy O O
that O O
his O O
visual B-ADR O
acuity I-ADR O
had I-ADR O
decreased I-ADR O

priapism B-ADR B-ADR
associated O O
with O O
zuclopenthixol B-DRUG B-DRUG

glomerulonephritis O B-ADR
in O O
procainamide B-DRUG B-DRUG
induced O O
lupus B-ADR B-ADR
erythematosus I-ADR I-ADR
: O O
report O O
of O O
a O O
case O O
and O O
review O O
of O O
the O O
literature O O

the O O
most O O
commonly O O
recognized O O
toxic O O
effect O O
of O O
ethambutol B-DRUG B-DRUG
is O O
optic B-ADR O
neuropathy I-ADR O
, O O
which O O
generally O O
is O O
considered O O
uncommon O O
and O O
reversible O O
in O O
medical O O
literature O O

after O O
treatment O O
with O O
cimetidine B-DRUG B-DRUG
, O O
there O O
was O O
a O O
rapid O O
deterioration O O
with O O
decreased B-ADR O
oxygen I-ADR O
saturation I-ADR O
and I-ADR O
arterial I-ADR O
po2 I-ADR O
values O O

after O O
reviewing O O
the O O
literature O O
we O O
suggest O O
the O O
cpm B-ADR O
was O O
a O O
complication O O
of O O
lithium B-DRUG B-DRUG
toxicity O O
which O O
affected O O
the O O
lateral O O
geniculate O O
nucleus O O
which O O
produced O O
blindness O B-ADR

ifosfamide B-DRUG B-DRUG
is O O
a O O
known O O
nephrotoxic O O
drug O O
with O O
demonstrated O O
tubulopathies B-ADR B-ADR

hyperpigmentation B-ADR B-ADR
during O O
interferon-alpha B-DRUG B-DRUG
therapy O O
for O O
chronic O O
hepatitis O O
c O O
virus O O
infection O O

risperidone B-DRUG B-DRUG
is O O
a O O
frequently O O
used O O
member O O
of O O
a O O
new O O
class O O
of O O
atypical O O
antipsychotics-the O O
serotonin-dopamine O O
antagonists O O
( O O
sdas O O
)- O O
due O O
to O O
its O O
comparatively O O
high O O
efficacy O O
and O O
low O O
d2 O O
/ O O
5ht2 O O
binding O O
ratio O O
, O O
which O O
results O O
in O O
a O O
low O O
incidence O O
of O O
extrapyramidal O O
side O O
effects O O
including O O
tardive O O
dyskinesia O O
( O O
td B-ADR B-ADR

papillary B-ADR B-ADR
necrosis I-ADR I-ADR
associated O O
with O O
the O O
hiv O O
protease O O
inhibitor O O
indinavir B-DRUG B-DRUG

he O O
had O O
hypokalemia B-ADR O
( O O
k O O
2.3 O O
mmol O O
/ O O
l O O
) O O
induced O O
by O O
licorice B-DRUG O
and O O
also O O
had O O
received O O
disopyramide O B-DRUG
for O O
arrhythmia O O
, O O
bicalutamide O O
for O O
prostate O O
cancer O O
, O O
and O O
silodosin O B-DRUG
for O O
prostate O O
hypertrophy O O

skin O O
rash O O
and O O
splinter B-ADR O
hemorrhages I-ADR O
from O O
ganciclovir B-DRUG B-DRUG

the O O
authors O O
suggest O O
that O O
in O O
the O O
absence O O
of O O
any O O
proven O O
benefit O O
of O O
itraconazole O B-DRUG
prophylaxis O O
, O O
and O O
given O O
the O O
interaction O O
of O O
this O O
drug O O
with O O
vincristine B-DRUG B-DRUG
leading O O
to O O
severe O O
and O O
even O O
potentially O O
fatal B-ADR O
toxicities I-ADR O
, O O
the O O
combination O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O

sweet B-ADR O
's I-ADR O
syndrome I-ADR O
is O O
an O O
acute O O
febrile O O
neutrophilic O O
dermatosis O O
that O O
is O O
a O O
known O O
complication O O
of O O
the O O
administration O O
of O O
filgrastim B-DRUG B-DRUG
, O O
a O O
drug O O
that O O
causes O O
increased O O
neutrophil O O
proliferation O O
and O O
differentiation O O

hepatocellular B-ADR B-ADR
damage I-ADR I-ADR
following O O
therapeutic O O
intravenous O O
iron B-DRUG B-DRUG
sucrose I-DRUG I-DRUG
infusion O O
in O O
a O O
child O O

our O O
patient O O
had O O
headache O O
, O O
mild B-ADR O
fever I-ADR O
, O O
nausea O O
, O O
vomiting O O
, O O
rash O O
, O O
and O O
eosinophilia O B-ADR
after O O
3 O O
weeks O O
of O O
disulfiram B-DRUG B-DRUG
therapy O O

hemolytic B-ADR B-ADR
uremic I-ADR I-ADR
syndrome I-ADR I-ADR
following O O
the O O
infusion O O
of O O
oxaliplatin B-DRUG B-DRUG
: O O
case O O
report O O

we O O
report O O
a O O
case O O
of O O
an O O
11-year-old O O
boy O O
who O O
experienced O O
an O O
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
after O O
administration O O
of O O
bacitracin B-DRUG B-DRUG
ointment O O

a O O
patient O O
is O O
presented O O
with O O
typical O O
hyperthyroidism O O
, O O
who O O
developed O O
a O O
severe O O
proximal O O
muscle O O
weakness O O
and O O
a O O
raised B-ADR O
creatine I-ADR O
phosphokinase I-ADR O
after O O
treatment O O
for O O
hyperthyroidism O O
with O O
propylthiouracil B-DRUG B-DRUG
( O O
100 O O
mg O O
orally O O
, O O
three O O
times O O
a O O
day O O

itraconazole-related O O
increased O O
vincristine B-ADR B-DRUG
neurotoxicity I-ADR B-ADR
: O O
case O O
report O O
and O O
review O O
of O O
literature O O

photo-onycholysis B-ADR B-ADR
caused O O
by O O
olanzapine O B-DRUG
and O O
aripiprazole B-DRUG B-DRUG

objective O O
: O O
1 O O
) O O
to O O
describe O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O
receiving O O
adalimumab B-DRUG B-DRUG
who O O
developed O O
fever O O
, O O
pancytopenia O O
, O O
splenomegaly O O
, O O
and O O
extreme B-ADR O
hyperferritinemia I-ADR O

a O O
22-year-old O O
black O O
man O O
developed O O
fever O O
, O O
chills O O
, O O
fatigue O O
, O O
night B-ADR O
sweats I-ADR O
, O O
tender O O
lymphadenopathy O O
, O O
and O O
a O O
generalized O O
, O O
pruritic O O
, O O
macular O O
eruption O O
3 O O
weeks O O
after O O
starting O O
minocycline B-DRUG B-DRUG
therapy O O
for O O
acne O O

we O O
describe O O
a O O
patient O O
with O O
acute O O
myeloblastic O O
leukemia O O
( O O
aml O O
) O O
who O O
developed O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
after O O
receiving O O
several O O
courses O O
of O O
chemotherapy O O
, O O
including O O
macrophage-colony-stimulating O O
factor O O
( O O
m-csf B-DRUG B-DRUG

a O O
55-yr-old O O
man O O
developed O O
prolonged O O
jaundice O O
and O O
sicca B-ADR O
complex I-ADR O
after O O
a O O
course O O
of O O
thiabendazole B-DRUG B-DRUG
therapy O O

autopsy O O
findings O O
were O O
consistent O O
with O O
bleomycin O B-DRUG
and O O
oxygen-induced O O
pulmonary B-ADR B-ADR
damage I-ADR I-ADR

cyclophosphamide B-DRUG B-DRUG
pneumonitis B-ADR B-ADR

on O O
day O O
7 O O
of O O
linezolid B-DRUG B-DRUG
treatment O O
, O O
the O O
patient O O
developed O O
severe B-ADR O
pruritus I-ADR O
, O O
macular O O
rash O O
, O O
facial O O
edema O O
, O O
eosinophilia O O
, O O
marked O O
increase O O
in O O
serum O O
creatinine O O
level O O
, O O
and O O
mild O O
hepatitis O O

here O O
we O O
report O O
a O O
patient O O
with O O
newly O O
diagnosed O O
acute O O
promyelocytic O O
leukemia O O
who O O
developed O O
acute O O
focal O O
myositis O O
, O O
synovitis O O
, O O
and O O
possible B-ADR O
vasculitis I-ADR O
, O O
after O O
receiving O O
all-trans B-DRUG B-DRUG
retinoic I-DRUG I-DRUG
acid I-DRUG I-DRUG
therapy O O

rifampin B-DRUG B-DRUG
( O O
rfp O B-DRUG
) O O
increases O O
hepatic O O
microsomal O O
enzyme O O
activity O O
, O O
and O O
there O O
are O O
case O O
reports O O
of O O
rfp-induced O O
hypothyroidism B-ADR B-ADR
, O O
all O O
associated O O
with O O
hashimoto O O
's O O
thyroiditis O B-ADR

teicoplanin-induced O O
agranulocytosis B-ADR B-ADR
that O O
followed O O
vancomycin-induced O O
agranulocytosis B-ADR B-ADR
suggests O O
a O O
possible O O
cross-reactivity O O
between O O
the O O
2 O O
drugs O O

we O O
report O O
a O O
case O O
of O O
penile B-ADR B-ADR
fibrosis I-ADR I-ADR
after O O
intracavernous O O
self-injection O O
of O O
a O O
combination O O
of O O
phentolamine O B-DRUG
and O O
papaverine B-DRUG B-DRUG

acute O O
valproate B-DRUG B-DRUG
ingestion O O
induces O O
symptomatic B-ADR B-ADR
methemoglobinemia I-ADR I-ADR

when O O
sasp O B-DRUG
was O O
changed O O
to O O
5-aminosalicylic O O
acid O O
( O O
5-asa B-DRUG O
) O O
, O O
his O O
skin O O
eruptions O O
were O O
resolved O O
, O O
however O O
, O O
he O O
developed O O
weakness O O
and O O
atrophy O O
in O O
his O O
right O O
arm O O
as O O
well O O
as O O
progressive O O
worsening O O
of O O
the O O
dysesthesia O O
in O O
his O O
legs O O
and O O
gait B-ADR O
disturbance I-ADR O

a O O
patient O O
presented O O
with O O
a O O
painful B-ADR O
, I-ADR O
oedematous I-ADR O
, I-ADR O
cyanosed I-ADR O
hand I-ADR O
having O O
injected O O
a O O
solution O O
of O O
diamorphine B-DRUG O
and O O
methylphenidate O B-DRUG
into O O
his O O
radial O O
artery O O

our O O
objective O O
is O O
to O O
present O O
a O O
retrospective O O
analysis O O
of O O
the O O
dwi O O
findings O O
in O O
four O O
patients O O
who O O
suffered O O
subacute B-ADR B-ADR
neurotoxicity I-ADR I-ADR
after O O
intrathecal O O
mtx B-DRUG B-DRUG

colonic B-ADR B-ADR
necrosis I-ADR I-ADR
is O O
known O O
as O O
a O O
rare O O
complication O O
following O O
the O O
administration O O
of O O
kayexalate B-DRUG B-DRUG
( O O
sodium O B-DRUG
polystryrene O I-DRUG
sulfonate O I-DRUG
) O O
in O O
sorbitol O O

in O O
addition O O
to O O
its O O
known O O
effect O O
on O O
gallbladder O O
stasis O O
, O O
octreotide B-DRUG B-DRUG
alters B-ADR O
bile I-ADR O
acid I-ADR O
composition I-ADR O
and O O
may O O
thus O O
hasten O O
intrahepatic O O
sludge O O
and O O
stone O O
formation O O

growth B-ADR O
and I-ADR O
adrenal I-ADR O
suppression I-ADR O
in O O
asthmatic O O
children O O
treated O O
with O O
high-dose O O
fluticasone B-DRUG B-DRUG
propionate I-DRUG I-DRUG

conclusion O O
: O O
in O O
some O O
abstainers O O
who O O
take O O
cyanamide B-DRUG B-DRUG
for O O
several O O
years O O
, O O
thin O O
septum-like O B-ADR
liver O I-ADR
fibrosis O I-ADR
progresses O O
along O O
with O O
the O O
emergence O O
of O O
ground-glass B-ADR B-ADR
hepatocytes I-ADR I-ADR

a O O
typical O O
case O O
of O O
dextran-40 B-DRUG B-DRUG
associated O O
acute B-ADR O
renal I-ADR O
failure I-ADR O
is O O
presented O O

in O O
this O O
article O O
lithium B-DRUG B-DRUG
is O O
not O O
discussed O O
, O O
although O O
there O O
are O O
a O O
number O O
of O O
concerns O O
about O O
lithium B-DRUG B-DRUG
's O O
potential O O
teratogenicity O B-ADR
, O O
and O O
it O O
has O O
been O O
implicated O O
in O O
epstein B-ADR O
's I-ADR O
anomaly I-ADR O
, O O
a O O
congenital O O
heart O O
defect O O
among O O
infants O O
born O O
to O O
women O O
taking O O
lithium B-DRUG B-DRUG
; O O
as O O
with O O
other O O
medications O O
, O O
however O O
, O O
the O O
data O O
have O O
specific O O
limitations O O

these O O
cases O O
were O O
chosen O O
for O O
study O O
because O O
they O O
were O O
all O O
deaths B-ADR O
as O O
a O O
result O O
of O O
suicidal O B-ADR
ingestion O I-ADR
of O O
drugs O O
in O O
which O O
quetiapine B-DRUG B-DRUG
was O O
considered O O
a O O
significant O O
factor O O

methotrexate-induced O O
pneumonitis B-ADR B-ADR
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
and O O
psoriatic O O
arthritis O O
: O O
report O O
of O O
five O O
cases O O
and O O
review O O
of O O
the O O
literature O O

conclusions O O
: O O
we O O
report O O
the O O
first O O
case O O
of O O
gemcitabine-induced O O
labd B-ADR B-ADR

eosinophilia B-ADR B-ADR
has O O
been O O
encountered O O
from O O
0.2 O O
to O O
61.7 O O
% O O
in O O
clozapine-treated O O
patients O O
, O O
mostly O O
with O O
a O O
transient O O
course O O
and O O
spontaneous O O
remission O O

from O O
1996 O O
to O O
2002 O O
several O O
medications O O
were O O
changed O O
due O O
to O O
their O O
adverse O O
effects O O
: O O
indinavir O O
( O O
renal O O
colic O O
and O O
fever O O
) O O
, O O
nelfinavir B-DRUG O
( O O
cutaneous B-ADR O
rash I-ADR O
) O O
, O O
and O O
efavirenz O B-DRUG
( O O
nausea O O
and O O
temporary O O
memory O O
loss O O

however O O
, O O
eo-induced O O
noncardiogenic B-ADR B-ADR
pulmonary I-ADR I-ADR
edema I-ADR I-ADR
has O O
not O O
been O O
reported O O
in O O
human O O

torsade B-ADR B-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR
represents O O
a O O
potential O O
complication O O
of O O
chronic O O
amiodarone B-DRUG B-DRUG
therapy O O

the O O
results O O
clearly O O
demonstrate O O
that O O
cph82 B-DRUG B-DRUG
was O O
associated O O
with O O
suppression O O
of O O
the O O
endogeneous O O
production O O
of O O
acth O O
and O O
cortisol O O
with O O
a O O
concomitant O O
paradoxical O O
picture O O
of O O
clinical O O
hypercortisolism B-ADR O

we O O
present O O
a O O
case O O
report O O
of O O
a O O
patient O O
with O O
typhoid O O
fever O O
who O O
experienced O O
a O O
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
subsequent O O
to O O
the O O
infusion O O
of O O
chloramphenicol B-DRUG B-DRUG
sodium I-DRUG I-DRUG
succinate I-DRUG I-DRUG

the O O
patient O O
presented O O
with O O
fulminant O O
microangiopathic O O
hemolytic O O
anemia O O
and O O
thrombocytopenia B-ADR O
within O O
48 O O
hr O O
of O O
initiating O O
therapy O O
with O O
trimethoprim-sulfamethoxazole O B-DRUG

atrioventricular O B-ADR
block O I-ADR
complicating O O
amiodarone-induced O O
hypothyroidism B-ADR B-ADR
in O O
a O O
patient O O
with O O
pre-excitation O O
and O O
rate-dependent O O
bilateral O O
bundle O O
branch O O
block O O

the O O
authors O O
present O O
an O O
elderly O O
patient O O
with O O
mixed O O
dementia O O
who O O
developed O O
td O B-ADR
at O O
multiple O O
sites O O
, O O
( O O
including O O
respiratory B-ADR O
dyskinesia I-ADR O
[ O O
rd O O
] O O
, O O
limb O O
dyskinesia O O
, O O
and O O
orofacial O O
dyskinesia O O
) O O
following O O
abrupt O O
withdrawal O O
of O O
risperidone B-DRUG B-DRUG
therapy O O

other O O
upper B-ADR B-ADR
tract I-ADR I-ADR
neoplasms I-ADR I-ADR
after O O
cyclophosphamide B-DRUG B-DRUG
are O O
reviewed O O

antibiotic-associated O O
colitis B-ADR B-ADR
( O O
pseudomembranous O B-ADR
colitis B-ADR I-ADR
) O O
developed O O
in O O
four O O
patients O O
with O O
spinal O O
cord O O
injury O O
and O O
taking O O
oral O O
trimethoprim-sulfamethoxazole O B-DRUG

although O O
other O O
nitrites O O
induce O O
methemoglobinemia B-ADR B-ADR
, O O
exposure O O
to O O
methyl B-DRUG B-DRUG
nitrite I-DRUG I-DRUG
during O O
phenylpropanolamine O B-DRUG
production O O
appears O O
to O O
be O O
a O O
new O O
cause O O
of O O
occupational O B-ADR
methemoglobinemia B-ADR I-ADR

our O O
review O O
of O O
194 O O
ra O O
patients O O
and O O
38 O O
psa O O
patients O O
receiving O O
mtx B-DRUG B-DRUG
has O O
identified O O
four O O
ra O O
patients O O
and O O
one O O
psa O O
patient O O
with O O
mtx-induced O O
pneumonitis B-ADR B-ADR
, O O
giving O O
a O O
prevalence O O
of O O
2.1 O O
% O O
and O O
0.03 O O
% O O
, O O
respectively O O

we O O
described O O
a O O
very O O
atypical O O
case O O
of O O
a O O
high O O
stage O O
, O O
high O O
grade O O
endometrial B-ADR O
cancer I-ADR O
associated O O
with O O
tamoxifen B-DRUG B-DRUG
in O O
a O O
64-year-old O O
woman O O
with O O
a O O
past O O
history O O
of O O
breast O O
cancer O O

we O O
report O O
the O O
first O O
biopsy O O
confirmed O O
occurrence O O
of O O
acute B-ADR O
interstitial I-ADR B-ADR
nephritis I-ADR I-ADR
in O O
a O O
patient O O
receiving O O
treatment O O
with O O
sunitinib B-DRUG B-DRUG
for O O
metastatic O O
renal O O
cell O O
cancer O O

a O O
22-year-old O O
drug-abuser O O
injected O O
flunitrazepam B-DRUG B-DRUG
tablets O O
dissolved O O
in O O
tap O O
water O O
into O O
her O O
left O O
femoral O O
artery O O
and O O
presented O O
with O O
clinical O O
signs O O
of O O
acute B-ADR O
ischaemia I-ADR O
of I-ADR O
the I-ADR O
left I-ADR O
leg I-ADR O

we O O
report O O
two O O
patients O O
with O O
infectious B-ADR B-ADR
mononucleosis-like I-ADR I-ADR
syndrome I-ADR I-ADR
induced O O
by O O
salazosulfapyridine B-DRUG B-DRUG
( O O
sasp O B-DRUG

the O O
first O O
patient O O
was O O
a O O
61-year-old O O
man O O
with O O
a O O
30-year O O
history O O
of O O
fistulizing O O
cd O O
in O O
whom O O
b-cell B-ADR O
non-hodgkin I-ADR O
's I-ADR O
lymphoma I-ADR O
was O O
diagnosed O O
9 O O
months O O
after O O
treatment O O
with O O
infliximab B-DRUG B-DRUG

after O O
ruling O O
out O O
a O O
hydrotelluric O O
source O O
of O O
fluorine O B-DRUG
, O O
the O O
patient O O
's O O
fluorosis B-ADR B-ADR
was O O
linked O O
to O O
chronic O O
use O O
of O O
niflumic B-DRUG B-DRUG
acid I-DRUG I-DRUG
, O O
following O O
the O O
publication O O
in O O
1978 O O
of O O
the O O
2 O O
previously O O
reported O O
cases O O
affected O O
by O O
this O O
drug O O

the O O
fluorine O O
contained O O
in O O
niflumic B-DRUG B-DRUG
acid I-DRUG I-DRUG
induced O O
a O O
marked O O
densification B-ADR O
of I-ADR O
trabecular I-ADR O
bone I-ADR O
in O O
all O O
3 O O
cases O O

five O O
cases O O
( O O
four O O
from O O
the O O
literature O O
and O O
one O O
new O O
case O O
) O O
are O O
presented O O
in O O
which O O
patients O O
unsuspected O O
of O O
having O O
vitamin O O
b12 O O
deficiency O O
developed O O
subacute B-ADR O
combined I-ADR O
degeneration I-ADR O
of I-ADR O
the I-ADR O
spinal I-ADR O
cord I-ADR O
following O O
nitrous B-DRUG B-DRUG
oxide I-DRUG I-DRUG
anesthesia O O

oesophageal B-ADR B-ADR
ulceration I-ADR I-ADR
due O O
to O O
emepronium B-DRUG B-DRUG
bromide I-DRUG I-DRUG

the O O
third O O
patient O O
had O O
been O O
suffering O O
from O O
serious O O
akathisia O B-ADR
while O O
on O O
risperidone B-DRUG B-DRUG
, O O
and O O
was O O
cured O O
after O O
switching O O
to O O
olanzapine O B-DRUG
, O O
but O O
thereafter O O
the O O
patient O O
suffered O O
from O O
rls B-ADR B-ADR
at O O
nighttime O O

we O O
describe O O
two O O
dark-skinned O O
patients O O
who O O
developed O O
hyperpigmented O O
skin O O
and O O
tongue B-ADR B-ADR
lesions I-ADR I-ADR
during O O
combination O O
therapy O O
with O O
ifn B-DRUG B-DRUG
and O O
ribavirin O B-DRUG

acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
after O O
rituximab B-DRUG B-DRUG
infusion O O

abdominal O B-ADR
wall O I-ADR
ulceration O I-ADR
and O O
mucinosis B-ADR O
secondary O O
to O O
recombinant B-DRUG O
human I-DRUG O
interferon-beta-1b I-DRUG O

ovarian O B-ADR
endometrioid O I-ADR
carcinoma O I-ADR
and O O
endometriosis B-ADR O
developing O O
in O O
a O O
postmenopausal O O
breast O O
cancer O O
patient O O
during O O
tamoxifen B-DRUG B-DRUG
therapy O O
: O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O

we O O
postulate O O
that O O
cyclosporin O B-DRUG
, O O
possibly O O
together O O
with O O
ganciclovir B-DRUG B-DRUG
, O O
can O O
produce O O
transient B-ADR O
brain I-ADR O
stem I-ADR O
or I-ADR O
neuromuscular I-ADR O
dysfunction I-ADR O
with O O
eye O O
movement O O
abnormality O O
in O O
occasional O O
patients O O

among O O
12 O O
thyrotoxic O O
patients O O
, O O
a O O
patient O O
with O O
arrhythmogenic O O
right O O
ventricular O O
dysplasia O O
, O O
who O O
had O O
been O O
taking O O
amiodarone B-DRUG B-DRUG
for O O
4 O O
years O O
, O O
developed O O
thyrotoxicosis O B-ADR
with O O
subacute O O
onset O O
, O O
accompanied O O
by O O
transiently O O
positive O O
thyrotropin O O
( O O
tsh O O
) O O
receptor O O
antibody O O
( O O
trab O O
) O O
, O O
or O O
thyrotropin-binding O O
inhibiting O O
immunoglobulin O O
( O O
tbii O O

a O O
case O O
of O O
high-grade O O
endometrial O O
stromal O O
sarcoma O O
, O O
confined O O
into O O
an O O
intrauterine B-ADR O
polypoid I-ADR O
growth I-ADR O
, O O
in O O
a O O
woman O O
with O O
a O O
history O O
of O O
breast O O
cancer O O
who O O
was O O
treated O O
with O O
adjuvant O O
tamoxifen B-DRUG B-DRUG

we O O
report O O
a O O
45-year-old O O
psoriasis O O
patient O O
who O O
developed O O
eruptive B-ADR B-ADR
mollusca I-ADR I-ADR
contagiosa I-ADR I-ADR
during O O
an O O
antipsoriatic O O
treatment O O
with O O
efalizumab B-DRUG B-DRUG

mycobacterium B-ADR B-ADR
marinum I-ADR I-ADR
infection I-ADR I-ADR
complicating O O
crohn O O
's O O
disease O O
, O O
treated O O
with O O
infliximab B-DRUG B-DRUG

propafenone-induced O O
ataxia B-ADR B-ADR
: O O
report O O
of O O
three O O
cases O O

we O O
describe O O
a O O
57-year-old O O
man O O
with O O
acral O O
erythrocyanosis O O
progressing O O
to O O
acute O O
digital O O
ischemia O O
and O O
gangrene B-ADR O
that O O
developed O O
after O O
combined O O
chemotherapy O O
( O O
bleomycin B-DRUG O
and O O
methotrexate O B-DRUG
) O O
used O O
to O O
treat O O
a O O
metastatic O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
hypopharynx O O

we O O
describe O O
a O O
premenopausal O O
woman O O
who O O
, O O
while O O
having O O
tamoxifen B-DRUG B-DRUG
due O O
to O O
a O O
diagnosis O O
of O O
in O O
situ O O
ductal O O
carcinoma O O
, O O
developed O O
endometriosis B-ADR B-ADR
requiring O O
surgery O O

we O O
report O O
the O O
case O O
of O O
a O O
patient O O
with O O
increased B-ADR O
cerebral I-ADR B-ADR
cortical I-ADR I-ADR
excitability I-ADR I-ADR
following O O
intoxication O O
with O O
flupirtine B-DRUG B-DRUG
, O O
a O O
centrally O O
acting O O
analgesic O O
and O O
antispastic O O
drug O O

the O O
association O O
between O O
heparin B-DRUG B-DRUG
and O O
priapism B-ADR O
is O O
often O O
recognized O O
; O O
abnormal O O
platelet O O
aggregation O O
could O O
play O O
a O O
role O O
in O O
the O O
pathogenesis O O
of O O
this O O
side O O
effect O O

introduction O O
of O O
etanercept B-DRUG B-DRUG
was O O
also O O
clinically O O
effective O O
but O O
followed O O
by O O
development O O
of O O
severe B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR

we O O
experienced O O
a O O
case O O
of O O
chronic O O
renal O O
failure O O
in O O
a O O
patient O O
suffering O O
from O O
acute B-ADR B-ADR
hemorrhagic I-ADR I-ADR
gastritis I-ADR I-ADR
associated O O
with O O
az B-DRUG B-ADR
intoxication O I-ADR

six O O
days O O
after O O
starting O O
acyclovir O B-DRUG
she O O
exhibited O O
signs O O
of O O
lithium B-ADR B-ADR
toxicity I-ADR I-ADR

nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
in O O
a O O
multiple O O
sclerosis O O
patient O O
treated O O
with O O
interferon B-DRUG B-DRUG
beta I-DRUG I-DRUG
1a I-DRUG I-DRUG

lethargy O B-ADR
in O O
a O O
newborn O O
: O O
lithium B-ADR B-DRUG
toxicity I-ADR O
or O O
lab O O
error O O

we O O
report O O
two O O
adults O O
who O O
received O O
gabapentin O B-DRUG
( O O
gbp B-DRUG O
) O O
and O O
subsequently O O
developed O O
behavioural B-ADR B-ADR
side I-ADR I-ADR
effects I-ADR I-ADR

we O O
stress O O
the O O
potential O O
of O O
benzarone B-DRUG B-DRUG
to O O
cause O O
hepatotoxicity B-ADR B-ADR
, O O
which O O
usually O O
resembles O O
severe O O
chronic O O
active O O
hepatitis O O

background O O
: O O
interferon B-DRUG O
( O O
ifn O O
)- O O
associated O O
retinopathy B-ADR B-ADR
is O O
typically O O
characterized O O
by O O
retinal O O
hemorrhages O O
and O O
cotton O O
wool O O
spots O O
at O O
the O O
posterior O O
fundus O O
, O O
but O O
visual O O
function O O
is O O
usually O O
maintained O O

we O O
report O O
the O O
first O O
case O O
of O O
fulminant O O
adult O O
respiratory O O
distress O O
syndrome O O
( O O
ards B-ADR O
) O O
associated O O
with O O
pegylated B-DRUG O
interferon I-DRUG O
alpha-2a I-DRUG O
( O O
pegifnalpha-2a O O
) O O
and O O
ribavirin O B-DRUG
use O O
for O O
hepatitis O O
c O O
, O O
complicated O O
by O O
subsequent O O
and O O
ultimately O O
fatal O O
sepsis O O
and O O
multiorgan O O
failure O O

clinicians O O
should O O
include O O
phenolphthalein B-DRUG B-DRUG
in O O
their O O
list O O
of O O
possible O O
causes O O
of O O
drug-induced O O
ten B-ADR B-ADR

the O O
authors O O
postulate O O
that O O
two O O
types O O
of O O
combined O O
lithium-neuroleptic O B-ADR
toxicity O I-ADR
occur O O
: O O
a O O
neuroleptic B-ADR O
malignant I-ADR O
extrapyramidal I-ADR O
syndrome I-ADR O
and O O
a O O
lithium O B-ADR
toxicity O I-ADR
that O O
occurs O O
in O O
combination O O
with O O
phenothiazines O O
, O O
primarily O O
thioridazine B-DRUG O

conclusion O O
: O O
during O O
and O O
after O O
ifn B-DRUG B-DRUG
therapy O O
, O O
oct O O
is O O
a O O
useful O O
examination O O
technique O O
for O O
revealing O O
macular B-ADR B-ADR
edema I-ADR I-ADR
in O O
patients O O
who O O
have O O
decreased O O
vision O O

we O O
report O O
on O O
a O O
patient O O
with O O
renal O O
artery O O
stenosis O O
who O O
had O O
only O O
1 O O
kidney O O
and O O
in O O
whom O O
acute O O
renal O O
impairment O O
developed O O
with O O
transient B-ADR B-ADR
anuria I-ADR I-ADR
after O O
the O O
administration O O
of O O
captopril B-DRUG B-DRUG

the O O
present O O
observation O O
suggests O O
, O O
that O O
a O O
batch O O
of O O
different O O
testing O O
doses O O
, O O
including O O
lower O O
testing O O
doses O O
may O O
help O O
to O O
differentiate O O
between O O
an O O
allergic O O
type O O
of O O
contact O O
dermatitis O O
and O O
an O O
irritant B-ADR O
type I-ADR O
of I-ADR O
reaction I-ADR O
after O O
treatment O O
with O O
calcipotriol B-DRUG B-DRUG

this O O
experience O O
supports O O
the O O
hypothesis O O
that O O
heparin B-DRUG B-DRUG
can O O
be O O
readministered O O
early O O
to O O
patients O O
with O O
heparin-associated O O
thrombocytopenia O O
and O O
thrombosis B-ADR O
, O O
provided O O
antiplatelet O B-DRUG
therapy O O
is O O
given O O

the O O
authors O O
report O O
a O O
case O O
of O O
balint O B-ADR
syndrome O I-ADR
with O O
irreversible O B-ADR
posterior B-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
on O O
mri O O
following O O
intrathecal O O
methotrexate O B-DRUG
and O O
cytarabine B-DRUG B-DRUG

objective O O
: O O
to O O
study O O
therapy O O
with O O
indapamide B-DRUG B-DRUG
impairing B-ADR O
carbohydrate I-ADR O
metabolism I-ADR O
in O O
essential O O
hypertension O O
patients O O
and O O
achieve O O
earlier O O
prevention O O
, O O
diagnoses O O
and O O
treatment O O
of O O
diabetes O B-ADR
induced O O
by O O
indapamide B-DRUG B-DRUG

syringotropic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reaction I-ADR I-ADR
associated O O
with O O
infliximab B-DRUG B-DRUG
and O O
leflunomide O B-DRUG
combination O O
therapy O O
in O O
a O O
child O O
with O O
psoriatic O O
arthritis O O

vision B-ADR O
declined I-ADR O
after O O
treatment O O
with O O
methylprednisolone B-DRUG B-DRUG
, O O
after O O
which O O
fundus O O
examination O O
became O O
consistent O O
with O O
progressive O O
outer O O
retinal O O
necrosis O O

intravenous O O
verapamil O B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension O O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death B-ADR O
; O O
quinidine B-DRUG B-DRUG
may O O
be O O
related O O
to O O
the O O
death B-ADR O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

the O O
purpose O O
of O O
this O O
report O O
is O O
to O O
document O O
a O O
new O O
case O O
of O O
in O O
utero O O
cp B-DRUG O
exposure O O
with O O
multiple B-ADR O
congenital I-ADR O
anomalies I-ADR O
and O O
to O O
establish O O
an O O
apparent O O
cp B-DRUG O
embryopathy O O
phenotype O O

the O O
center O O
for O O
disease O O
control O O
has O O
received O O
numerous O O
reports O O
of O O
an O O
eosinophilia-myalgia B-ADR B-ADR
syndrome I-ADR I-ADR
related O O
to O O
products O O
containing O O
l-tryptophan B-DRUG B-DRUG

during O O
intravenous O O
treatment O O
with O O
terlipressin B-DRUG B-DRUG
for O O
recurrent O O
gastrointestinal O O
( O O
gi O O
) O O
bleeding O O
, O O
a O O
50-year-old O O
male O O
with O O
no O O
history O O
of O O
heart O O
disease O O
developed O O
a O O
newly O O
prolonged B-ADR O
qt I-ADR O
interval I-ADR O
and O O
torsade O B-ADR
de O I-ADR
pointes O I-ADR

conclusions O O
: O O
in O O
our O O
reported O O
case O O
, O O
a O O
local O O
hyperproduction B-ADR O
of I-ADR O
tnf-alpha I-ADR B-DRUG
from O O
macrophages O O
that O O
was O O
induced O O
by O O
the O O
injected O O
insulin B-DRUG B-DRUG
could O O
explain O O
the O O
dedifferentiation O O
of O O
the O O
adipocytes O O
of O O
the O O
subcutaneous O O
tissue O O
and O O
the O O
reversion O O
that O O
was O O
induced O O
by O O
the O O
local O O
injection O O
of O O
dexamethasone O B-DRUG

usefulness O O
of O O
antiplatelet O O
drugs O O
in O O
the O O
management O O
of O O
heparin-associated O O
thrombocytopenia B-ADR B-ADR
and O O
thrombosis O O

we O O
report O O
in O O
detail O O
an O O
unusual O O
adverse O O
reaction O O
to O O
infliximab B-DRUG B-DRUG
therapy O O
, O O
a O O
drug-induced O O
lupus-like B-ADR O
clinical I-ADR B-ADR
syndrome I-ADR I-ADR

hypertension B-ADR B-ADR
develops O O
in O O
most O O
patients O O
after O O
transplantation O O
when O O
immunosuppression O O
is O O
based O O
on O O
cyclosporine O B-DRUG
and O O
prednisone B-DRUG B-DRUG

introduction O O
: O O
we O O
describe O O
the O O
neurointensive O O
care O O
( O O
nic O O
) O O
management O O
of O O
a O O
patient O O
with O O
severe O O
cerebral O O
swelling O O
and O O
raised B-ADR O
intracranial I-ADR O
pressure I-ADR O
( O O
icp O O
) O O
after O O
severe O O
sodium O O
valproic O O
acid O O
( O O
vpa B-DRUG O
) O O
intoxication O O

after O O
discontinuation O O
of O O
danazol B-DRUG B-DRUG
the O O
diabetes B-ADR B-ADR
completely O O
resolved O O

a O O
5-month-old O O
infant O O
became O O
lethargic O B-ADR
and O O
poorly B-ADR O
responsive I-ADR O
after O O
receiving O O
1 O O
drop O O
of O O
brimonidine B-DRUG B-DRUG
in O O
each O O
eye O O

he O O
developed O O
recurrent O O
skin O O
rash O O
, O O
fever O O
, O O
hypereosinophilia B-ADR O
, O O
and O O
acute O O
renal O O
failure O O
after O O
rechallenge O O
with O O
chlorambucil B-DRUG B-DRUG

the O O
authors O O
report O O
two O O
cases O O
of O O
delayed B-ADR O
elimination I-ADR O
of O O
methotrexate O B-DRUG
in O O
patients O O
receiving O O
ciprofloxacin B-DRUG B-DRUG
, O O
with O O
severe O B-ADR
toxicity O I-ADR

type B-ADR B-ADR
1 I-ADR I-ADR
diabetes I-ADR I-ADR
mellitus I-ADR I-ADR
provoked O O
by O O
peginterferon O B-DRUG
alpha-2b O I-DRUG
plus O O
ribavirin B-DRUG B-DRUG
treatment O O
for O O
chronic O O
hepatitis O O
c O O

two O O
patients O O
are O O
described O O
who O O
developed O O
testicular O B-ADR
swelling O I-ADR
and O O
pain B-ADR O
during O O
treatment O O
with O O
desipramine B-DRUG B-DRUG

while O O
40 O O
mg O O
/ O O
day O O
of O O
prednisolone B-DRUG B-DRUG
improved O B-ADR
hepatic O I-ADR
dysfunction O I-ADR
dramatically O O
, O O
her O O
diabetic B-ADR O
milieu I-ADR O
deteriorated I-ADR O
seriously O O

an O O
83-year-old O O
man O O
receiving O O
glipizide O B-DRUG
10 O O
mg O O
bid O O
developed O O
symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
within O O
three O O
days O O
of O O
adding O O
trimethoprim O O
/ O O
sulfamethoxazole O O
( O O
tmp B-DRUG O
/ O O
smx O O
) O O
to O O
his O O
regimen O O

these O O
findings O O
mean O O
that O O
the O O
effect O O
of O O
the O O
mp B-DRUG O
pulse O O
therapy O O
on O O
renal O O
function O O
depends O O
on O O
the O O
clinical O O
state O O
of O O
the O O
patient O O
and O O
that O O
renal O O
deterioration O O
after O O
the O O
pulse O O
therapy O O
may O O
be O O
more O O
marked O O
in O O
patients O O
who O O
are O O
more O O
nephrotic O O
and O O
more O O
impaired O O
in O O
renal O O
function O O
and O O
suggest O O
that O O
increasing O O
sodium O O
and O O
water O O
retention O O
during O O
an O O
mp B-DRUG B-DRUG
therapy O O
and O O
the O O
associated O O
renal O O
interstitial O O
edema O O
, O O
proposed O O
as O O
one O O
of O O
the O O
mechanisms O O
of O O
acute O O
renal O O
failure O O
occurring O O
in O O
patients O O
with O O
minimal-change O O
nephrotic O O
syndrome O O
, O O
may O O
be O O
responsible O O
for O O
the O O
mp-induced O O
transient B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR

it O O
was O O
hypothesized O O
that O O
valproic O B-DRUG
acid O I-DRUG
may O O
interfere O O
with O O
glucuronidation O O
of O O
lamotrigine B-DRUG B-DRUG
, O O
leading O O
to O O
increased O O
serum O O
lamotrigine B-DRUG B-DRUG
levels O O
, O O
or O O
perhaps O O
alter O O
the O O
drug O O
's O O
metabolism O O
, O O
resulting O O
in O O
accumulation B-ADR O
of I-ADR O
a I-ADR O
toxic I-ADR O
intermediate I-ADR O
metabolite I-ADR O

alopecia O B-ADR
, O O
nausea B-ADR O
, O O
and O O
vomiting O O
were O O
attributed O O
to O O
the O O
cyclophosphamide B-DRUG B-DRUG
component O O
of O O
the O O
therapy O O

although O O
useful O O
in O O
the O O
management O O
of O O
chronic O O
alcoholism O O
, O O
disulfiram B-DRUG B-DRUG
is O O
being O O
increasingly O O
associated O O
with O O
a O O
wide O O
spectrum O O
of O O
side O O
effects O O
and O O
untoward O O
medical O O
sequelae O O
, O O
which O O
now O O
include O O
catatonia B-ADR B-ADR

we O O
report O O
the O O
case O O
of O O
a O O
27-year-old O O
indian O O
woman O O
who O O
developed O O
maculopapular O B-ADR
rash O I-ADR
and O O
angioedema B-ADR O
secondary O O
to O O
carbamazepine B-DRUG B-DRUG
administration O O

exfoliative B-ADR B-ADR
dermatitis I-ADR I-ADR
secondary O O
to O O
tobramycin B-DRUG B-DRUG
sulfate I-DRUG I-DRUG

hypokalemia B-ADR B-ADR
after O O
normal O O
doses O O
of O O
neubulized O O
albuterol O B-DRUG
( O O
salbutamol B-DRUG B-DRUG

sporadic B-ADR B-ADR
rippling I-ADR I-ADR
muscle I-ADR I-ADR
disease I-ADR I-ADR
unmasked O O
by O O
simvastatin B-DRUG B-DRUG

a O O
small O O
number O O
of O O
oxaliplatin-related O O
hemolytic B-ADR O
and I-ADR O
/ I-ADR O
or I-ADR O
thrombocytopenic I-ADR O
reactions I-ADR O
have O O
been O O
reported O O

because O O
of O O
a O O
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
, O O
initial O O
therapy O O
with O O
penicillin B-DRUG O
g I-DRUG O
and O O
gentamicin O B-DRUG
was O O
stopped O O
and O O
substituted O O
with O O
cefazolin O B-DRUG

massive O O
cbz B-DRUG B-DRUG
od O O
may O O
produce O O
a O O
reversible O O
encephalopathy O O
that O O
includes O O
cortical B-ADR O
hyperexcitability I-ADR O
, O O
a O O
profound O O
burst-suppression O O
eeg O O
pattern O O
, O O
and O O
cranial O O
nerve O O
areflexia O O

we O O
report O O
on O O
a O O
patient O O
with O O
renal O O
artery O O
stenosis O O
who O O
had O O
only O O
1 O O
kidney O O
and O O
in O O
whom O O
acute B-ADR O
renal I-ADR O
impairment I-ADR O
developed O O
with O O
transient O B-ADR
anuria O I-ADR
after O O
the O O
administration O O
of O O
captopril B-DRUG B-DRUG

a O O
73-year-old O O
woman O O
with O O
non-hodgkin O O
's O O
lymphoma O O
had O O
two O O
episodes O O
of O O
severe O O
, O O
bilateral O O
, O O
sensori-neural B-ADR B-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR
after O O
vincristine B-DRUG B-DRUG
therapy O O

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever O O
, O O
skin B-ADR O
eruptions I-ADR O
, O O
cervical O O
lymphadenopathy O O
, O O
hepatosplenomegaly O O
, O O
atypical O O
lymphocytosis O O
, O O
and O O
eosinophilia O O
two O O
weeks O O
after O O
receiving O O
trimethoprim O O
( O O
tmp O O
)- O O
sulfamethoxazole B-DRUG O
( O O
smx O O
) O O
treatment O O

there O O
have O O
been O O
more O O
than O O
20 O O
observations O O
of O O
the O O
appearance O O
or O O
aggravation O O
of O O
this O O
granulomatosis B-ADR B-ADR
with O O
interferon O B-DRUG
alfa O I-DRUG
and O O
more O O
recently O O
with O O
the O O
combination O O
of O O
interferon O B-DRUG
alfa O I-DRUG
plus O O
ribavirin B-DRUG B-DRUG

knowledge O O
regarding O O
potential O O
adverse O O
effects O O
of O O
cap B-DRUG B-DRUG
is O O
paramount O O
and O O
dose O O
modification O O
is O O
indicated O O
with O O
development O O
of O O
neurotoxicity B-ADR B-ADR

we O O
believe O O
that O O
the O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
in O O
our O O
patient O O
was O O
associated O O
with O O
anastrozole B-DRUG B-DRUG

the O O
authors O O
describe O O
a O O
case O O
of O O
combined O O
lithium B-DRUG B-DRUG
and O O
haloperidol O B-DRUG
toxicity O O
characterized O O
by O O
hyperpyrexia O O
, O O
severe B-ADR O
rigidity I-ADR O
, O O
mutism O O
, O O
and O O
development O O
of O O
irreversible O B-ADR
tardive O I-ADR
dyskinesia O I-ADR

the O O
first O O
patient O O
developed O O
mild O O
nitritoid O O
symptoms O O
and O O
pain O O
in O O
a O O
band-like O O
distribution O O
, O O
corresponding O O
to O O
t10-t12 B-ADR O
dermatomes I-ADR O
, O O
shortly O O
after O O
gold O B-DRUG
sodium O I-DRUG
thiomalate O I-DRUG
( O O
gstm B-DRUG O
) O O
injection O O

background O O
: O O
we O O
describe O O
the O O
ophthalmic O O
features O O
and O O
clinical O O
course O O
of O O
two O O
cases O O
of O O
acute O O
syphilitic O O
posterior O O
placoid O O
chorioretinitis O O
( O O
asppc B-ADR O
) O O
that O O
developed O O
after O O
intravitreal O O
triamcinolone O B-DRUG
acetonide O I-DRUG
( O O
ivta B-DRUG O
) O O
injection O O

interestingly O O
, O O
the O O
use O O
of O O
carboplatin O B-DRUG
( O O
cbdca O O
) O O
and O O
vds O O
in O O
the O O
subsequent O O
treatment O O
course O O
was O O
well O O
tolerated O O
indicating O O
that O O
the O O
siadh B-ADR B-ADR
was O O
most O O
likely O O
to O O
have O O
been O O
induced O O
by O O
administration O O
of O O
cddp B-DRUG B-DRUG

nail B-ADR B-ADR
staining I-ADR I-ADR
from O O
hydroquinone B-DRUG B-DRUG
cream O O

background O O
: O O
interferon B-DRUG O
( O O
ifn O O
)- O O
associated O O
retinopathy O B-ADR
is O O
typically O O
characterized O O
by O O
retinal B-ADR O
hemorrhages I-ADR O
and O O
cotton O O
wool O O
spots O O
at O O
the O O
posterior O O
fundus O O
, O O
but O O
visual O O
function O O
is O O
usually O O
maintained O O

we O O
report O O
a O O
43-year-old O O
woman O O
who O O
developed O O
sore O O
throat O O
, O O
swelling B-ADR O
of I-ADR O
the I-ADR O
lips I-ADR O
and I-ADR O
oral I-ADR O
cavity I-ADR O
and O O
dysphagia O O
, O O
2 O O
weeks O O
after O O
the O O
use O O
of O O
budesonide O B-DRUG
spray O O
( O O
budefat B-DRUG O
) O O
for O O
treatment O O
of O O
bronchial O O
asthma O O

painful B-ADR B-ADR
neutrophilic O I-ADR
skin O I-ADR
lesions O I-ADR
were O O
observed O O
in O O
two O O
children O O
receiving O O
granulocyte O O
colony-stimulating O O
factor O O
( O O
g-csf B-DRUG B-DRUG
) O O
for O O
treatment O O
of O O
idiopathic O O
neutropenia O O

paradoxical O B-ADR
ventricular O I-ADR
tachycardia O I-ADR
and O O
fibrillation B-ADR O
after O O
intravenous O O
bretylium B-DRUG B-DRUG
therapy O O

after O O
a O O
second O O
dose O O
of O O
metoclopramide B-DRUG B-DRUG
, O O
these O O
symptoms O O
recurred O O
and O O
were O O
associated O O
with O O
confusion B-ADR O
, O O
agitation O O
, O O
fever O O
, O O
diaphoresis O O
, O O
tachypnea O O
, O O
tachycardia O O
, O O
and O O
hypertension O O

intravenous O O
verapamil B-DRUG B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension O O
, O O
and O O
bradycardia B-ADR O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death O O
; O O
quinidine O B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

we O O
report O O
the O O
case O O
of O O
a O O
43-year-old O O
man O O
with O O
itp O O
refractory O O
to O O
steroids O O
and O O
intravenous O O
immunoglobulin O B-DRUG
who O O
developed O O
acute B-ADR O
respiratory I-ADR O
distress I-ADR O
syndrome I-ADR O
( O O
ards O B-ADR
) O O
after O O
a O O
single O O
infusion O O
of O O
rituximab B-DRUG B-DRUG

severe B-ADR O
raynaud I-ADR O
's I-ADR O
phenomenon I-ADR O
with O O
yohimbine B-DRUG B-DRUG
therapy O O
for O O
erectile O O
dysfunction O O

although O O
this O O
type O O
of O O
hyperpigmentation B-ADR B-ADR
has O O
been O O
previously O O
seen O O
in O O
patients O O
with O O
cancer O O
who O O
are O O
receiving O O
bleomycin B-DRUG B-DRUG
, O O
this O O
is O O
, O O
to O O
our O O
knowledge O O
, O O
the O O
first O O
reported O O
case O O
of O O
bleomycin-induced O O
hyperpigmentation B-ADR B-ADR
in O O
an O O
aids O O
patient O O
and O O
should O O
be O O
added O O
to O O
the O O
growing O O
list O O
of O O
cutaneous O B-ADR
eruptions O I-ADR
seen O O
in O O
these O O
patients O O

intrahepatic O B-ADR
cholestasis O I-ADR
and O O
cutaneous B-ADR O
bullae I-ADR O
associated O O
with O O
glibenclamide B-DRUG B-DRUG
therapy O O

an O O
encephalopathy O B-ADR
and O O
cardiomyopathy B-ADR B-ADR
developed O O
in O O
a O O
seventeen-year-old O O
girl O O
with O O
chemotherapy-induced O O
renal O O
failure O O
while O O
receiving O O
an O O
intravesical O O
aluminum B-DRUG O
infusion O O
for O O
hemorrhagic O O
cystitis O O

objective O O
: O O
to O O
report O O
the O O
case O O
of O O
a O O
young O O
woman O O
with O O
graves' O O
disease O O
in O O
whom O O
ototoxicity O B-ADR
developed O O
because O O
of O O
propylthiouracil O O
( O O
ptu B-DRUG O
)- O O
induced O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
anca O O
)- O O
associated O O
vasculitis O B-ADR

results O O
: O O
in O O
a O O
22-year-old O O
thai O O
woman O O
with O O
graves' O O
disease O O
, O O
tinnitus O O
, O O
hearing O O
impairment O O
in O O
the O O
left O O
ear O O
( O O
with O O
progression O O
to O O
the O O
right O O
ear O O
) O O
, O O
and O O
vertigo O O
developed O O
after O O
3 O O
years O O
of O O
therapy O O
with O O
ptu B-DRUG B-DRUG

purpose O O
: O O
a O O
case O O
of O O
probable O O
enoxaparin-induced O O
hepatotoxicity B-ADR B-ADR
is O O
described O O

we O O
have O O
cared O O
for O O
three O O
children O O
in O O
whom O O
four O O
episodes O O
of O O
dystonia B-ADR B-ADR
proceeding O O
to O O
opisthotonus O B-ADR
occurred O O
in O O
association O O
with O O
carbamazepine B-DRUG B-DRUG
use O O

currently O O
the O O
use O O
of O O
zidovudine B-DRUG B-DRUG
is O O
one O O
of O O
the O O
few O O
specific O O
measures O O
available O O
, O O
and O O
as O O
a O O
potentially O O
teratogenic O O
and O O
fetotoxic O O
agent O O
, O O
any O O
decision O O
for O O
its O O
use O O
requires O O
evaluation O O
of O O
the O O
potential O O
for O O
fetal B-ADR O
damage I-ADR O

the O O
principle O O
treatment O O
for O O
dpd-deficient O O
patients O O
with O O
severe B-ADR O
acute I-ADR O
5-fu I-ADR B-DRUG
reactions I-ADR O
is O O
supportive O O
care O O
; O O
however O O
, O O
the O O
administration O O
of O O
thymidine O B-DRUG
potentially O O
may O O
reverse O O
severe O O
5-fu-induced O O
neurologic O B-ADR
symptoms O I-ADR
such O O
as O O
encephalopathy O B-ADR
and O O
coma O B-ADR

background O O
: O O
cyanamide B-DRUG B-DRUG
, O O
an O O
aversive O O
agent O O
widely O O
used O O
in O O
japan O O
, O O
is O O
known O O
to O O
induce O O
various O O
degrees O O
of O O
hepatic B-ADR O
lesion I-ADR O
with I-ADR O
ground-glass I-ADR O
inclusion I-ADR O
bodies I-ADR O

three O O
patients O O
, O O
in O O
whom O O
tumour O O
overkill O O
by O O
cytotoxic O O
treatment O O
, O O
including O O
high O O
dose O O
methotrexate B-DRUG B-DRUG
with O O
folinic O O
acid O O
rescue O O
, O O
resulted O O
in O O
the O O
' O O
phosphate B-ADR O
shower I-ADR O
syndrome I-ADR O
' O O
( O O
hyper-uricaemia O O
, O O
hyperkalaemia O O
and O O
hyperphosphataemia O O
with O O
hypocalcaemia O O
and O O
tetany O O
, O O
with O O
metabolic O O
acidosis O O
and O O
acute O O
renal O O
impairment O O
) O O
are O O
described O O

acute B-ADR B-ADR
eosinophilic I-ADR I-ADR
pneumonia I-ADR I-ADR
caused O O
by O O
calcium B-DRUG B-DRUG
stearate I-DRUG I-DRUG
, O O
an O O
additive O O
agent O O
for O O
an O O
oral O O
antihistaminic O O
medication O O

objective O O
: O O
to O O
report O O
2 O O
cases O O
of O O
serotonin O B-ADR
syndrome O I-ADR
with O O
serious O O
extrapyramidal B-ADR B-ADR
movement I-ADR I-ADR
disorders I-ADR I-ADR
occurring O O
when O O
metoclopramide O B-DRUG
was O O
coadministered O O
with O O
sertraline O B-DRUG
or O O
venlafaxine B-DRUG B-DRUG

a O O
case O O
of O O
normotensive B-ADR B-ADR
scleroderma I-ADR I-ADR
renal I-ADR I-ADR
crisis I-ADR I-ADR
after O O
high-dose O O
methylprednisolone B-DRUG B-DRUG
treatment O O

colchicine-induced O O
rhabdomyolysis B-ADR B-ADR

conclusions O O
: O O
the O O
use O O
of O O
fluorouracil O B-DRUG
treatment O O
with O O
careful O O
monitoring O O
can O O
be O O
considered O O
in O O
a O O
patient O O
with O O
mild O B-ADR
allergic B-ADR I-ADR
reactions I-ADR I-ADR
to O O
capecitabine B-DRUG B-DRUG

chromosome B-ADR B-ADR
abnormalities I-ADR I-ADR
after O O
chlorambucil B-DRUG B-DRUG
therapy O O
of O O
polycythaemia O O
vera O O

although O O
lung O O
specimens O O
were O O
lacking O O
from O O
these O O
three O O
patients O O
, O O
it O O
is O O
suggested O O
that O O
the O O
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
of O O
ccnu B-DRUG B-DRUG
may O O
be O O
dose-related O O

a O O
case O O
of O O
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
bullosum I-ADR I-ADR
in O O
patient O O
of O O
lepromatous O O
leprosy O O
with O O
pulmonary O O
tuberculosis O O
due O O
to O O
rifampicin B-DRUG B-DRUG
is O O
described O O

we O O
report O O
a O O
case O O
of O O
sjs B-ADR B-ADR
in O O
a O O
14-year-old O O
male O O
with O O
nephrotic O O
syndrome O O
, O O
who O O
was O O
treated O O
with O O
oral O O
prednisolone B-DRUG B-DRUG
for O O
6 O O
weeks O O

both O O
patients O O
were O O
then O O
treated O O
with O O
a O O
carboplatin O B-DRUG
alternative O O
to O O
cisplatin B-DRUG B-DRUG
in O O
the O O
following O O
courses O O
, O O
which O O
resulted O O
in O O
neither O O
a O O
relapse O O
of O O
the O O
colitis B-ADR O
nor O O
a O O
recurrence O O
of O O
the O O
malignancies O O
up O O
to O O
this O O
time O O

we O O
reviewed O O
the O O
records O O
of O O
3 O O
patients O O
with O O
lymphoproliferative O O
disorders O O
who O O
experienced O O
acute B-ADR B-ADR
coronary I-ADR I-ADR
syndromes I-ADR I-ADR
associated O O
with O O
their O O
initial O O
infusion O O
of O O
rituximab B-DRUG B-DRUG

we O O
describe O O
a O O
patient O O
who O O
presented O O
with O O
bloody B-ADR B-ADR
diarrhoea I-ADR I-ADR
after O O
15 O O
mg O O
meloxicam B-DRUG B-DRUG
daily O O
for O O
10 O O
days O O
for O O
osteoarthritis O O

discussion O O
: O O
methotrexate-induced O O
papular B-ADR B-ADR
eruption I-ADR I-ADR
is O O
rarely O O
reported O O
shortly O O
after O O
beginning O O
methotrexate O B-DRUG
therapy O O
in O O
patients O O
with O O
acute O O
exacerbation O O
of O O
collagen O O
vascular O O
diseases O O

severe B-ADR B-ADR
hemolytic I-ADR I-ADR
uremic I-ADR I-ADR
syndrome I-ADR I-ADR
in O O
an O O
advanced O O
ovarian O O
cancer O O
patient O O
treated O O
with O O
carboplatin O B-DRUG
and O O
gemcitabine B-DRUG B-DRUG

fatal B-ADR B-ADR
interstitial I-ADR I-ADR
pneumonitis I-ADR I-ADR
associated O O
with O O
docetaxel B-DRUG B-DRUG
administration O O
in O O
a O O
patient O O
with O O
hormone-refractory O O
prostate O O
cancer O O

in O O
a O O
postural O O
challenge O O
test O O
after O O
administration O O
of O O
isosorbide B-DRUG B-DRUG
dinitrate I-DRUG I-DRUG
( O O
5 O O
mg O O
) O O
, O O
blood O O
pressure O O
decreased O O
from O O
120 O O
/ O O
67 O O
to O O
65 O O
/ O O
35 O O
mmhg O O
, O O
followed O O
by O O
syncope B-ADR O
with O O
a O O
sudden O O
decrease O O
in O O
pulse O O
rate O O
from O O
85 O O
to O O
60 O O
beats O O
/ O O
min O O

graves' O B-ADR
hyperthyroidism O I-ADR
following O O
transient B-ADR B-ADR
thyrotoxicosis I-ADR I-ADR
during O O
interferon B-DRUG B-DRUG
therapy O O
for O O
chronic O O
hepatitis O O
type O O
c O O

we O O
cared O O
for O O
a O O
patient O O
with O O
progressive O O
renal O O
impairment O O
who O O
presented O O
with O O
blurred O O
vision O O
, O O
qrs O O
broadening O O
and O O
cardiac B-ADR O
failure I-ADR O
due O O
to O O
chronic O O
cibenzoline B-DRUG B-DRUG
intoxication O O

we O O
present O O
a O O
case O O
of O O
photo-onycholysis B-ADR B-ADR
in O O
a O O
patient O O
treated O O
with O O
doxycycline B-DRUG B-DRUG
for O O
acne O O
vulgaris O O

we O O
describe O O
a O O
patient O O
with O O
transitional O O
cell O O
carcinoma O O
of O O
the O O
renal O O
pelvis O O
who O O
developed O O
respiratory O O
dysfunction O O
and O O
an O O
abnormal B-ADR O
chest I-ADR O
x-ray I-ADR O
with I-ADR O
diffuse I-ADR O
interstitial I-ADR O
opacities I-ADR O
while O O
on O O
chemotherapy O O
with O O
piritrexim B-DRUG B-DRUG
, O O
a O O
methotrexate O B-DRUG
analog O O

studies O O
performed O O
10 O O
years O O
ago O O
on O O
25 O O
patients O O
with O O
mtx-induced O O
liver B-ADR B-ADR
cirrhosis I-ADR I-ADR
indicated O O
that O O
this O O
type O O
of O O
cirrhosis O B-ADR
was O O
not O O
of O O
an O O
aggressive O O
nature O O

after O O
therapy O O
for O O
diabetic O O
coma O O
with O O
insulin O B-DRUG
( O O
containing O O
the O O
preservative O O
cresol B-DRUG O
) O O
and O O
electrolyte O O
solutions O O
was O O
started O O
, O O
the O O
patient O O
complained O O
of O O
increasing B-ADR O
myalgia I-ADR O
, O O
developed O O
a O O
high O O
fever O O
and O O
respiratory O O
and O O
metabolic O O
acidosis O O
and O O
lost O O
consciousness O O

hepatobiliary B-ADR B-ADR
disorders I-ADR I-ADR
associated O O
with O O
orally O O
administered O O
terbinafine B-DRUG B-DRUG
have O O
rarely O O
been O O
reported O O

favorable O O
outcome O O
of O O
de O O
novo O O
hepatitis B-ADR B-ADR
b I-ADR I-ADR
infection I-ADR I-ADR
after O O
liver O O
transplantation O O
with O O
lamivudine O B-DRUG
and O O
adefovir B-DRUG B-DRUG
therapy O O

pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
associated O O
with O O
erlotinib B-DRUG B-DRUG

a O O
case O O
is O O
reported O O
of O O
a O O
child O O
with O O
fatal B-ADR B-ADR
pulmonary I-ADR I-ADR
fibrosis I-ADR I-ADR
following O O
bcnu B-DRUG B-DRUG
therapy O O

both O O
pan B-DRUG O
and O O
methotrexate O B-DRUG
have O O
been O O
independently O O
demonstrated O O
to O O
cause O O
sensorineural B-ADR B-ADR
hearing I-ADR I-ADR
loss I-ADR I-ADR

we O O
report O O
a O O
patient O O
with O O
recurrent O O
, O O
increasingly O O
severe O O
episodes O O
of O O
ppe O B-ADR
, O O
ultimately O O
complicated O O
by O O
a O O
severe O B-ADR
bullous B-ADR I-ADR
eruption I-ADR I-ADR
, O O
following O O
successive O O
cycles O O
of O O
high-dose O O
cytarabine B-DRUG B-DRUG
for O O
the O O
treatment O O
of O O
acute O O
lymphoblastic O O
leukaemia O O

vancomycin B-DRUG B-DRUG
is O O
widely O O
used O O
against O O
methicillin-resistant O O
staphylococcus O O
aureus O O
infections O O
, O O
but O O
it O O
is O O
associated O O
with O O
many O O
adverse O O
effects O O
such O O
as O O
nephrotoxicity O O
, O O
ototoxicity O O
, O O
gastrointestinal B-ADR O
disturbances I-ADR O
, O O
blood O O
disorders O O
, O O
and O O
two O O
types O O
of O O
hypersensitivity O O
reactions O O
- O O
an O O
anaphylactoid O O
reaction O O
known O O
as O O
" O O
red O O
man O O
syndrome O O
" O O
and O O
anaphylaxis O B-ADR

ballistic O B-ADR
movements O I-ADR
due O O
to O O
ischemic B-ADR B-ADR
infarcts I-ADR I-ADR
after O O
intravenous O O
heroin B-DRUG B-DRUG
overdose O O
: O O
report O O
of O O
two O O
cases O O

severe B-ADR B-ADR
hepatotoxicity I-ADR I-ADR
from O O
phenobarbital B-DRUG B-DRUG
occurred O O
in O O
an O O
infant O O
boy O O
who O O
had O O
a O O
complicated O O
illness O O
with O O
chronic O O
bilateral O O
subdural O O
hematomas O O
and O O
sepsis O O

we O O
present O O
a O O
case O O
of O O
hemolytic-uremic B-ADR B-ADR
syndrome I-ADR I-ADR
that O O
developed O O
during O O
the O O
4th O O
cycle O O
of O O
combination O O
chemotherapy O O
with O O
oxaliplatin O B-DRUG
, O O
5-fluorouracil O O
and O O
leucovorin B-DRUG B-DRUG

a O O
67-year-old O O
patient O O
, O O
with O O
primary O O
polymyositis O O
and O O
without O O
previous O O
evidence O O
of O O
liver O O
disease O O
, O O
developed O O
clinical O O
and O O
biochemical O O
features O O
of O O
severe B-ADR B-ADR
cholestasis I-ADR I-ADR
3 O O
months O O
after O O
initiation O O
of O O
azathioprine B-DRUG B-DRUG
therapy O O

however O O
, O O
a O O
new O O
episode O O
of O O
neutropenia B-ADR B-ADR
, O O
with O O
a O O
wbc O O
count O O
of O O
2.8 O O
x O O
10 O O
( O O
3 O O
)/ O O
mm3 O O
and O O
anc O O
of O O
0.448 O O
x O O
10 O O
( O O
3 O O
)/ O O
mm3 O O
, O O
occurred O O
11 O O
days O O
after O O
teicoplanin B-DRUG B-DRUG
initiation O O

rifampin O B-DRUG
( O O
rfp B-DRUG B-DRUG
) O O
increases O O
hepatic O O
microsomal O O
enzyme O O
activity O O
, O O
and O O
there O O
are O O
case O O
reports O O
of O O
rfp-induced O O
hypothyroidism B-ADR B-ADR
, O O
all O O
associated O O
with O O
hashimoto O O
's O O
thyroiditis O B-ADR

gabapentin B-DRUG B-DRUG
withdrawal O O
presenting O O
as O O
status B-ADR B-ADR
epilepticus I-ADR I-ADR

a O O
55-year-old O O
woman O O
presented O O
an O O
episode O O
of O O
acute O O
urticaria O O
and O O
labial B-ADR O
angioedema I-ADR O
60 O O
minutes O O
after O O
ingesting O O
500 O O
mg O O
of O O
cloxacillin B-DRUG B-DRUG
for O O
a O O
skin O O
abscess O O

edema B-ADR B-ADR
associated O O
with O O
ibuprofen B-DRUG B-DRUG
therapy O O

fever O O
and O O
maculopapular B-ADR B-ADR
rashes I-ADR I-ADR
appeared O O
at O O
10 O O
days O O
after O O
phenytoin B-DRUG B-DRUG
initiation O O
, O O
and O O
then O O
the O O
drug O O
was O O
discontinued O O

the O O
chemotherapeutics O O
, O O
including O O
vincristine O B-DRUG
, O O
actinomycin B-DRUG O
d I-DRUG O
, O O
and O O
epirubicin O O
in O O
case O O
1 O O
and O O
vincristine O B-DRUG
and O O
actinomycin B-DRUG O
d I-DRUG O
in O O
case O O
2 O O
, O O
were O O
given O O
before O O
the O O
hepatotoxicity B-ADR B-ADR
developed O O

sarcoma B-ADR B-ADR
complicating O O
therapy O O
with O O
cyclophosphamide B-DRUG B-DRUG

we O O
report O O
a O O
case O O
of O O
intrathecal O O
methotrexate B-DRUG B-DRUG
neurotoxicity B-ADR B-ADR
manifesting O O
as O O
left O O
arm O O
weakness O O
and O O
aphasia O O

the O O
second O O
patient O O
, O O
who O O
developed O O
cholestasis B-ADR B-ADR
after O O
receiving O O
trimethoprim-sulfamethoxazole B-DRUG B-DRUG
, O O
had O O
marked O O
duct O O
paucity O O
in O O
the O O
liver O O
biopsy O O

sulfasalazine B-DRUG B-DRUG
has O O
been O O
associated O O
with O O
bronchopulmonary O O
complications O O
of O O
inflammatory O O
bowel O O
disease O O
( O O
ibd B-ADR B-ADR
) O O
in O O
adults O O

introduction-the O O
aim O O
of O O
this O O
case O O
report O O
is O O
to O O
present O O
a O O
15-year O O
follow-up O O
of O O
a O O
patient O O
with O O
phenytoin B-DRUG B-DRUG
( O O
pht O O
) O O
intoxication O O
with O O
unilateral B-ADR O
gingival I-ADR O
hyperplasia I-ADR O
( O O
gh O O

there O O
are O O
no O O
previous O O
reports O O
in O O
the O O
literature O O
about O O
the O O
emergence O O
of O O
cml B-ADR B-ADR
during O O
treatment O O
with O O
hydroxyurea B-DRUG B-DRUG

presented O O
is O O
a O O
case O O
of O O
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
induced O O
by O O
acetazolamide B-DRUG B-DRUG
therapy O O
for O O
glaucoma O O

several O O
case O O
reports O O
of O O
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
with O O
use O O
of O O
acetazolamide O B-DRUG
, O O
and O O
two O O
cases O O
with O O
use O O
of O O
methazolamide B-DRUG B-DRUG
, O O
have O O
appeared O O
in O O
the O O
literature O O

exacerbations B-ADR O
of I-ADR O
the I-ADR O
heart I-ADR O
failure I-ADR O
were O O
temporally O O
related O O
to O O
the O O
administration O O
of O O
the O O
antitumor O O
antibiotics O O
actinomycin-d O O
( O O
nsc-3053 O O
) O O
and O O
mithramycin O O
( O O
nsc-24559 B-DRUG O

cytarabine-induced O O
cerebellar B-ADR B-ADR
syndrome I-ADR I-ADR
: O O
case O O
report O O
and O O
literature O O
review O O

conclusions O O
: O O
we O O
conclude O O
that O O
a O O
high O O
dose O O
combined O O
with O O
a O O
short O O
infusion O O
time O O
increases O O
the O O
risk O O
of O O
anaphylactoid B-ADR B-ADR
reactions I-ADR I-ADR
with O O
the O O
administration O O
of O O
intraperitoneal O O
cisplatin B-DRUG B-DRUG

discussion O O
: O O
the O O
main O O
adverse O O
effects O O
of O O
leflunomide B-DRUG B-DRUG
consist O O
of O O
diarrhea O O
, O O
nausea B-ADR O
, O O
liver O O
enzyme O O
elevation O O
, O O
hypertension O O
, O O
alopecia O O
, O O
and O O
allergic O O
skin O O
reactions O O

a O O
child O O
in O O
whom O O
a O O
phenobarbital B-DRUG B-DRUG
hypersensitivity B-ADR O
drug O O
reaction O O
developed O O
which O O
consisted O O
of O O
fever O O
, O O
a O O
pruritic O O
desquamating O O
erythrodermic O O
rash O O
, O O
alopecia O O
, O O
icterus O O
, O O
protein-losing O O
enteropathy O O
, O O
myositis O O
, O O
and O O
nephritis O O
, O O
is O O
described O O

one O O
case O O
of O O
priapism B-ADR B-ADR
occurred O O
during O O
heparin B-DRUG B-DRUG
therapy O O
for O O
a O O
previous O O
surgical O O
operation O O
to O O
the O O
knee O O
is O O
reported O O

etoposide-related O O
myocardial B-ADR B-ADR
infarction I-ADR I-ADR

it O O
was O O
concluded O O
that O O
anca B-ADR B-DRUG
is O O
closely O O
related O O
to O O
the O O
pathogenesis O O
of O O
crescentic O B-ADR
glomerulonephritis O I-ADR
and O O
that O O
treatment O O
with O O
ptu B-DRUG B-DRUG
appeared O O
to O O
induce O O
anca B-ADR B-ADR

splenic B-ADR B-ADR
hemorrhage I-ADR I-ADR
: O O
a O O
complication O O
of O O
tissue B-DRUG B-DRUG
plasminogen I-DRUG I-DRUG
activator I-DRUG I-DRUG
treatment O O

we O O
describe O O
a O O
patient O O
in O O
whom O O
noncardiogenic B-ADR B-ADR
pulmonary I-ADR I-ADR
edema I-ADR I-ADR
developed O O
during O O
intrabiliary O O
infusion O O
of O O
monooctanoin B-DRUG B-DRUG

we O O
discuss O O
a O O
patient O O
who O O
developed O O
severe O O
renal O O
tubular O O
dysfunction O O
secondary O O
to O O
short-term O O
therapy O O
with O O
amikacin B-DRUG B-DRUG
, O O
resulting O O
in O O
refractory O O
hypokalemia O O
, O O
hypocalcemia O O
, O O
hypomagnesemia O O
, O O
metabolic O O
alkalosis O O
, O O
and O O
polyuria B-ADR O

objective O O
: O O
to O O
report O O
the O O
occurrence O O
of O O
acute B-ADR O
cytolytic I-ADR B-ADR
hepatitis I-ADR I-ADR
in O O
a O O
patient O O
exposed O O
to O O
pulse O O
itraconazole B-DRUG B-DRUG
therapy O O
for O O
24 O O
weeks O O
and O O
provide O O
a O O
concise O O
review O O
of O O
the O O
literature O O
on O O
cases O O
of O O
itraconazole-induced O O
hepatitis O B-ADR

a O O
patient O O
developed O O
papilloedema O B-ADR
and O O
hepatic B-ADR O
dysfunction I-ADR O
while O O
being O O
treated O O
with O O
perhexiline B-DRUG B-DRUG
maleate I-DRUG I-DRUG

this O O
review O O
presents O O
the O O
first O O
case O O
series O O
of O O
dic O B-ADR
associated O O
with O O
acute O O
hemoglobinemia O O
or O O
hemoglobinuria B-ADR O
following O O
anti-d B-DRUG B-DRUG
igiv I-DRUG I-DRUG
administration O O
for O O
itp O O

a O O
51-year O O
old O O
physically O O
fit O O
woman O O
experienced O O
angio-oedema B-ADR O
and O O
hypotensive O B-ADR
shock O I-ADR
after O O
irbesartan B-DRUG B-DRUG
ingestion O O
requiring O O
noradrenaline O B-DRUG
infusion O O

usefulness O O
of O O
antiplatelet O O
drugs O O
in O O
the O O
management O O
of O O
heparin-associated O O
thrombocytopenia O B-ADR
and O O
thrombosis B-ADR O

reversible O O
findings O O
of O O
restricted O O
diffusion O O
in O O
5-fluorouracil B-DRUG B-DRUG
neurotoxicity B-ADR B-ADR

exacerbation O O
of O O
anthracycline-induced O O
early B-ADR O
chronic I-ADR O
cardiomyopathy I-ADR O
with O O
atra O O
: O O
role O O
of O O
b-type O O
natriuretic O O
peptide O O
as O O
an O O
indicator O O
of O O
cardiac O O
dysfunction O O

the O O
polycystic O O
changes O O
disappeared O O
from O O
the O O
ovaries O O
in O O
2 O O
of O O
the O O
women O O
after O O
valproate B-DRUG B-DRUG
therapy O O
was O O
discontinued O O
, O O
and O O
the O O
2 O O
women O O
who O O
had O O
gained O O
weight O O
and O O
developed O O
amenorrhea B-ADR B-ADR
while O O
being O O
treated O O
with O O
valproate B-DRUG B-DRUG
lost O O
weight O O
and O O
resumed O O
menstruating O O
after O O
the O O
change O O
in O O
medication O O

an O O
episode O O
of O O
leukoencephalopathy B-ADR B-ADR
is O O
reported O O
in O O
a O O
13-year-old O O
girl O O
who O O
, O O
after O O
standard O O
radiotherapy O O
for O O
a O O
posterior O O
fossa O O
medulloblastoma O O
, O O
received O O
8 O O
treatments O O
with O O
a O O
protocol O O
containing O O
a O O
4-hour O O
infusion O O
of O O
500 O O
mg O O
/ O O
m2 O O
methotrexate B-DRUG B-DRUG
and O O
12 O O
mg O O
intrathecal O O
methotrexate B-DRUG B-DRUG

bisphosphonate-related O O
osteonecrosis B-ADR B-ADR
of I-ADR O
the I-ADR O
skull I-ADR O
base I-ADR O

intravenous O O
verapamil B-DRUG B-DRUG
therapy O O
in O O
babies O O
may O O
cause O O
apnea O O
, O O
hypotension B-ADR O
, O O
and O O
bradycardia O O
; O O
continued O O
episodes O O
of O O
atrial O O
flutter O O
in O O
a O O
child O O
may O O
cause O O
sudden O O
death O O
; O O
quinidine O B-DRUG
may O O
be O O
related O O
to O O
the O O
death O O
; O O
children O O
with O O
" O O
familial O O
seizure O O
disorders O O
" O O
may O O
in O O
fact O O
have O O
the O O
long O O
qt O O
interval O O
syndrome O O

the O O
induced O O
hyperglycaemia O B-ADR
could O O
not O O
be O O
controlled O O
sufficiently O O
, O O
despite O O
a O O
high O O
dose O O
of O O
insulin B-DRUG B-DRUG
(> O O
110 O O
units O O
/ O O
day O O
) O O
, O O
suggesting O O
the O O
existence O O
of O O
insulin B-DRUG B-DRUG
insensitivity O O
and O O
hyperinsulinaemia B-ADR O

recurrent O O
septicemia B-ADR O
with O O
lethal O O
outcome O O
during O O
and O O
after O O
cyclosporine B-DRUG B-DRUG
therapy O O
in O O
severe O O
ulcerative O O
colitis O O

two O O
patients O O
treated O O
with O O
5-fluorouracil O B-DRUG
( O O
5-fu B-DRUG B-DRUG
) O O
for O O
disseminated O O
adenocarcinoma O O
of O O
the O O
colon O O
developed O O
cerebellar B-ADR B-ADR
dysfunction I-ADR I-ADR
typical O O
of O O
5-fu B-DRUG B-DRUG
neurotoxicity O B-ADR

to O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
of O O
an O O
angio-oedema B-ADR B-ADR
associated O O
with O O
vrc B-DRUG B-ADR

patients O O
receiving O O
amifostine B-DRUG B-DRUG
who O O
develop O O
only O O
fever O O
should O O
be O O
evaluated O O
for O O
an O O
adverse O O
drug O O
reaction O O
, O O
as O O
well O O
as O O
for O O
sepsis B-ADR O
and O O
fevers O O
of O O
neutropenia O B-ADR
, O O
and O O
it O O
may O O
be O O
necessary O O
to O O
discontinue O O
the O O
drug O O

the O O
case O O
demonstrates O O
that O O
hypersensitivity O B-ADR
reaction O I-ADR
to O O
pranlukast B-DRUG B-DRUG
and O O
resultant O O
atin B-ADR O
is O O
possible O O
, O O
and O O
that O O
periodic O O
urine O O
testing O O
in O O
patients O O
receiving O O
pranlukast B-DRUG B-DRUG
should O O
be O O
considered O O

the O O
latter O O
form O O
( O O
macrodantin B-DRUG B-DRUG
) O O
is O O
reported O O
to O O
engender O O
less O O
gastrointestinal O O
intolerance O O
but O O
it O O
can O O
produce O O
the O O
same O O
adverse O O
effects O O
as O O
the O O
conventional O O
form O O
-- O O
liver O O
damage O O
, O O
acute O O
and O O
chronic O O
pulmonary O O
reactions O O
, O O
peripheral B-ADR O
neuropathy I-ADR O
, O O
blood O O
dyscrasias O O
and O O
allergic O O
reactions O O
-- O O
and O O
does O O
so O O
just O O
as O O
rapidly O O
and O O
floridly O O
; O O
one O O
such O O
case O O
is O O
reported O O
here O O

we O O
report O O
the O O
first O O
case O O
of O O
herpes B-ADR B-ADR
esophagitis I-ADR I-ADR
in O O
a O O
renal O O
transplant O O
patient O O
treated O O
with O O
cyclosporine B-DRUG B-DRUG
a I-DRUG O
while O O
on O O
chronic O O
steroid O O
therapy O O

in O O
the O O
third O O
child O O
, O O
the O O
tics B-ADR B-ADR
ceased O O
after O O
cbz B-DRUG B-DRUG
discontinuation O O

in O O
this O O
article O O
, O O
we O O
describe O O
another O O
case O O
of O O
subcutaneous O O
changes O O
following O O
repeated O O
glatiramer B-DRUG B-DRUG
acetate I-DRUG I-DRUG
injection O O
, O O
presented O O
as O O
localized B-ADR O
panniculitis I-ADR O
in O O
the O O
area O O
around O O
the O O
injection O O
sites O O
, O O
in O O
a O O
46-year-old O O
female O O
patient O O
who O O
was O O
treated O O
with O O
glatiramer B-DRUG B-DRUG
acetate I-DRUG I-DRUG
for O O
18 O O
months O O

hyperkalaemia O B-ADR
with O O
renal B-ADR O
tubular I-ADR O
dysfunction I-ADR O
by O O
oral O O
therapy O O
of O O
sulfamethoxazole-trimethoprim O B-DRUG
( O O
co-trimoxazole B-DRUG O
) O O
is O O
described O O
in O O
2 O O
elderly O O
japanese O O
patients O O
with O O
lymphoid O O
malignancy O O
, O O
who O O
developed O O
pneumocystis O O
carinii O O
pneumonia O O
and O O
improved O O

a O O
case O O
of O O
liver B-ADR B-ADR
damage I-ADR I-ADR
following O O
treatment O O
with O O
danazol B-DRUG B-DRUG
for O O
fibrocystic O O
breast O O
disease O O
is O O
reported O O

bisphosphonate B-DRUG B-DRUG
induced O O
osteochemonecrosis B-ADR B-ADR
of I-ADR O
the I-ADR O
jaw I-ADR O
mimicking O O
a O O
tumour O O

obsessive-compulsive B-ADR B-ADR
symptoms I-ADR I-ADR
suddenly O O
emerged O O
10 O O
days O O
after O O
starting O O
risperidone B-DRUG B-DRUG
and O O
resolved O O
within O O
3 O O
days O O
of O O
discontinuation O O

capecitabine-induced O O
multifocal B-ADR B-ADR
leukoencephalopathy I-ADR I-ADR
: O O
a O O
report O O
of O O
five O O
cases O O

the O O
authors O O
report O O
a O O
case O O
of O O
acute O B-ADR
pancreatitis B-ADR I-ADR
( O O
ap O O
) O O
occurring O O
in O O
a O O
patient O O
under O O
treatment O O
with O O
carbamazepine B-DRUG B-DRUG
( O O
cbz O B-DRUG
) O O
for O O
post-traumatic O O
petit O O
mal O O
epilepsy O O
, O O
and O O
review O O
the O O
current O O
literature O O
of O O
drug-induced O O
ap O B-ADR

after O O
reviewing O O
the O O
literature O O
we O O
suggest O O
the O O
cpm O O
was O O
a O O
complication O O
of O O
lithium B-DRUG B-DRUG
toxicity O O
which O O
affected O O
the O O
lateral O O
geniculate O O
nucleus O O
which O O
produced O O
blindness B-ADR B-ADR

five O O
and O O
one-half O O
years O O
after O O
the O O
diagnosis O O
of O O
myeloma O O
, O O
while O O
in O O
remission O O
on O O
cyclophosphamide B-DRUG B-DRUG
therapy O O
, O O
the O O
patient O O
experienced O O
severe O O
abdominal O O
right O O
lower O B-ADR
quadrant O I-ADR
pain O I-ADR
due O O
to O O
a O O
large O O
cecal B-ADR O
lymphoma I-ADR O

the O O
case O O
demonstrates O O
that O O
hypersensitivity O B-ADR
reaction O I-ADR
to O O
pranlukast B-DRUG B-DRUG
and O O
resultant O O
atin B-ADR O
is O O
possible O O
, O O
and O O
that O O
periodic O O
urine O O
testing O O
in O O
patients O O
receiving O O
pranlukast B-DRUG B-DRUG
should O O
be O O
considered O O

conclusion O O
: O O
we O O
believe O O
this O O
to O O
be O O
the O O
first O O
reported O O
case O O
of O O
rhgh-induced O O
hypercalcemia B-ADR B-ADR
in O O
an O O
hiv-infected O O
patient O O

we O O
describe O O
a O O
patient O O
with O O
transitional O O
cell O O
carcinoma O O
of O O
the O O
renal O O
pelvis O O
who O O
developed O O
respiratory B-ADR O
dysfunction I-ADR O
and O O
an O O
abnormal O O
chest O O
x-ray O O
with O O
diffuse O O
interstitial O O
opacities O O
while O O
on O O
chemotherapy O O
with O O
piritrexim B-DRUG B-DRUG
, O O
a O O
methotrexate O B-DRUG
analog O O

a O O
14-year-old O O
female O O
developed O O
systemic O O
lupus O O
erythematosus O O
( O O
sle O O
)- O O
like O O
symptoms O O
, O O
rash O O
, O O
fever B-ADR O
, O O
leukopenia O O
and O O
positive O O
anti-nuclear O O
antibody O O
( O O
ana O O
) O O
two O O
weeks O O
after O O
administration O O
of O O
carbamazepine B-DRUG B-DRUG
( O O
cbz O B-DRUG
; O O
tegretol O O
) O O
used O O
against O O
benign O O
rolandic O O
epilepsy O O

warfarin-associated O O
bleeding B-ADR O
generally O O
is O O
considered O O
deleterious O O
; O O
however O O
, O O
in O O
our O O
patient O O
it O O
unmasked O O
an O O
early O O
stage O O
of O O
colon O O
cancer O O
and O O
thus O O
may O O
have O O
saved O O
the O O
patient O O
's O O
life O O

the O O
elicitation O O
of O O
a O O
movement B-ADR B-ADR
disorder I-ADR I-ADR
by O O
trazodone B-DRUG B-DRUG
: O O
case O O
report O O

in O O
this O O
case O O
report O O
, O O
we O O
have O O
described O O
a O O
patient O O
with O O
crohn O O
's O O
disease O O
who O O
developed O O
subfulminant B-ADR B-ADR
hepatitis I-ADR I-ADR
b I-ADR I-ADR
after O O
the O O
fourth O O
infusion O O
of O O
infliximab B-DRUG B-DRUG
due O O
to O O
an O O
unrecognized O O
hbs-antigen O O
carrier O O
state O O

methotrexate-induced O O
hepatic B-ADR B-ADR
necrosis I-ADR I-ADR
requiring O O
liver O O
transplantation O O
in O O
a O O
patient O O
with O O
rheumatoid O O
arthritis O O

after O O
taking O O
cholestyramine B-DRUG B-DRUG
ii I-DRUG I-DRUG
sachets O O
twice O O
daily O O
for O O
two O O
months O O
she O O
presented O O
with O O
lethargy B-ADR O
, O O
confusion O O
and O O
drowsiness O B-ADR

a O O
67-year-old O O
man O O
with O O
bipolar O O
disorder O O
developed O O
a O O
creutzfeldt-jakob B-ADR B-ADR
like I-ADR I-ADR
syndrome I-ADR I-ADR
during O O
lithium B-DRUG B-DRUG
carbonate I-DRUG I-DRUG
treatment O O

a O O
child O O
in O O
whom O O
a O O
phenobarbital B-DRUG B-DRUG
hypersensitivity O O
drug O O
reaction O O
developed O O
which O O
consisted O O
of O O
fever O O
, O O
a O O
pruritic O O
desquamating O O
erythrodermic O O
rash O O
, O O
alopecia O O
, O O
icterus O O
, O O
protein-losing O O
enteropathy O O
, O O
myositis O O
, O O
and O O
nephritis B-ADR O
, O O
is O O
described O O

case O O
report O O
: O O
we O O
hereby O O
report O O
a O O
case O O
of O O
radiation O B-ADR
recall O I-ADR
dermatitis O I-ADR
and O O
myositis B-ADR B-ADR
occurring O O
on O O
gemcitabine B-DRUG B-DRUG
monotherapy O O
, O O
five O O
months O O
after O O
completing O O
chemoradiation O B-DRUG
for O O
locally O O
advanced O O
pancreatic O O
cancer O O

supravenous B-ADR B-ADR
hyperpigmentation I-ADR I-ADR
in O O
association O O
with O O
chop B-DRUG O
chemotherapy O O
of O O
a O O
cd30 O O
( O O
ki-1 O O
)- O O
positive O O
anaplastic O O
large-cell O O
lymphoma O O

drug O O
induced O O
polymyositis B-ADR B-ADR
secondary O O
to O O
leuprolide O B-DRUG
acetate O I-DRUG
( O O
lupron B-DRUG B-DRUG
) O O
therapy O O
for O O
prostate O O
carcinoma O O

based O O
on O O
the O O
history O O
and O O
clinical O O
features O O
, O O
a O O
diagnosis O O
of O O
insulin-induced O O
lipohypertrophy B-ADR B-ADR
was O O
made O O

seizures O O
and O O
extrapyramidal B-ADR O
symptoms I-ADR O
in O O
a O O
patient O O
with O O
tourette O O
's O O
syndrome O O
, O O
asperger O O
's O O
syndrome O O
, O O
and O O
multiple O O
sclerosis O O
treated O O
with O O
interferon B-DRUG B-DRUG
beta-1a I-DRUG I-DRUG
and O O
clomipramine O B-DRUG

method O O
: O O
the O O
authors O O
followed O O
a O O
patient O O
with O O
chronic O O
hcv O O
who O O
received O O
interferon B-DRUG O
and O O
ribavirin O B-DRUG
and O O
who O O
developed O O
hallucinations B-ADR B-ADR
ultimately O O
requiring O O
psychiatric O O
hospitalization O O

protease O O
inhibitors O O
( O O
ritonavir O O
and O O
saquinavir O B-DRUG
) O O
were O O
added O O
to O O
the O O
treatment O O
and O O
the O O
patient O O
developed O O
progressive O B-ADR
ataxia O I-ADR
related O O
to O O
carbamazepine B-ADR B-ADR
toxicity I-ADR I-ADR

we O O
have O O
described O O
three O O
patients O O
with O O
hepatitis O O
c O O
for O O
whom O O
ifn-alpha B-DRUG O
and O O
ribavirin O B-DRUG
were O O
prescribed O O
and O O
who O O
developed O O
two O O
successive O O
phases O O
of O O
silent O O
thyroiditis O O
followed O O
by O O
hyperthryroidism B-ADR B-ADR
relapse O I-ADR
due O O
to O O
graves' O O
disease O O

this O O
paper O O
reports O O
on O O
a O O
6.9-year-old O O
autistic O O
male O O
who O O
developed O O
repeated O O
episodes O O
of O O
acute B-ADR B-ADR
dystonic I-ADR I-ADR
reactions I-ADR I-ADR
associated O O
with O O
pimozide O B-DRUG
administration O O
at O O
the O O
doses O O
of O O
0.096 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
0.032 O O
mg O O
/ O O
kg O O
/ O O
day O O
and O O
32 O O
hours O O
following O O
pimozide O B-DRUG
withdrawal O O
, O O
as O O
well O O
as O O
during O O
subsequent O O
thioridazine B-DRUG B-DRUG
administration O O

acute B-ADR B-ADR
myocardial I-ADR I-ADR
ischemia I-ADR I-ADR
following O O
accidental O O
intravenous O O
administration O O
of O O
epinephrine B-DRUG B-DRUG
in O O
high O O
concentration O O

purpose O O
: O O
topiramate-induced O O
angle-closure B-ADR B-ADR
glaucoma I-ADR I-ADR
( O O
tiacg O O
) O O
is O O
believed O O
to O O
be O O
related O O
to O O
its O O
sulfonamide O O
moiety O O

case O O
report O O
: O O
we O O
report O O
a O O
case O O
of O O
intracerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
occurring O O
in O O
a O O
middle-aged O O
man O O
who O O
suffered O O
from O O
chronic O O
sinusitis O O
and O O
had O O
been O O
ingesting O O
pseudoephedrine B-DRUG B-DRUG
daily O O
for O O
one O O
year O O

hepatotoxicity B-ADR B-ADR
related O O
to O O
itraconazole B-DRUG B-DRUG
: O O
report O O
of O O
three O O
cases O O

fludarabine B-DRUG B-DRUG
induced O O
lung B-ADR B-ADR
toxicity I-ADR I-ADR
must O O
be O O
considered O O
in O O
all O O
patients O O
who O O
develop O O
unexplained O O
lung O O
disease O O
while O O
receiving O O
fludarabine O B-DRUG

we O O
present O O
a O O
fatal O O
case O O
of O O
subacute O O
methanol B-DRUG B-DRUG
toxicity O O
with O O
associated O O
diffuse B-ADR O
brain I-ADR O
involvement I-ADR O
, O O
including O O
bilateral O O
putaminal O O
necrosis O O
and O O
cerebral O O
edema O O
with O O
ventricular O O
compression O O

based O O
on O O
the O O
naranjo O O
probability O O
scale O O
, O O
serotonin B-ADR B-ADR
syndrome I-ADR I-ADR
was O O
a O O
probable O O
adverse O O
reaction O O
associated O O
with O O
co-administration O O
of O O
citalopram B-DRUG B-DRUG
and O O
fentanyl O B-DRUG

a O O
patient O O
with O O
chronic O O
myeloid O O
leukaemia O O
treated O O
with O O
busulphan B-DRUG B-DRUG
for O O
4-5 O O
years O O
, O O
developed O O
signs O O
of O O
busulphan B-DRUG B-DRUG
toxicity O O
and O O
portal O O
hypertension O O
with O O
ascites B-ADR O
, O O
oesophageal O O
varices O O
and O O
jaundice O O

a O O
27-year-old O O
man O O
who O O
had O O
a O O
history O O
of O O
bronchial O O
asthma O O
, O O
eosinophilic O O
enteritis O O
, O O
and O O
eosinophilic O O
pneumonia O O
presented O O
with O O
fever O O
, O O
skin O O
eruptions O O
, O O
cervical B-ADR O
lymphadenopathy I-ADR O
, O O
hepatosplenomegaly O O
, O O
atypical O O
lymphocytosis O O
, O O
and O O
eosinophilia O O
two O O
weeks O O
after O O
receiving O O
trimethoprim B-DRUG O
( O O
tmp O O
)- O O
sulfamethoxazole O O
( O O
smx O O
) O O
treatment O O

while O O
doxorubicin B-DRUG B-DRUG
was O O
administered O O
, O O
the O O
patient O O
presented O O
thoracic O O
pain O O
and O O
breathing B-ADR O
distress I-ADR O
due O O
to O O
superior O B-ADR
vena O I-ADR
cava O I-ADR
perforation O I-ADR
by O O
the O O
central O O
catheter O O
and O O
subsequent O O
extravasation O O
of O O
the O O
drug O O
into O O
the O O
mediastinum O O

conclusions O O
: O O
life-threatening O O
adrenal B-ADR O
suppression I-ADR O
, O O
requiring O O
hydrocortisone O B-DRUG
supplementation O O
and O O
intensive O O
therapy O O
, O O
was O O
observed O O
and O O
successfully O O
treated O O
in O O
a O O
newborn O O
, O O
whose O O
mother O O
had O O
received O O
high-dose O O
methylprednisolone B-DRUG B-DRUG
in O O
late O O
pregnancy O O

methods O O
: O O
repeated O O
blood O O
samples O O
were O O
drawn O O
in O O
a O O
patient O O
with O O
severe O O
acyclovir B-DRUG B-DRUG
overdose O O
who O O
developed O O
coma B-ADR B-ADR
and O O
nonoliguric O O
renal O O
failure O O

eeg B-ADR B-ADR
abnormalities I-ADR I-ADR
were O O
observed O O
in O O
two O O
of O O
the O O
nine O O
children O O
during O O
chlorambucil B-DRUG B-DRUG
therapy O O

rapid O O
resolution O O
of O O
topiramate-induced O O
angle-closure B-ADR B-ADR
glaucoma I-ADR I-ADR
with O O
methylprednisolone O B-DRUG
and O O
mannitol O B-DRUG

we O O
report O O
a O O
case O O
of O O
stevens-johnson O O
syndrome O O
/ O O
toxic O O
epidermal O O
necrolysis O O
( O O
sjs O O
/ O O
ten B-ADR O
) O O
secondary O O
to O O
trimethoprim-sulfamethoxazole B-DRUG O
( O O
tmp-sx O B-DRUG
) O O
therapy O O
for O O
presumed O O
community-associated O O
methicillin-resistant O O
staphylococcus O O
aureus O O
( O O
ca-mrsa O O
) O O
infection O O

in O O
rare O O
cases O O
mitomycin B-DRUG O
c I-DRUG O
( O O
mmc O B-DRUG
) O O
may O O
induce O O
cancer-associated O O
hemolytic B-ADR O
uremic I-ADR O
syndrome I-ADR O
, O O
which O O
is O O
characterized O O
by O O
hemolytic O O
anemia O O
, O O
thrombocytopenia O O
and O O
progressive O O
renal O O
failure O O

the O O
patient O O
experienced O O
hallucinations O O
, O O
agitation O O
, O O
vomiting O O
, O O
tachycardia O O
and O O
seizures B-ADR B-ADR
after O O
ingestion O O
of O O
1050 O O
( O O
48 O O
mg O O
/ O O
kg O O
) O O
of O O
extended-release O O
bupropion B-DRUG B-DRUG

six O O
of O O
13 O O
outpatients O O
with O O
schizophrenia O O
who O O
participated O O
in O O
a O O
ten-week O O
open O O
trial O O
of O O
risperidone B-DRUG B-DRUG
had O O
an O O
initial O O
good O O
response O O
to O O
the O O
medication O O
followed O O
by O O
development O O
of O O
intolerable O O
affect O O
, O O
including O O
feelings O O
of O O
agitation O O
and O O
depression O O
and O O
periods O O
of O O
crying O O
and O O
insomnia B-ADR B-ADR

severe B-ADR B-ADR
apnea I-ADR I-ADR
in O O
an O O
infant O O
exposed O O
to O O
lamotrigine B-DRUG B-DRUG
in O O
breast O O
milk O O

tenofovir-associated O O
nephrotoxicity B-ADR B-ADR
in O O
two O O
hiv-infected O O
adolescent O O
males O O

a O O
previous O O
study O O
of O O
patients O O
with O O
" O O
quinine-associated O O
ttp B-ADR O
/ I-ADR O
hus I-ADR O
" O O
found O O
that O O
adamts13 O B-DRUG
activities O O
were O O
not O O
abnormal O O
in O O
12 O O
/ O O
12 O O
patients O O

can O O
magnesium B-DRUG B-DRUG
sulfate I-DRUG I-DRUG
therapy O O
impact O O
lactogenesis B-ADR O

large O O
dose O O
of O O
methylphenidate B-DRUG B-DRUG
may O O
cause O O
cataract O B-ADR
and O O
glaucoma B-ADR B-ADR

bortezomib-induced O O
paralytic B-ADR B-ADR
ileus I-ADR I-ADR
is O O
a O O
potential O O
gastrointestinal O O
side O O
effect O O
of O O
this O O
first-in-class O O
anticancer O O
proteasome O O
inhibitor O O

we O O
report O O
the O O
first O O
case O O
of O O
fulminant O O
adult B-ADR O
respiratory I-ADR O
distress I-ADR O
syndrome I-ADR O
( O O
ards O O
) O O
associated O O
with O O
pegylated B-DRUG O
interferon I-DRUG O
alpha-2a I-DRUG O
( O O
pegifnalpha-2a O O
) O O
and O O
ribavirin O B-DRUG
use O O
for O O
hepatitis O O
c O O
, O O
complicated O O
by O O
subsequent O O
and O O
ultimately O O
fatal O O
sepsis O O
and O O
multiorgan O O
failure O O

we O O
report O O
the O O
case O O
of O O
a O O
man O O
, O O
treated O O
with O O
mesalazine B-DRUG B-DRUG
for O O
crohn O O
's O O
disease O O
who O O
developed O O
drug-induced O O
pericarditis B-ADR B-ADR

complications O O
of O O
chemotherapy O O
for O O
a O O
synovial O O
sarcoma O O
in O O
an O O
eight-year O O
old O O
boy O O
included O O
cisplatinum B-DRUG O
nephrotoxicity B-ADR O
and O O
adriamycin O B-DRUG
cardiotoxicity O B-ADR

one O O
patient O O
required O O
nursing O O
home O O
placement O O
and O O
a O O
feeding O B-ADR
gastrostomy O I-ADR
as O O
a O O
result O O
of O O
the O O
worsening B-ADR B-ADR
parkinsonism I-ADR I-ADR
during O O
risperidone B-DRUG B-DRUG
treatment O O
, O O
but O O
was O O
able O O
to O O
return O O
home O O
and O O
have O O
the O O
gastrostomy O B-ADR
removed O O
after O O
switching O O
from O O
risperidone B-DRUG B-DRUG
to O O
clozapine O B-DRUG

we O O
report O O
a O O
girl O O
with O O
the O O
rett O O
syndrome O O
who O O
had O O
acute B-ADR B-ADR
encephalopathy I-ADR I-ADR
probably O O
induced O O
by O O
calcium B-DRUG B-DRUG
hopantenate I-DRUG I-DRUG
( O O
hopa O O

hydroxyurea-induced O O
acute B-ADR B-ADR
interstitial I-ADR I-ADR
pneumonitis I-ADR I-ADR
in O O
a O O
patient O O
with O O
essential O O
thrombocythemia O O

here O O
we O O
present O O
the O O
case O O
of O O
a O O
generalized B-ADR B-ADR
lichen I-ADR I-ADR
nitidus I-ADR I-ADR
with O O
involvement O O
of O O
the O O
palms O O
in O O
a O O
patient O O
with O O
hepatitis O O
c O O
after O O
systemic O O
treatment O O
with O O
interferon B-DRUG B-DRUG
alpha I-DRUG I-DRUG
and O O
ribavirin O B-DRUG

reye O B-ADR
syndrome O I-ADR
( O O
rs B-ADR O
) O O
is O O
believed O O
to O O
occur O O
infrequently O O
among O O
children O O
receiving O O
long-term O O
aspirin B-DRUG B-DRUG
therapy O O

because O O
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
may O O
be O O
induced O O
by O O
ifn B-DRUG B-DRUG
therapy O O
, O O
the O O
ifn B-DRUG B-DRUG
was O O
stopped O O

in O O
deciding O O
if O O
tamoxifen B-DRUG B-DRUG
therapy O O
is O O
warranted O O
, O O
all O O
potentially O O
life-threatening O O
adverse O O
events O O
associated O O
with O O
tamoxifen B-DRUG B-DRUG
should O O
be O O
considered O O
, O O
including O O
endometrial B-ADR O
adenocarcinoma I-ADR O
or O O
uterine O O
sarcoma O O

six O O
of O O
13 O O
outpatients O O
with O O
schizophrenia O O
who O O
participated O O
in O O
a O O
ten-week O O
open O O
trial O O
of O O
risperidone B-DRUG B-DRUG
had O O
an O O
initial O O
good O O
response O O
to O O
the O O
medication O O
followed O O
by O O
development O O
of O O
intolerable B-ADR O
affect I-ADR O
, O O
including O O
feelings O O
of O O
agitation O O
and O O
depression O O
and O O
periods O O
of O O
crying O O
and O O
insomnia O B-ADR

we O O
describe O O
the O O
case O O
of O O
acute B-ADR B-ADR
hepatitis I-ADR I-ADR
induced O O
by O O
gliclazide B-DRUG B-DRUG
, O O
a O O
second O O
generation O O
sulfonylurea O B-DRUG

